WO2023020315A1 - 靶向pd-l1/pd-1的抗体及其应用 - Google Patents

靶向pd-l1/pd-1的抗体及其应用 Download PDF

Info

Publication number
WO2023020315A1
WO2023020315A1 PCT/CN2022/110795 CN2022110795W WO2023020315A1 WO 2023020315 A1 WO2023020315 A1 WO 2023020315A1 CN 2022110795 W CN2022110795 W CN 2022110795W WO 2023020315 A1 WO2023020315 A1 WO 2023020315A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
targeting moiety
amino acid
acid sequence
sequence shown
Prior art date
Application number
PCT/CN2022/110795
Other languages
English (en)
French (fr)
Inventor
康平
Original Assignee
南京吉盛澳玛生物医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202210868109.1A external-priority patent/CN116102655A/zh
Application filed by 南京吉盛澳玛生物医药有限公司 filed Critical 南京吉盛澳玛生物医药有限公司
Publication of WO2023020315A1 publication Critical patent/WO2023020315A1/zh

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins

Definitions

  • This application relates to the field of biomedicine, in particular to an antibody targeting PD-L1/PD-1 and its application.
  • P-L1 Programmed death receptor ligand 1
  • CD274 cluster of differentiation 274
  • B7 homolog 1 B7-H1
  • PD-L1 is a 40KDa type I transmembrane protein, generally in activated T Cells, B cells, monocytes, dendritic cells, macrophages and many non-hematopoietic cells.
  • PD-L1 can bind to programmed death receptor 1 (PD-1) and B7-1 (CD80).
  • PD-1 programmed death receptor 1
  • CD80 B7-1
  • the PD-L1/PD-1 signaling pathway is a very important co-inhibitory signaling pathway in the immune response, which negatively regulates the immune response of T cells, inhibits the activity of T cells, and reduces the secretion of cytokines.
  • PD-L1 can be expressed in many tumor tissues, including gastric cancer, lung cancer, breast cancer, pancreatic cancer, ovarian cancer, colon cancer, mast cell tumors, and malignant melanoma, as well as in bone marrow cells infiltrating the tumor microenvironment Expression, protect tumor cells from immune attack.
  • anti-PD-L1 antibody and anti-PD-1 antibody can benefit many cancer patients, but some patients still do not respond to monotherapy.
  • Multispecific antibodies that can bind PD-1 protein and PD-L1 protein are expected to enhance anti-tumor activity. Therefore, there is an urgent need to develop PD1/PD-L1 bispecific antibodies capable of blocking the PD-L1/PD-1 signaling pathway.
  • the application provides an isolated antigen-binding protein, which has one or more of the following properties: 1) can bind both PD-1 protein and PD-L1 protein; 2) the first polypeptide chain and the second polypeptide chain The natural pairing of the two polypeptide chains does not require unnatural engineered pairing, which overcomes the mismatch problem in the production process of general multispecific antibodies and reduces costs; 3) Compared with general multispecific antibodies, the area covered by the antigen is 30% larger and 4) capable of efficiently killing tumor cells.
  • the antigen binding protein comprises a first polypeptide chain, a second polypeptide chain, the first polypeptide chain comprises a first targeting moiety, and the second polypeptide chain comprises a second target targeting moiety, the first targeting moiety and the second targeting moiety independently bind to immune cell-associated antigens, and the first polypeptide chain is connected to the second polypeptide chain through a disulfide bond.
  • the immune cells include T cells, macrophages, dendritic cells and/or NK cells.
  • the immune cell-associated antigens include PD-1, PD-L1, CD3, CD16a and/or CD28.
  • the first targeting moiety and the second targeting moiety bind the same immune cell-associated antigen.
  • both the first targeting moiety and the second targeting moiety bind to the PD-1 protein or the PD-L1 protein.
  • the first targeting moiety specifically binds the PD-1 protein
  • the second targeting moiety specifically binds the PD-L1 protein.
  • the first targeting moiety specifically binds to the PD-L1 protein
  • the second targeting moiety specifically binds to the PD-1 protein
  • the first targeting moiety specifically binds the PD-1 protein
  • the second targeting moiety specifically binds the CD28 or CD16a protein.
  • the first targeting moiety specifically binds CD28 or CD16a protein
  • the second targeting moiety specifically binds PD-1 protein
  • said first polypeptide chain further comprises a third targeting moiety.
  • the third targeting moiety in the first polypeptide chain is directly or indirectly linked to the C-terminus of the first targeting moiety.
  • the third targeting moiety in the first polypeptide chain is connected to the C-terminus of the first targeting moiety through a linker.
  • the third targeting moiety targets an immune cell-associated antigen.
  • the immune cell-associated antigens include PD-1, PD-L1, CD3, CD16a and/or CD28.
  • the third targeting moiety targets CD3 or CD16a protein.
  • the third targeting moiety targets a tumorigenesis-associated antigen.
  • the third targeting moiety targets EGFR and/or cMet.
  • the third targeting moiety targets a tumor-associated antigen.
  • the tumor-associated antigens include PD-L1, HER2, CD47, CD19 and/or CD20.
  • said second polypeptide chain further comprises a fourth targeting moiety.
  • the fourth targeting moiety in the second polypeptide chain is directly or indirectly linked to the C-terminus of the second targeting moiety.
  • the fourth targeting moiety in the second polypeptide chain is connected to the C-terminus of the second targeting moiety through a linker.
  • the fourth targeting moiety targets an immune cell-associated antigen.
  • the immune cell-associated antigens include PD-1, PD-L1, CD3, CD16a and/or CD28.
  • the fourth targeting moiety targets a tumorigenesis-associated antigen.
  • the fourth targeting moiety targets EGFR and/or cMet.
  • the fourth targeting moiety targets a tumor-associated antigen.
  • the tumor-associated antigens include PD-L1, HER2, CD47, CD19 and/or CD20.
  • the first polypeptide chain comprises a cytokine.
  • the cytokines include IL-2, IFNa, IFNb, and/or IL-15.
  • the second polypeptide chain comprises a cytokine.
  • the cytokines include IL-2, IFNa, IFNb, and/or IL-15.
  • the first targeting moiety targets PD-L1
  • the second targeting moiety targets PD-L1
  • the fourth targeting moiety targets PD-1, CD3 or CD16a.
  • the first targeting moiety targets PD-1
  • the second targeting moiety targets PD-1
  • the fourth targeting moiety targets PD-L1, CD3 or CD16a.
  • the first targeting moiety targets PD-L1
  • the second targeting moiety targets PD-1
  • the third targeting moiety targets CD3 or CD16a.
  • the first targeting moiety targets PD-1
  • the second targeting moiety targets PD-L1
  • the third targeting moiety targets CD3 or CD16a.
  • the first targeting moiety in the isolated antigen binding protein targets CD28 or CD16a
  • the second targeting moiety targets PD-1
  • the fourth targeting moiety targets PD-L1, HER2, CD47, CD19 and/or CD20.
  • the first targeting moiety in the isolated antigen binding protein targets PD-1
  • the second targeting moiety targets CD28 or CD16a
  • the fourth targeting moiety targets PD-L1, HER2, CD47, CD19 and/or CD20.
  • the first targeting moiety in the isolated antigen binding protein targets CD28 or CD16a
  • the second targeting moiety targets PD-1
  • the third targeting moiety targets EGFR or cMET
  • the fourth targeting moiety targets PD-L1, HER2, CD47, CD19 and/or CD20.
  • the first targeting moiety in the isolated antigen binding protein targets PD-1
  • the second targeting moiety targets CD28 or CD16a
  • the third targeting moiety targets PD-L1, HER2, CD47, CD19 and/or CD20
  • the fourth targeting moiety targets EGFR or cMET.
  • the first targeting moiety in the isolated antigen binding protein targets PD-1
  • the second targeting moiety targets PD-1
  • the second polypeptide chain comprises IL-2 or IL-15.
  • the first targeting moiety in the isolated antigen binding protein targets PD-L1
  • the second targeting moiety targets PD-L1
  • the second polypeptide chain comprises IL-2 or IL-15.
  • the first targeting moiety in the isolated antigen binding protein targets PD-1
  • the second targeting moiety targets PD-L1
  • the first polypeptide chain comprises IL -2 or IL-15
  • the fourth targeting moiety comprises CD3 or CD16a.
  • the first targeting moiety in the isolated antigen binding protein targets PD-L1
  • the second targeting moiety targets PD-1
  • the first polypeptide chain comprises IL -2 or IL-15
  • the fourth targeting moiety comprises CD3 or CD16a.
  • the first targeting moiety in the isolated antigen binding protein targets PD-L1
  • the second targeting moiety targets PD-1
  • the first polypeptide chain comprises IL -2 or IL-15.
  • the first targeting moiety in the isolated antigen binding protein targets PD-1
  • the second targeting moiety targets PD-L1
  • the first polypeptide chain comprises IL -2 or IL-15.
  • the first targeting moiety in the isolated antigen binding protein targets PD-1
  • the second targeting moiety targets PD-1
  • the first polypeptide chain comprises IL -2 or IL-15
  • the fourth targeting moiety targets PD-L1.
  • the first targeting moiety in the isolated antigen binding protein targets PD-L1
  • the second targeting moiety targets PD-L1
  • the first polypeptide chain comprises IL -2 or IL-15
  • the fourth targeting moiety targets PD-1.
  • the first targeting moiety in the isolated antigen binding protein targets PD-1
  • the second targeting moiety targets PD-L1
  • the third targeting moiety targets CD3 or CD16a
  • the second polypeptide chain comprises IL-2 or IL-15.
  • the first targeting moiety in the isolated antigen binding protein targets PD-L1
  • the second targeting moiety targets PD-1
  • the third targeting moiety targets CD3 or CD16a
  • the second polypeptide chain comprises IL-2 or IL-15.
  • the first targeting moiety comprises HCDR3 comprising the amino acid sequence shown in SEQ ID NO:51.
  • the first targeting moiety comprises HCDR3 comprising the amino acid sequence shown in any one of SEQ ID NO:9 and SEQ ID NO:10.
  • the first targeting moiety comprises HCDR2 comprising the amino acid sequence shown in SEQ ID NO:6.
  • the first targeting moiety comprises HCDR1 comprising the amino acid sequence shown in SEQ ID NO:3.
  • the first targeting moiety comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH shown in SEQ ID NO:52.
  • the first targeting moiety comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH shown in any one of SEQ ID NO:29 to SEQ ID NO:31.
  • the first targeting moiety comprises a heavy chain variable region VH
  • the VH comprises the HCDR1, HCDR2 and HCDR3
  • the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:51
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:6
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:3.
  • said first targeting moiety comprises a heavy chain variable region VH, said VH comprising said HCDR1, HCDR2 and HCDR3, said HCDR3 comprising SEQ ID NO:9 and SEQ ID NO:10
  • VH heavy chain variable region
  • HCDR1 comprises the amino acid sequence shown in SEQ ID NO:3.
  • HCDR1, HCDR2 and HCDR3 in the first targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • HCDR1 SEQ ID NO:3
  • HCDR2 SEQ ID NO:6
  • HCDR3 SEQ ID NO:9
  • HCDR1 SEQ ID NO:3
  • HCDR2 SEQ ID NO:6
  • HCDR3 SEQ ID NO:10.
  • the first targeting moiety comprises H-FR1
  • the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
  • the H-FR1 comprises SEQ ID NO : the amino acid sequence shown in 47.
  • the H-FR1 comprises the amino acid sequence shown in any one of SEQ ID NO:1 and SEQ ID NO:2.
  • the first targeting moiety comprises H-FR2
  • the H-FR2 is located between the HCDR1 and the HCDR2
  • the H-FR2 comprises SEQ ID NO:48 amino acid sequence.
  • the H-FR2 comprises the amino acid sequence shown in any one of SEQ ID NO:4 and SEQ ID NO:5.
  • the first targeting moiety comprises H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 comprises SEQ ID NO:49 amino acid sequence.
  • the H-FR3 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:7 and SEQ ID NO:8.
  • the first targeting moiety comprises H-FR4, the N-terminus of the H-FR4 is directly or indirectly connected to the C-terminus of the HCDR3, and the H-FR4 comprises SEQ ID NO : The amino acid sequence shown in 50.
  • the H-FR4 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:11 and SEQ ID NO:12.
  • the first targeting moiety comprises H-FR1, H-FR2, H-FR3 and H-FR4, and the H-FR1 comprises the amino acid sequence shown in SEQ ID NO:47; the H-FR2 comprises the amino acid sequence shown in SEQ ID NO:48; said H-FR3 comprises the amino acid sequence shown in SEQ ID NO:49; and said H-FR4 comprises the amino acid sequence shown in SEQ ID NO:50.
  • the first targeting moiety comprises H-FR1, H-FR2, H-FR3 and H-FR4, and the H-FR1 comprises any of SEQ ID NO:1 and SEQ ID NO:2
  • the amino acid sequence shown in one item the H-FR2 includes the amino acid sequence shown in any one of SEQ ID NO:4 and SEQ ID NO:5
  • the H-FR3 includes SEQ ID NO:7 and SEQ ID NO : the amino acid sequence shown in any one of 8
  • the H-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO: 11 and SEQ ID NO: 12.
  • said H-FR1, H-FR2, H-FR3 and H-FR4 in said first targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • H-FR1 SEQ ID NO:1
  • H-FR2 SEQ ID NO:4
  • H-FR3 SEQ ID NO:7
  • H-FR4 SEQ ID NO:11
  • H-FR1 SEQ ID NO:2
  • H-FR2 SEQ ID NO:5
  • H-FR3 SEQ ID NO:8
  • H-FR4 SEQ ID NO:12.
  • the first targeting moiety comprises a heavy chain variable region VH comprising the amino acid sequence shown in SEQ ID NO:52.
  • the first targeting moiety comprises a heavy chain variable region VH comprising the amino acid sequence shown in any one of SEQ ID NO:29 to SEQ ID NO:31.
  • the first targeting moiety comprises LCDR3 comprising the amino acid sequence shown in SEQ ID NO:57.
  • the first targeting moiety comprises LCDR3 comprising the amino acid sequence shown in any one of SEQ ID NO:21 to SEQ ID NO:26.
  • the first targeting moiety comprises LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 18.
  • the first targeting moiety comprises LCDR1 comprising the amino acid sequence shown in SEQ ID NO:15.
  • the first targeting moiety comprises LCDR1, LCDR2 and LCDR3 of the light chain variable region VL shown in SEQ ID NO:58.
  • the first targeting moiety comprises LCDR1, LCDR2 and LCDR3 of the light chain variable region VL shown in any one of SEQ ID NO:32 to SEQ ID NO:38.
  • the first targeting moiety comprises a light chain variable region VL
  • the VL comprises the LCDR1, LCDR2 and LCDR3, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:57;
  • the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:18; and
  • the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:15.
  • said first targeting moiety comprises a light chain variable region VL comprising said LCDR1, LCDR2 and LCDR3, said LCDR3 comprising SEQ ID NO:21 to SEQ ID NO:26
  • the amino acid sequence shown in any one The LCDR2 includes the amino acid sequence shown in SEQ ID NO: 18; and the LCDR1 includes the amino acid sequence shown in SEQ ID NO: 15.
  • the LCDR1, LCDR2 and LCDR3 in the first targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:21;
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:22;
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:23;
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:24;
  • LCDR1 SEQ ID NO: 15, LCDR2: SEQ ID NO: 18 and LCDR3: SEQ ID NO: 25;
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:26.
  • the first targeting moiety comprises L-FR1
  • the C-terminus of the L-FR1 is directly or indirectly connected to the N-terminus of the LCDR1
  • the L-FR1 comprises SEQ ID NO : the amino acid sequence shown in 53.
  • the L-FR1 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:13 and SEQ ID NO:14.
  • the first targeting moiety comprises L-FR2
  • the L-FR2 is located between the LCDR1 and the LCDR2
  • the L-FR2 comprises SEQ ID NO:54 amino acid sequence.
  • the L-FR2 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:16 and SEQ ID NO:17.
  • the first targeting moiety comprises L-FR3, the L-FR3 is located between the LCDR2 and the LCDR3, and the L-FR3 comprises SEQ ID NO:55 amino acid sequence.
  • the L-FR3 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:19 and SEQ ID NO:20.
  • the first targeting moiety comprises L-FR4, the N-terminus of the L-FR4 is directly or indirectly connected to the C-terminus of the LCDR3, and the L-FR4 comprises SEQ ID NO : the amino acid sequence shown in 56.
  • the L-FR4 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:27 and SEQ ID NO:28.
  • the first targeting moiety comprises L-FR1, L-FR2, L-FR3 and L-FR4, and the L-FR1 comprises the amino acid sequence shown in SEQ ID NO:53; the L-FR2 comprises the amino acid sequence shown in SEQ ID NO:54; said L-FR3 comprises the amino acid sequence shown in SEQ ID NO:55; and said L-FR4 comprises the amino acid sequence shown in SEQ ID NO:56.
  • the first targeting moiety comprises L-FR1, L-FR2, L-FR3 and L-FR4, and the L-FR1 comprises any of SEQ ID NO:13 and SEQ ID NO:14
  • the amino acid sequence shown in one item the L-FR2 includes the amino acid sequence shown in any one of SEQ ID NO:16 and SEQ ID NO:17
  • the L-FR3 includes SEQ ID NO:19 and SEQ ID NO : the amino acid sequence shown in any one of 20
  • the L-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO: 27 and SEQ ID NO: 28.
  • said L-FR1, L-FR2, L-FR3, and L-FR4 in said first targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • L-FR1 SEQ ID NO:13
  • L-FR2 SEQ ID NO:16
  • L-FR3 SEQ ID NO:19
  • L-FR4 SEQ ID NO:27;
  • L-FR1 SEQ ID NO:14
  • L-FR2 SEQ ID NO:17
  • L-FR3 SEQ ID NO:20
  • L-FR4 SEQ ID NO:28.
  • the first targeting moiety comprises a VL comprising the amino acid sequence shown in any one of SEQ ID NO:58.
  • said VL in said first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:32 to SEQ ID NO:38.
  • the first targeting moiety comprises HCDR3 comprising the amino acid sequence shown in SEQ ID NO:76.
  • the first targeting moiety comprises HCDR2 comprising the amino acid sequence shown in SEQ ID NO:70.
  • the first targeting moiety comprises HCDR1 comprising the amino acid sequence shown in SEQ ID NO:61.
  • the first targeting moiety comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH shown in SEQ ID NO: 122.
  • the first targeting moiety comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH shown in any one of SEQ ID NO:95 to SEQ ID NO:104.
  • the first targeting moiety comprises a heavy chain variable region VH
  • the VH comprises the HCDR1, HCDR2 and HCDR3
  • the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:76
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:70
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:61.
  • the first targeting moiety comprises H-FR1
  • the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
  • the H-FR1 comprises SEQ ID NO : the amino acid sequence shown in 115.
  • the H-FR1 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:59 to SEQ ID NO:60.
  • the first targeting moiety comprises H-FR2
  • the H-FR2 is located between the HCDR1 and the HCDR2
  • the H-FR2 comprises SEQ ID NO: 116 amino acid sequence.
  • the H-FR2 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:62 to SEQ ID NO:69.
  • the first targeting moiety comprises H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 comprises SEQ ID NO: 117 amino acid sequence.
  • the H-FR3 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:71 to SEQ ID NO:75.
  • the first targeting moiety comprises H-FR4, the N-terminus of the H-FR4 is directly or indirectly connected to the C-terminus of the HCDR3, and the H-FR4 comprises SEQ ID NO : the amino acid sequence shown in 118.
  • the H-FR4 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:77 to SEQ ID NO:78.
  • the first targeting moiety comprises H-FR1, H-FR2, H-FR3 and H-FR4, and the H-FR1 comprises the amino acid sequence shown in SEQ ID NO: 115; the H-FR2 comprises the amino acid sequence shown in SEQ ID NO:116; the H-FR3 comprises the amino acid sequence shown in SEQ ID NO:117; and the H-FR4 comprises the amino acid sequence shown in SEQ ID NO:118.
  • the first targeting moiety comprises H-FR1, H-FR2, H-FR3 and H-FR4, and the H-FR1 comprises any of SEQ ID NO:59 to SEQ ID NO:60
  • the H-FR2 includes the amino acid sequence shown in any one of SEQ ID NO:62 to SEQ ID NO:69
  • the H-FR3 includes SEQ ID NO:71 to SEQ ID NO
  • the H-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO: 77 to SEQ ID NO: 78.
  • said H-FR1, H-FR2, H-FR3 and H-FR4 in said first targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • H-FR1 SEQ ID NO:59
  • H-FR2 SEQ ID NO:62
  • H-FR3 SEQ ID NO:71
  • H-FR4 SEQ ID NO:77;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:63
  • H-FR3 SEQ ID NO:72
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:64
  • H-FR3 SEQ ID NO:73
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:65
  • H-FR3 SEQ ID NO:74
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:66
  • H-FR3 SEQ ID NO:75
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:67
  • H-FR3 SEQ ID NO:72
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:65
  • H-FR3 SEQ ID NO:72
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:64
  • H-FR3 SEQ ID NO:74
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:68
  • H-FR3 SEQ ID NO:72
  • H-FR4 SEQ ID NO:78
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:69
  • H-FR3 SEQ ID NO:73
  • H-FR4 SEQ ID NO:78.
  • the first targeting moiety comprises a heavy chain variable region VH comprising the amino acid sequence shown in SEQ ID NO: 122.
  • the VH in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:95 to SEQ ID NO:104.
  • the first targeting moiety comprises LCDR3 comprising the amino acid sequence shown in SEQ ID NO:94.
  • the first targeting moiety comprises LCDR2 comprising the amino acid sequence shown in SEQ ID NO:87.
  • the first targeting moiety comprises LCDR1 comprising the amino acid sequence shown in SEQ ID NO:82.
  • the first targeting moiety comprises LCDR1, LCDR2 and LCDR3 of the light chain variable region VL shown in any one of SEQ ID NO: 123.
  • the first targeting moiety comprises LCDR1, LCDR2 and LCDR3 of the light chain variable region VL shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111.
  • the first targeting moiety comprises a light chain variable region VL
  • the VL comprises the LCDR1, LCDR2 and LCDR3
  • the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:94
  • the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:87
  • the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:82.
  • the first targeting moiety comprises L-FR1
  • the C-terminus of the L-FR1 is directly or indirectly connected to the N-terminus of the LCDR1
  • the L-FR1 comprises SEQ ID NO : the amino acid sequence shown in 119.
  • the L-FR1 comprises the amino acid sequence shown in any one of SEQ ID NO:79 to SEQ ID NO:81.
  • the first targeting moiety comprises L-FR2
  • the L-FR2 is located between the LCDR1 and the LCDR2
  • the L-FR2 comprises SEQ ID NO: 120 amino acid sequence.
  • the L-FR2 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:83 to SEQ ID NO:86.
  • the first targeting moiety comprises L-FR3, the L-FR3 is located between the LCDR2 and the LCDR3, and the L-FR3 comprises SEQ ID NO: 121 amino acid sequence.
  • the L-FR3 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:88 to SEQ ID NO:93.
  • the first targeting moiety comprises L-FR4, the N-terminus of the L-FR4 is directly or indirectly connected to the C-terminus of the LCDR3, and the L-FR4 comprises SEQ ID NO : the amino acid sequence shown in 56.
  • the L-FR4 in the first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:27 to SEQ ID NO:28.
  • the first targeting moiety comprises L-FR1, L-FR2, L-FR3 and L-FR4, and the L-FR1 comprises the amino acid sequence shown in SEQ ID NO: 119; the L-FR2 comprises the amino acid sequence shown in SEQ ID NO:120; said L-FR3 comprises the amino acid sequence shown in SEQ ID NO:121; and said L-FR4 comprises the amino acid sequence shown in SEQ ID NO:56.
  • the first targeting moiety comprises L-FR1, L-FR2, L-FR3 and L-FR4, and the L-FR1 comprises any of SEQ ID NO:79 to SEQ ID NO:81
  • the amino acid sequence shown in one item the L-FR2 includes the amino acid sequence shown in any one of SEQ ID NO:83 to SEQ ID NO:86
  • the L-FR3 includes SEQ ID NO:88 to SEQ ID NO
  • the L-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO:27 to SEQ ID NO:28.
  • said L-FR1, L-FR2, L-FR3, and L-FR4 in said first targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • L-FR1 SEQ ID NO:79
  • L-FR2 SEQ ID NO:83
  • L-FR3 SEQ ID NO:88
  • L-FR4 SEQ ID NO:27;
  • L-FR1 SEQ ID NO:80
  • L-FR2 SEQ ID NO:84
  • L-FR3 SEQ ID NO:89
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:81
  • L-FR2 SEQ ID NO:85
  • L-FR3 SEQ ID NO:90
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:81
  • L-FR2 SEQ ID NO:85
  • L-FR3 SEQ ID NO:91
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:80
  • L-FR2 SEQ ID NO:85
  • L-FR3 SEQ ID NO:90
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:80
  • L-FR2 SEQ ID NO:85
  • L-FR3 SEQ ID NO:92
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:80
  • L-FR2 SEQ ID NO:86
  • L-FR3 SEQ ID NO:93
  • L-FR4 SEQ ID NO:28.
  • the first targeting moiety comprises a VL comprising the amino acid sequence shown in SEQ ID NO: 123.
  • said VL in said first targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111.
  • the first targeting moiety in the isolated antigen binding protein targets CD28
  • the first targeting moiety comprises VH
  • the VH comprises the amino acid sequence shown in SEQ ID NO: 176 .
  • the first targeting moiety in the isolated antigen binding protein targets CD16a
  • the first targeting moiety comprises VH
  • the VH comprises the amino acid sequence shown in SEQ ID NO: 168 .
  • the second targeting moiety comprises HCDR3 comprising the amino acid sequence shown in SEQ ID NO:51.
  • the second targeting moiety comprises HCDR3 comprising the amino acid sequence shown in any one of SEQ ID NO:9 and SEQ ID NO:10.
  • the second targeting moiety comprises HCDR2 comprising the amino acid sequence shown in SEQ ID NO:6.
  • the second targeting moiety comprises HCDR1 comprising the amino acid sequence shown in SEQ ID NO:3.
  • the second targeting moiety comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH shown in SEQ ID NO:52.
  • the second targeting moiety comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH shown in any one of SEQ ID NO:29 to SEQ ID NO:31.
  • the second targeting moiety comprises a heavy chain variable region VH
  • the VH comprises the HCDR1, HCDR2 and HCDR3
  • the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:51
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:6
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:3.
  • the second targeting moiety comprises a heavy chain variable region VH, the VH comprising the HCDR1, HCDR2 and HCDR3, the HCDR3 comprising SEQ ID NO: 9 and SEQ ID NO: 10
  • the amino acid sequence shown in any one The HCDR2 comprises the amino acid sequence shown in SEQ ID NO:6; And the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:3.
  • said HCDR1, HCDR2 and HCDR3 in said second targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • HCDR1 SEQ ID NO:3
  • HCDR2 SEQ ID NO:6
  • HCDR3 SEQ ID NO:9
  • HCDR1 SEQ ID NO:3
  • HCDR2 SEQ ID NO:6
  • HCDR3 SEQ ID NO:10.
  • the second targeting moiety comprises H-FR1
  • the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
  • the H-FR1 comprises SEQ ID NO : the amino acid sequence shown in 47.
  • the H-FR1 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:1 and SEQ ID NO:2.
  • the second targeting moiety comprises H-FR2
  • the H-FR2 is located between the HCDR1 and the HCDR2
  • the H-FR2 comprises SEQ ID NO:48 amino acid sequence.
  • the H-FR2 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:4 and SEQ ID NO:5.
  • the second targeting moiety comprises H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 comprises SEQ ID NO:49 amino acid sequence.
  • the H-FR3 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:7 and SEQ ID NO:8.
  • the second targeting moiety comprises H-FR4, the N-terminus of the H-FR4 is directly or indirectly connected to the C-terminus of the HCDR3, and the H-FR4 comprises SEQ ID NO : The amino acid sequence shown in 50.
  • the H-FR4 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:11 and SEQ ID NO:12.
  • the second targeting moiety comprises H-FR1, H-FR2, H-FR3 and H-FR4, and the H-FR1 comprises the amino acid sequence shown in SEQ ID NO:47; the H-FR2 comprises the amino acid sequence shown in SEQ ID NO:48; said H-FR3 comprises the amino acid sequence shown in SEQ ID NO:49; and said H-FR4 comprises the amino acid sequence shown in SEQ ID NO:50.
  • the second targeting moiety comprises H-FR1, H-FR2, H-FR3 and H-FR4, and the H-FR1 comprises any of SEQ ID NO:1 and SEQ ID NO:2
  • the H-FR2 includes the amino acid sequence shown in any one of SEQ ID NO:4 and SEQ ID NO:5
  • the H-FR3 includes SEQ ID NO:7 and SEQ ID NO : the amino acid sequence shown in any one of 8
  • the H-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO: 11 and SEQ ID NO: 12.
  • said H-FR1, H-FR2, H-FR3 and H-FR4 in said second targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • H-FR1 SEQ ID NO:1
  • H-FR2 SEQ ID NO:4
  • H-FR3 SEQ ID NO:7
  • H-FR4 SEQ ID NO:11
  • H-FR1 SEQ ID NO:2
  • H-FR2 SEQ ID NO:5
  • H-FR3 SEQ ID NO:8
  • H-FR4 SEQ ID NO:12.
  • the second targeting moiety comprises a heavy chain variable region VH comprising the amino acid sequence shown in SEQ ID NO:52.
  • the second targeting moiety comprises a heavy chain variable region VH comprising the amino acid sequence shown in any one of SEQ ID NO:29 to SEQ ID NO:31.
  • the second targeting moiety comprises LCDR3 comprising the amino acid sequence shown in SEQ ID NO:57.
  • the second targeting moiety comprises LCDR3 comprising the amino acid sequence shown in any one of SEQ ID NO:21 to SEQ ID NO:26.
  • the second targeting moiety comprises LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 18.
  • the second targeting moiety comprises LCDR1 comprising the amino acid sequence shown in SEQ ID NO:15.
  • the second targeting moiety comprises LCDR1, LCDR2 and LCDR3 of the light chain variable region VL shown in SEQ ID NO:58.
  • the second targeting moiety comprises LCDR1, LCDR2 and LCDR3 of the light chain variable region VL shown in any one of SEQ ID NO:32 to SEQ ID NO:38.
  • the second targeting moiety comprises a light chain variable region VL
  • the VL comprises the LCDR1, LCDR2 and LCDR3, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:57;
  • the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:18; and
  • the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:15.
  • said second targeting moiety comprises a light chain variable region VL comprising said LCDR1, LCDR2 and LCDR3, said LCDR3 comprising SEQ ID NO:21 to SEQ ID NO:26
  • the amino acid sequence shown in any one The LCDR2 includes the amino acid sequence shown in SEQ ID NO: 18; and the LCDR1 includes the amino acid sequence shown in SEQ ID NO: 15.
  • said LCDR1, LCDR2, and LCDR3 in said second targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:21;
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:22;
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:23;
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:24;
  • LCDR1 SEQ ID NO: 15, LCDR2: SEQ ID NO: 18 and LCDR3: SEQ ID NO: 25;
  • LCDR1 SEQ ID NO:15
  • LCDR2 SEQ ID NO:18
  • LCDR3 SEQ ID NO:26.
  • the second targeting moiety comprises L-FR1
  • the C-terminus of the L-FR1 is directly or indirectly connected to the N-terminus of the LCDR1
  • the L-FR1 comprises SEQ ID NO : the amino acid sequence shown in 53.
  • the L-FR1 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:13 and SEQ ID NO:14.
  • the second targeting moiety comprises L-FR2, and the L-FR2 is located between the LCDR1 and the LCDR2, and the L-FR2 comprises SEQ ID NO:54 amino acid sequence.
  • the L-FR2 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:16 and SEQ ID NO:17.
  • the second targeting moiety comprises L-FR3, the L-FR3 is located between the LCDR2 and the LCDR3, and the L-FR3 comprises SEQ ID NO:55 amino acid sequence.
  • the L-FR3 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:19 and SEQ ID NO:20.
  • the second targeting moiety comprises L-FR4, the N-terminus of the L-FR4 is directly or indirectly connected to the C-terminus of the LCDR3, and the L-FR4 comprises SEQ ID NO : the amino acid sequence shown in 56.
  • the L-FR4 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:27 and SEQ ID NO:28.
  • the second targeting moiety comprises L-FR1, L-FR2, L-FR3 and L-FR4, and the L-FR1 comprises the amino acid sequence shown in SEQ ID NO:53; the L-FR2 comprises the amino acid sequence shown in SEQ ID NO:54; said L-FR3 comprises the amino acid sequence shown in SEQ ID NO:55; and said L-FR4 comprises the amino acid sequence shown in SEQ ID NO:56.
  • the second targeting moiety comprises L-FR1, L-FR2, L-FR3 and L-FR4, and the L-FR1 comprises any of SEQ ID NO:13 and SEQ ID NO:14
  • the amino acid sequence shown in one item the L-FR2 includes the amino acid sequence shown in any one of SEQ ID NO:16 and SEQ ID NO:17
  • the L-FR3 includes SEQ ID NO:19 and SEQ ID NO : the amino acid sequence shown in any one of 20
  • the L-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO: 27 and SEQ ID NO: 28.
  • said L-FR1, L-FR2, L-FR3, and L-FR4 in said second targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • L-FR1 SEQ ID NO:13
  • L-FR2 SEQ ID NO:16
  • L-FR3 SEQ ID NO:19
  • L-FR4 SEQ ID NO:27;
  • L-FR1 SEQ ID NO:14
  • L-FR2 SEQ ID NO:17
  • L-FR3 SEQ ID NO:20
  • L-FR4 SEQ ID NO:28.
  • the second targeting moiety comprises a VL comprising the amino acid sequence shown in any one of SEQ ID NO:58.
  • said VL in said second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:32 to SEQ ID NO:38.
  • the second targeting moiety comprises HCDR3 comprising the amino acid sequence shown in SEQ ID NO:76.
  • the second targeting moiety comprises HCDR2 comprising the amino acid sequence shown in SEQ ID NO:70.
  • the second targeting moiety comprises HCDR1 comprising the amino acid sequence shown in SEQ ID NO:61.
  • the second targeting moiety comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH shown in SEQ ID NO: 122.
  • the second targeting moiety comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH shown in any one of SEQ ID NO:95 to SEQ ID NO:104.
  • the second targeting moiety comprises a heavy chain variable region VH
  • the VH comprises the HCDR1, HCDR2 and HCDR3
  • the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:76
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:70
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:61.
  • the second targeting moiety comprises H-FR1
  • the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
  • the H-FR1 comprises SEQ ID NO : the amino acid sequence shown in 115.
  • the H-FR1 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:59 to SEQ ID NO:60.
  • the second targeting moiety comprises H-FR2
  • the H-FR2 is located between the HCDR1 and the HCDR2
  • the H-FR2 comprises SEQ ID NO: 116 amino acid sequence.
  • the H-FR2 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:62 to SEQ ID NO:69.
  • the second targeting moiety comprises H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 comprises SEQ ID NO: 117 amino acid sequence.
  • the H-FR3 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:71 to SEQ ID NO:75.
  • the second targeting moiety comprises H-FR4, the N-terminus of the H-FR4 is directly or indirectly connected to the C-terminus of the HCDR3, and the H-FR4 comprises SEQ ID NO : the amino acid sequence shown in 118.
  • the H-FR4 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:77 to SEQ ID NO:78.
  • the second targeting moiety comprises H-FR1, H-FR2, H-FR3 and H-FR4, and the H-FR1 comprises the amino acid sequence shown in SEQ ID NO: 115; the H-FR2 comprises the amino acid sequence shown in SEQ ID NO:116; the H-FR3 comprises the amino acid sequence shown in SEQ ID NO:117; and the H-FR4 comprises the amino acid sequence shown in SEQ ID NO:118.
  • the second targeting moiety comprises H-FR1, H-FR2, H-FR3 and H-FR4, and the H-FR1 comprises any of SEQ ID NO:59 to SEQ ID NO:60
  • the H-FR2 includes the amino acid sequence shown in any one of SEQ ID NO: 62 to SEQ ID NO: 69
  • the H-FR3 includes SEQ ID NO: 71 to SEQ ID NO
  • the H-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO: 77 to SEQ ID NO: 78.
  • said H-FR1, H-FR2, H-FR3 and H-FR4 in said second targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • H-FR1 SEQ ID NO:59
  • H-FR2 SEQ ID NO:62
  • H-FR3 SEQ ID NO:71
  • H-FR4 SEQ ID NO:77;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:63
  • H-FR3 SEQ ID NO:72
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:64
  • H-FR3 SEQ ID NO:73
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:65
  • H-FR3 SEQ ID NO:74
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:66
  • H-FR3 SEQ ID NO:75
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:67
  • H-FR3 SEQ ID NO:72
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:65
  • H-FR3 SEQ ID NO:72
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:64
  • H-FR3 SEQ ID NO:74
  • H-FR4 SEQ ID NO:78;
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:68
  • H-FR3 SEQ ID NO:72
  • H-FR4 SEQ ID NO:78
  • H-FR1 SEQ ID NO:60
  • H-FR2 SEQ ID NO:69
  • H-FR3 SEQ ID NO:73
  • H-FR4 SEQ ID NO:78.
  • the second targeting moiety comprises a heavy chain variable region VH comprising the amino acid sequence shown in SEQ ID NO: 122.
  • the VH comprises the amino acid sequence shown in any one of SEQ ID NO:95 to SEQ ID NO:104.
  • the second targeting moiety comprises LCDR3 comprising the amino acid sequence shown in SEQ ID NO:94.
  • the second targeting moiety comprises LCDR2 comprising the amino acid sequence shown in SEQ ID NO:87.
  • the second targeting moiety comprises LCDR1 comprising the amino acid sequence shown in SEQ ID NO:82.
  • the second targeting moiety comprises LCDR1, LCDR2 and LCDR3 of the light chain variable region VL shown in any one of SEQ ID NO:123.
  • the second targeting moiety comprises LCDR1, LCDR2 and LCDR3 of the light chain variable region VL shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111.
  • the second targeting moiety comprises a light chain variable region VL
  • the VL comprises the LCDR1, LCDR2 and LCDR3
  • the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:94
  • the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:87
  • the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:82.
  • the second targeting moiety comprises L-FR1
  • the C-terminus of the L-FR1 is directly or indirectly connected to the N-terminus of the LCDR1
  • the L-FR1 comprises SEQ ID NO : the amino acid sequence shown in 119.
  • the L-FR1 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:79 to SEQ ID NO:81.
  • the second targeting moiety comprises L-FR2
  • the L-FR2 is located between the LCDR1 and the LCDR2
  • the L-FR2 comprises SEQ ID NO: 120 amino acid sequence.
  • the L-FR2 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:83 to SEQ ID NO:86.
  • the second targeting moiety comprises L-FR3, the L-FR3 is located between the LCDR2 and the LCDR3, and the L-FR3 comprises SEQ ID NO: 121 amino acid sequence.
  • the L-FR3 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:88 to SEQ ID NO:93.
  • the second targeting moiety comprises L-FR4, the N-terminus of the L-FR4 is directly or indirectly connected to the C-terminus of the LCDR3, and the L-FR4 comprises SEQ ID NO : the amino acid sequence shown in 56.
  • the L-FR4 in the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO:27 to SEQ ID NO:28.
  • the second targeting moiety comprises L-FR1, L-FR2, L-FR3 and L-FR4, and the L-FR1 comprises the amino acid sequence shown in SEQ ID NO: 119; the L-FR2 comprises the amino acid sequence shown in SEQ ID NO:120; said L-FR3 comprises the amino acid sequence shown in SEQ ID NO:121; and said L-FR4 comprises the amino acid sequence shown in SEQ ID NO:56.
  • the second targeting moiety comprises L-FR1, L-FR2, L-FR3 and L-FR4, and the L-FR1 comprises any of SEQ ID NO:79 to SEQ ID NO:81
  • the amino acid sequence shown in one item the L-FR2 includes the amino acid sequence shown in any one of SEQ ID NO:83 to SEQ ID NO:86
  • the L-FR3 includes SEQ ID NO:88 to SEQ ID NO
  • the L-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO:27 to SEQ ID NO:28.
  • the L-FR1, L-FR2, L-FR3 and L-FR4 in the second targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • L-FR1 SEQ ID NO:79
  • L-FR2 SEQ ID NO:83
  • L-FR3 SEQ ID NO:88
  • L-FR4 SEQ ID NO:27;
  • L-FR1 SEQ ID NO:80
  • L-FR2 SEQ ID NO:84
  • L-FR3 SEQ ID NO:89
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:81
  • L-FR2 SEQ ID NO:85
  • L-FR3 SEQ ID NO:90
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:81
  • L-FR2 SEQ ID NO:85
  • L-FR3 SEQ ID NO:91
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:80
  • L-FR2 SEQ ID NO:85
  • L-FR3 SEQ ID NO:90
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:80
  • L-FR2 SEQ ID NO:85
  • L-FR3 SEQ ID NO:92
  • L-FR4 SEQ ID NO:28;
  • L-FR1 SEQ ID NO:80
  • L-FR2 SEQ ID NO:86
  • L-FR3 SEQ ID NO:93
  • L-FR4 SEQ ID NO:28.
  • the second targeting moiety comprises a VL comprising the amino acid sequence shown in SEQ ID NO: 123.
  • the VL of the second targeting moiety comprises the amino acid sequence shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111.
  • the second targeting moiety in the isolated antigen binding protein targets CD28
  • the second targeting moiety comprises VH
  • the VH comprises the amino acid sequence shown in SEQ ID NO: 176 .
  • the second targeting moiety in the isolated antigen binding protein targets CD16a
  • the second targeting moiety comprises VH
  • the VH comprises the amino acid sequence shown in SEQ ID NO: 168 .
  • the isolated antigen binding protein comprises a first targeting moiety and a second targeting moiety, the first targeting moiety comprising SEQ ID NO: 29 to SEQ ID NO: 31, SEQ ID NO :32 to the amino acid sequence shown in any one of SEQ ID NO:38, SEQ ID NO:95 to SEQ ID NO:104, and SEQ ID NO:105 to SEQ ID NO:111;
  • the second targeting moiety comprises Any of SEQ ID NO: 29 to SEQ ID NO: 31, SEQ ID NO: 32 to SEQ ID NO: 38, SEQ ID NO: 95 to SEQ ID NO: 104, and SEQ ID NO: 105 to SEQ ID NO: 111
  • the first targeting moiety and the second targeting moiety comprise an amino acid sequence selected from any of the following groups:
  • a first targeting moiety SEQ ID NO: 100 and a second targeting moiety: SEQ ID NO: 31;
  • a first targeting moiety SEQ ID NO: 102 and a second targeting moiety: SEQ ID NO: 31;
  • a first targeting moiety SEQ ID NO:31 and a second targeting moiety: SEQ ID NO:98;
  • a first targeting moiety SEQ ID NO:31 and a second targeting moiety: SEQ ID NO:102;
  • a first targeting moiety SEQ ID NO: 100 and a second targeting moiety: SEQ ID NO: 36;
  • a first targeting moiety SEQ ID NO:31 and a second targeting moiety: SEQ ID NO:176;
  • First targeting moiety SEQ ID NO: 168 and second targeting moiety: SEQ ID NO: 31.
  • the second polypeptide chain comprises a heavy chain constant region
  • the heavy chain constant region comprises an IgG-derived constant region or an IgY-derived constant region.
  • said heavy chain constant region in said second polypeptide chain comprises an IgG-derived constant region.
  • said heavy chain constant region in said second polypeptide chain comprises a constant region derived from IgGl, IgG2, IgG3 or IgG4.
  • said heavy chain constant region in said second polypeptide chain comprises an IgG1 derived Fc region.
  • the Fc region of said heavy chain constant region in said second polypeptide chain comprises a N297A mutation, and residues are numbered according to the Kabat system.
  • the Fc region in the heavy chain constant region comprises M252Y, S254T and T256E mutations, and the residues are numbered according to the Kabat system.
  • said heavy chain constant region in said second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 112 to SEQ ID NO: 113.
  • the first polypeptide chain comprises a light chain constant region
  • the light chain constant region comprises a constant region derived from Ig ⁇ or a constant region derived from Ig ⁇ .
  • the light chain constant region comprises a constant region derived from human Ig ⁇ .
  • the light chain constant region comprises the amino acid sequence shown in SEQ ID NO: 114.
  • the third targeting moiety in the isolated antigen binding protein comprises a VH comprising any one of SEQ ID NOs: 168, 170, 172, 174, 176 and 178 amino acid sequence.
  • the third targeting moiety in the isolated antigen binding protein comprises a VL comprising any one of SEQ ID NOs: 169, 171, 173, 175, 177 and 179 amino acid sequence.
  • said third targeting moiety in said isolated antigen binding protein comprises an antibody or an antigen binding fragment.
  • the antigen-binding fragment of the isolated antigen-binding protein is selected from the group consisting of Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di- scFv, VHH and dAb.
  • said third targeting moiety in said isolated antigen binding protein is a scFv.
  • the C-terminus of the VH in the third targeting moiety of the isolated antigen binding protein is directly or indirectly linked to the N-terminus of the VL.
  • the C-terminus of the VL in the third targeting moiety of the isolated antigen binding protein is directly or indirectly linked to the N-terminus of the VH.
  • said fourth targeting moiety in said isolated antigen binding protein comprises a VH comprising SEQ ID NO: 29-31, 95-104, 168, 170, 172, 174, 176 and the amino acid sequence shown in any one of 178.
  • said fourth targeting moiety in said isolated antigen binding protein comprises a VL comprising SEQ ID NO: 32-38, 105-111, 169, 171, 173, 175, 177 and the amino acid sequence shown in any one of 179.
  • said fourth targeting moiety in said isolated antigen binding protein comprises an antibody or an antigen binding fragment.
  • the antigen-binding fragment of the isolated antigen-binding protein is selected from the group consisting of Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di- scFv, VHH and dAb.
  • said fourth targeting moiety in said isolated antigen binding protein is a scFv.
  • the C-terminus of the VH of the fourth targeting moiety in the isolated antigen binding protein is directly or indirectly linked to the N-terminus of the VL.
  • the C-terminus of the VL of the fourth targeting moiety in the isolated antigen binding protein is directly or indirectly linked to the N-terminus of the VH.
  • the antigen-binding protein comprises two first polypeptide chains and two second polypeptide chains, the two first polypeptide chains are connected by a disulfide bond, and the two The first polypeptide chain and the two second polypeptide chains form an IgG-like antibody.
  • the antigen binding protein comprises a monoclonal antibody, a single chain antibody, a chimeric antibody, a humanized antibody, a multispecific antibody, a bispecific antibody and/or a fully human antibody.
  • the application provides one or more polypeptides comprising said isolated antigen binding protein.
  • the application provides one or more immunoconjugates comprising said isolated antigen binding protein or said polypeptide.
  • the present application provides one or more isolated nucleic acid molecules encoding said isolated antigen binding protein, or said polypeptide.
  • the application provides one or more vectors comprising said isolated nucleic acid molecule.
  • the application provides one or more cells comprising said isolated antigen binding protein, said polypeptide, said immunoconjugate, said isolated nucleic acid molecule and/or said carrier.
  • the present application provides a method for preparing the isolated antigen-binding protein or the polypeptide, the method comprising culturing the cells.
  • the present application provides one or more pharmaceutical compositions comprising said isolated antigen binding protein, said polypeptide, said immunoconjugate, said isolated nucleic acid molecule, said carrier, the cells, and/or pharmaceutically acceptable adjuvants and/or excipients.
  • the present application provides a method for inhibiting the interaction between PD-1 and PD-L1, which comprises administering to a subject in need an effective amount of the isolated antigen-binding protein, the polypeptide, the The immunoconjugate, the isolated nucleic acid molecule, the carrier, and/or the cell.
  • the present application provides the isolated antigen-binding protein, the polypeptide, the immunoconjugate, the isolated nucleic acid molecule, the carrier, the cell and/or the Use of the pharmaceutical composition in the preparation of medicines for preventing and/or treating diseases or conditions.
  • the disease or condition comprises a tumor.
  • the tumor comprises a solid tumor.
  • the tumor comprises a non-solid tumor.
  • the tumor comprises breast cancer, lung cancer, gastric cancer, bowel cancer, kidney cancer, melanoma, non-small cell lung cancer, colon cancer, bladder cancer, ovarian cancer, pancreatic cancer, and/or liver cancer.
  • the present application provides the isolated antigen-binding protein, the polypeptide, the immunoconjugate, the isolated nucleic acid molecule, the carrier, the cell and/or the A pharmaceutical composition for preventing, alleviating and/or treating diseases or conditions.
  • the disease or condition comprises a tumor.
  • the tumor comprises a solid tumor.
  • the tumor comprises a non-solid tumor.
  • the tumor comprises breast cancer, lung cancer, gastric cancer, bowel cancer, kidney cancer, melanoma, non-small cell lung cancer, colon cancer, bladder cancer, ovarian cancer, pancreatic cancer, and/or liver cancer.
  • the present application provides a method for preventing and/or treating a disease or disorder, comprising administering to a subject in need an effective amount of the isolated antigen-binding protein, the polypeptide, the Immunoconjugate, said isolated nucleic acid molecule, said carrier, and/or said cell.
  • the disease or condition comprises a tumor.
  • the tumor comprises a solid tumor.
  • the tumor comprises a non-solid tumor.
  • the tumor comprises breast cancer, lung cancer, gastric cancer, bowel cancer, kidney cancer, melanoma, non-small cell lung cancer, colon cancer, bladder cancer, ovarian cancer, pancreatic cancer, and/or liver cancer.
  • Figures 1A-1B show schematic structures of exemplary antigen-binding proteins described herein.
  • Figure 2 shows the binding results of the exemplary bispecific antibody described in this application to HEK293 cells with high expression of PD-1, high expression of PDL1 or wild type.
  • Figure 3 shows the results of the ELISA experiment of the exemplary bispecific antibody described in this application.
  • isolated generally means obtained from the natural state by artificial means. If an "isolated" substance or component occurs in nature, it may be that its natural environment has been altered, the substance has been isolated from its natural environment, or both. For example, an unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity isolated from this natural state is called isolation. of.
  • isolated does not exclude the admixture of artificial or synthetic substances, nor the presence of other impure substances which do not affect the activity of the substance.
  • the term “antigen-binding protein” generally refers to a polypeptide molecule capable of specifically recognizing and/or neutralizing a specific antigen.
  • the term “antigen-binding protein” may include “antibody” or "antigen-binding fragment”.
  • the antibody may comprise an immunoglobulin composed of at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, and may include any molecule comprising an antigen-binding portion thereof.
  • antibody may include monoclonal antibodies, antibody fragments or antibody derivatives, including but not limited to murine antibodies, human antibodies (fully human antibodies), humanized antibodies, chimeric antibodies, bispecific antibodies, multispecific Antibodies, single-chain antibodies (eg, scFv), and antibody fragments (eg, Fab, Fab', VHH, and (Fab)2 fragments) that bind to an antigen.
  • antibody may also include all recombinant forms of antibodies, such as antibodies expressed in prokaryotic cells, aglycosylated antibodies, and any antigen-binding antibody fragments and derivatives thereof described herein.
  • Each heavy chain can be composed of a heavy chain variable region (VH) and a heavy chain constant region.
  • Each light chain can be composed of a light chain variable region (VL) and a light chain constant region.
  • VH and VL regions can be further distinguished into hypervariable regions called complementarity determining regions (CDRs), which are interspersed in more conserved regions called framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Each VH and VL may consist of three CDR and four FR regions, which may be arranged in the following order from amino-terminus to carboxy-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
  • the variable regions of the heavy and light chains contain binding domains that interact with antigen (eg, human PD-L1).
  • the constant regions of the antibodies mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component (Clq) of the classical complement system.
  • the exact boundaries of the CDRs have been defined differently from system to system.
  • the system described by Kabat Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides a sequence that can be applied to any variable region of an antigen-binding fragment
  • a clear residue numbering system also provides the precise residue boundaries that define the CDRs. These CDRs can be referred to as Kabat CDRs.
  • the term "antigen-binding fragment” generally refers to one or more fragments of an antibody that specifically bind to an antigen.
  • the antigen-binding function of antibodies can be realized by full-length fragments of antibodies.
  • the antigen-binding function of an antibody can also be achieved by comprising a heavy chain of a fragment of Fv, ScFv, dsFv, Fab, Fab' or F(ab'), or by comprising a Fv, scFv, dsFv, Fab, Fab' or Light chain of a fragment of F(ab')2.
  • Fab fragment usually a monovalent fragment consisting of VL, VH, CL and CH domains;
  • F(ab')2 fragment comprising two Fab fragments linked by a disulfide bond at the hinge region (3) Fd fragment composed of VH and CH domains; (4) Fv fragment composed of VL and VH domains of antibody single arm; (5) dAb fragment composed of VH domains (Ward et al., (1989) Nature 341:544-546); (6) an isolated complementarity determining region (CDR) and (7) a combination of two or more isolated CDRs optionally linked by a linker.
  • CDR complementarity determining region
  • the monovalent single-chain molecule Fv formed by the pairing of VL and VH (see Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc.Natl.Acad.Sci.85 :5879-5883).
  • a type of antibody VHH that lacks the light chain of the antibody and only has the variable region of the heavy chain can also be included (for example, see Kang Xiaozhen et al., Acta Biological Engineering, 2018, 34(12): 1974-1984).
  • the "antigen binding portion” may also include an immunoglobulin fusion protein comprising a binding domain selected from: (1) a binding domain polypeptide fused to an immunoglobulin hinge region polypeptide; (2) a binding domain polypeptide fused to an immunoglobulin hinge region polypeptide; an immunoglobulin heavy chain CH2 constant region fused to the hinge region; and (3) an immunoglobulin heavy chain CH3 constant region fused to the CH2 constant region.
  • an immunoglobulin fusion protein comprising a binding domain selected from: (1) a binding domain polypeptide fused to an immunoglobulin hinge region polypeptide; (2) a binding domain polypeptide fused to an immunoglobulin hinge region polypeptide; an immunoglobulin heavy chain CH2 constant region fused to the hinge region; and (3) an immunoglobulin heavy chain CH3 constant region fused to the CH2 constant region.
  • the term "monoclonal antibody” generally refers to a population of substantially homogeneous antibodies, ie, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that are present in minor amounts.
  • Monoclonal antibodies are highly specific, directed against a single antigenic site.
  • the monoclonal antibodies can be produced by hybridoma technology or produced in bacterial, eukaryotic or plant cells by using recombinant DNA methods.
  • Monoclonal antibodies can also be obtained from phage antibody libraries using techniques such as those described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., Mol. Biol., 222:581-597 (1991) conduct.
  • chimeric antibody generally refers to an antibody in which a part of each heavy or light chain amino acid sequence is homologous to the corresponding amino acid sequence in an antibody from a specific species, or belongs to a specific class, and The remainder of the chain is then homologous to the corresponding sequence in another species.
  • the variable regions of both the light and heavy chains are derived from the variable regions of antibodies from one animal species (e.g., mouse, rat, etc.), while the constant portions are homologous to antibody sequences from another species (e.g., human) .
  • B cells or hybridoma cells of non-human origin can be used to produce variable regions combined with constant regions of human origin.
  • variable region has the advantage of being easy to prepare and its specificity is not affected by the source of the constant region it is combined with.
  • the constant region of the chimeric antibody can be derived from humans, the possibility of the chimeric antibody triggering an immune response when injected is lower than that of an antibody whose constant region is of non-human origin.
  • humanized antibody generally refers to a chimeric antibody that contains less sequence from a non-human immunoglobulin, thereby reducing the immunogenicity of a heterologous antibody when introduced into a human, while simultaneously Preserves the full antigen-binding affinity and specificity of the antibody.
  • CDR grafting (Jones et al., Nature 321:522 (1986)) and variants thereof; including “reshaping", (Verhoeyen, et al., 1988 Science 239:1534-1536; Riechmann , et al., 1988 Nature 332:323-337; Tempest, et al., Bio/Technol 1991 9:266-271), "high addition” (hyperchimerization), (Queen, et al., 1989 Proc Natl Acad Sci USA 86:10029-10033; Co, et al., 1991 Proc Natl Acad Sci USA 88:2869-2873; Co, et al., 1992 J Immunol 148:1149-1154) and "veneering", (Mark, et al., "Derivation of therapeutically active humanized and veneered anti-CD18 antibodies.” In: Metcalf B W, Dalton B J, eds.
  • murine antibody generally refers to an antibody whose variable region framework and CDR regions are derived from mouse germline immunoglobulin sequences. In addition, if the antibody comprises a constant region, these also are derived from mouse germline immunoglobulin sequences.
  • the murine antibody of the present application may contain amino acid residues not encoded by mouse germline immunoglobulin sequences, for example, may include mutations introduced by random or point mutations in vitro or by somatic mutations in vivo.
  • bispecific antibody generally refers to an antibody or antigen-binding fragment that contains two specific antigen-binding sites.
  • bispecific antibodies can be homodimers or heterodimers.
  • the bispecific antibody can bind to PD-1 protein and PD-L1 protein, can effectively inhibit the activation of PD-L1 and PD-1, and then treat PD1/PD-L1 related diseases (for example, tumor).
  • PD-L1 generally refers to the programmed death-ligand 1 protein, its functional variants and/or its functionally active fragments.
  • PD-L1 is also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), and is a protein encoded by the CD274 gene (in humans).
  • CD274 cluster of differentiation 274
  • B7-H1 B7 homolog 1
  • PD-L1 binds to its receptors, such as programmed death 1 (PD-1), which is expressed in activated T cells, B cells, and macrophages (Ishida et al., 1992 EMBO J, 11: 3887-3395; Okazaki et al., Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
  • PD-1 programmed death 1
  • PD-L1 encompasses any native PD-L1 of any vertebrate origin, including mammals, such as primates (eg, humans) and rodents (eg, mice and rats).
  • the term encompasses "full length", unprocessed PD-L1 as well as any form of PD-L1 that results from processing in the cell.
  • PD-L1 can exist as a transmembrane protein or as a soluble protein.
  • the term also encompasses naturally occurring variants of PD-L1, such as splice variants or allelic variants.
  • the amino acid sequence of an exemplary full-length human PD-L1 protein can be found under UniProt accession number Q9NZQ7.
  • such “functionally active fragments” may include fragments that retain at least one endogenous function of a naturally occurring protein (eg, binding to an antigen binding protein described herein).
  • the “functionally active fragment” may include a domain that binds to the antigen-binding protein of the present application.
  • PD-1 protein protein
  • PD-1 PD-1 antigen
  • PD-1 may be human PD-1, whose accession number in UniProt/Swiss-Prot is Q15116.
  • PD-1 can be a functionally active fragment of human PD-1.
  • such "functionally active fragments” may include fragments that retain at least one endogenous function of a naturally occurring protein (eg, binding to an antigen binding protein described herein).
  • the "functionally active fragment” may include a domain that binds to the antigen-binding protein of the present application.
  • the present application may also include functionally active fragments, derivatives, analogs, homologues and fragments thereof.
  • a functionally active fragment refers to a polypeptide having substantially the same amino acid sequence or encoded by a substantially identical nucleotide sequence as the naturally occurring sequence and capable of possessing one or more activities of the naturally occurring sequence.
  • a functionally active fragment of any given sequence is one in which a specific sequence of residues (whether amino acid or nucleotide residues) has been modified such that the polypeptide or polynucleotide substantially retains at least A sequence of endogenous function.
  • Sequences encoding functionally active fragments can be obtained by addition, deletion, substitution, modification, substitution and/or variation of at least one amino acid residue and/or nucleotide residue present in naturally occurring proteins and/or polynucleotides , as long as the original functional activity is maintained.
  • derivative generally refers to any substitution, variation, modification, substitution, deletion and/or Or addition, so long as the resulting polypeptide or polynucleotide substantially retains at least one of its endogenous functions.
  • analogue generally refers to polypeptides or polynucleotides, including any mimetic of polypeptides or polynucleotides, that is, having at least one endogenous function of the polypeptide or polynucleotide simulated by the mimetic of chemical compounds.
  • amino acid substitutions e.g., at least 1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 20) amino acid substitutions can be made so long as the modified sequence remains substantially as desired. activity or ability. Amino acid substitutions may involve the use of non-naturally occurring analogs.
  • homologue generally refers to an amino acid sequence or nucleotide sequence having a certain homology to a naturally occurring sequence.
  • the term “homology” may be equated with sequence "identity”.
  • homologous sequences may include amino acid sequences that may be at least 80%, 85%, 90%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to the subject sequence .
  • a homologue will comprise the same active site, etc., as the subject amino acid sequence.
  • Homology can be considered in terms of similarity (ie, amino acid residues having similar chemical properties/functions), or can be expressed in terms of sequence identity.
  • sequence having a percentage identity of any one of the SEQ ID NOs of the mentioned amino acid sequence or nucleotide sequence means having said percentage identity over the entire length of the mentioned SEQ ID NO the sequence of.
  • sequence alignment can be performed by various means known to those skilled in the art, for example, using BLAST, BLAST-2, ALIGN, NEEDLE or Megalign (DNASTAR) software and the like. Those skilled in the art can determine appropriate parameters for alignment, including any algorithms needed to achieve optimal alignment across the full-length sequences being compared.
  • proteins or polypeptides used in this application may also have deletions, insertions, or substitutions of amino acid residues that produce silent changes and result in functionally equivalent proteins.
  • Deliberate amino acid substitutions can be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or amphipathic nature of the residues, so long as endogenous function is preserved.
  • negatively charged amino acids include aspartic acid and glutamic acid
  • positively charged amino acids include lysine and arginine
  • amino acids with uncharged polar headgroups with similar hydrophilicity values include aspartic acid.
  • Paragine, Glutamine, Serine, Threonine and Tyrosine are examples of amino acid residues that produce silent changes and result in functionally equivalent proteins.
  • the term "tumor” generally refers to a neoplasm formed by the proliferation of local tissue cells under the action of various tumorigenic factors.
  • the tumor can include a solid tumor.
  • the tumor can include a non-solid tumor.
  • the tumor can include a tumor associated with expression of PD-L1.
  • the term "tumor associated with the expression of PD-L1” generally refers to a tumor formed due to changes in the expression of PD-L1 leading to disease progression or escape from immune surveillance.
  • the "tumor associated with the expression of PD-L1" may be a tumor formed by the upregulation of PD-L1 expression leading to disease progression or escape from immune surveillance.
  • the tumor associated with the protein expression of PD-L1 may be a PD-L1 positive tumor.
  • the protein expression of PD-L1 on the surface of tumor cells or in the tumor microenvironment is about 1%, 5%, 10%, 15%, 20%, 25% higher , 30%, 35%, 40%, 50%, 60%, 70%, 80% or higher.
  • the term "solid tumor” generally refers to a tangible mass that can be detected clinically (eg, X-ray film, CT scan, B-ultrasound or palpation).
  • the solid tumor may include breast cancer, lung cancer, gastric cancer, bowel cancer, renal cancer, melanoma, non-small cell lung cancer, colon cancer, bladder cancer, ovarian cancer, pancreatic cancer, and/or liver cancer.
  • non-solid tumor generally refers to a tumor that cannot be seen or touched by X-ray films, CT scans, B-ultrasound and palpation.
  • the non-solid tumor can include leukemia.
  • the non-solid tumor can include lymphoma.
  • the non-solid tumor can include multiple myeloma.
  • tumor-associated antigen generally refers to an antigenic molecule present on tumor cells or normal cells.
  • the tumor-associated antigen may be present in normal cells in a small amount, but highly expressed in tumor cells.
  • the tumor-associated antigens may include, but are not limited to, embryonic proteins, glycoprotein antigens, and/or squamous cell antigens.
  • the tumor-associated antigens may include CD19, CD20, CD47, HER2, EGFR, CD22 and/or PD-L1.
  • the term "immune cell-associated antigen” generally refers to antigenic molecules present on immune cells.
  • the immune cell-associated antigens may include antigens associated with immunosuppression (eg, PD-1 antigen).
  • the immune cell-associated antigens may include T cell or NK cell antigens (eg, CD3, CD16a, etc.).
  • cytokines generally refers to a class of cytokines that are synthesized and secreted by immune cells and certain non-immune cells (such as endothelial cells, epidermal cells, fibroblasts, etc.) after stimulation, and have a wide range of biological activities. of small molecular proteins.
  • the cytokines can modulate the immune response by binding to the corresponding receptors to regulate cell growth, differentiation and effects.
  • the cytokines may include, but are not limited to, interleukins (e.g., IL-2, IL-7, IL-15, etc.), interferons (e.g., IFNa, IFNb), tumor necrosis factor superfamily, colony-stimulating factor , chemokines, growth factors, etc.
  • the cytokines can include variants of interleukins (e.g., IL-2 variants R38A, I80F, R81D, L85V, I86V, I92F, which bind to the IL-2 ⁇ receptor and bind to the IL-2 ⁇ receptor weak bonding).
  • the cytokines may include interferon variants (eg, IFN ⁇ variant R144A mutant, which has significantly reduced binding to the IFNAR2 receptor, which reduces the toxic side effects of IFN ⁇ ).
  • the term “immunoconjugate” generally refers to a conjugate formed by conjugating (for example, covalently linking through a linker molecule) the other therapeutic agent to the isolated antigen-binding protein, the conjugate
  • the other therapeutic agent can be delivered to a target cell (eg, a tumor cell) by specific binding of the isolated antigen binding protein to an antigen on the target cell.
  • the antigen may also be secreted by the target cell and located in the space outside the target cell.
  • subject generally refers to human or non-human animals, including but not limited to cats, dogs, horses, pigs, cows, sheep, rabbits, mice, rats or monkeys.
  • nucleic acid molecule generally refers to an isolated form of nucleotides, deoxyribonucleotides or ribonucleotides or analogs thereof of any length isolated from their natural environment or artificially synthesized.
  • the term "vector” generally refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • the vectors can transfer inserted nucleic acid molecules into and/or between cells.
  • the vectors may include vectors mainly used for inserting DNA or RNA into cells, vectors mainly used for replicating DNA or RNA, and vectors mainly used for expression of transcription and/or translation of DNA or RNA.
  • the vector may be a polynucleotide capable of being transcribed and translated into a polypeptide when introduced into a suitable cell.
  • the vector produces the desired expression product by culturing appropriate cells containing the vector.
  • the vector may comprise a lentiviral vector.
  • the term "cell” generally refers to an individual cell that can or has contained a plasmid or vector comprising a nucleic acid molecule described herein, or is capable of expressing a polypeptide described herein or an antigen binding protein described herein , cell line or cell culture.
  • the cells may include progeny of a single cell. Due to natural, accidental or deliberate mutations, the progeny cells may not necessarily be completely identical in morphology or genome to the original parent cells, but it is sufficient to be able to express the polypeptide or antigen-binding protein described in this application.
  • the cells can be obtained by transfecting cells in vitro with the vectors described in this application.
  • the cells can be prokaryotic cells (such as Escherichia coli) or eukaryotic cells (such as yeast cells, such as COS cells, Chinese hamster ovary (CHO) cells, HeLa cells, HEK293 cells, COS-1 cells, NSO cells or myeloma cells).
  • the cells can be immune cells.
  • the immune cells may be selected from the group consisting of T cells, B cells, natural killer cells (NK cells), macrophages, NKT cells, monocytes, dendritic cells, granulocytes, lymphocytes, leukocytes and / or peripheral blood mononuclear cells.
  • treating generally refers to: (i) preventing a disease, disorder and/or condition from occurring in a patient who may be predisposed to it but has not been diagnosed with it; (ii) inhibiting the disease , disorder or condition, i.e. arresting its development; and (iii) relieving the disease, disorder or condition, i.e. making the disease, disorder and/or condition and/or symptoms associated with the disease, disorder and/or condition subside.
  • polypeptide polypeptide
  • peptide protein
  • protein protein
  • proteins are used interchangeably and generally refer to a polymer of amino acids of any length.
  • the polymer can be linear or branched, it can contain modified amino acids, and it can be interrupted by non-amino acids. These terms also encompass amino acid polymers that have been modified. These modifications may include: disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation (such as binding to a labeling component).
  • amino acid includes natural and/or unnatural or synthetic amino acids, including glycine and D and L optical isomers, as well as amino acid analogs and peptidomimetics.
  • polynucleotide used interchangeably and generally refer to nucleosides of any length
  • a polymeric form of an acid such as deoxyribonucleotides or ribonucleotides, or analogs thereof.
  • a polynucleotide can have any three-dimensional structure and can perform any function, known or unknown.
  • polynucleotides coding or non-coding regions of a gene or gene fragment, multiple loci (one locus) defined by junctional analysis, exons, introns, messenger RNA (mRNA), Transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), micro-RNA (miRNA), ribozyme, cDNA, recombinant polynucleotide, branched polynucleotide, plasmid, vector, any sequence Isolated DNA of any sequence, isolated RNA, nucleic acid probes, and primers.
  • mRNA messenger RNA
  • Transfer RNA Transfer RNA
  • ribosomal RNA short interfering RNA
  • shRNA short hairpin RNA
  • miRNA micro-RNA
  • ribozyme ribozyme
  • cDNA recombinant polynucleotide
  • branched polynucleotide plasmid
  • vector any
  • a polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modification of the nucleotide structure can be performed before or after polymer assembly. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides can be further modified after polymerization, such as by conjugation with labeled components.
  • K D (likewise, “K D " or “K D ”) generally refers to "affinity constant” or “equilibrium dissociation constant” and refers to a titration measurement at equilibrium, or Value obtained by dividing the dissociation rate constant (kd) by the association rate constant (ka).
  • a binding protein e.g., an isolated antigen-binding protein described herein
  • an antigen e.g., PD-L1 protein, binding affinity of PD-1 protein.
  • the KD value can be determined by Biacore (Biomolecular Interaction Analysis) (for example, an instrument available from BIAcore International AB, a GE Healthcare company, Uppsala, Sweden), and other experimental approaches and instruments such as Octet can also be used.
  • the KD value can also be determined using KinExA (Kinetic Exclusion Assay) available from Sapidyne Instruments (Boise, Idaho), or using a surface plasmon resonance (SPR) instrument.
  • the KD value can also be determined by an amine coupling kit.
  • the term "about” generally refers to a range of 0.5%-10% above or below the specified value, such as 0.5%, 1%, 1.5%, 2%, 2.5%, above or below the specified value. 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%.
  • the application provides an isolated antigen-binding protein, which may comprise a first polypeptide chain, a second polypeptide chain, the first polypeptide chain includes a first targeting moiety, and the second polypeptide chain Comprising a second targeting moiety, the first targeting moiety and the second targeting moiety independently bind PD-1 protein or PD-L1 protein, and the first targeting moiety and the second targeting moiety bind Different from the protein, the first polypeptide chain is connected to the second polypeptide chain through a disulfide bond.
  • the antigen binding protein can comprise the exemplary structures shown in Figures 1A-1B.
  • the CDR of an antibody is also called complementarity determining region, which is a part of the variable region.
  • the amino acid residues in this region may make contacts with the antigen or antigenic epitope.
  • Antibody CDRs can be determined by a variety of coding systems, such as CCG, Kabat, Chothia, IMGT, AbM, comprehensive consideration of Kabat/Chothia, etc. These numbering systems are known in the art, see, for example, http://www.bioinf.org.uk/abs/index.html#kabatnum. Those skilled in the art can use different coding systems to determine the CDR region according to the sequence and structure of the antibody. There may be differences in the CDR regions using different coding systems.
  • the CDR covers the CDR sequence divided according to any CDR division method; also covers its variants, the variants include the amino acid sequence of the CDR through substitution, deletion and/or addition of one or more amino acids .
  • the variants include the amino acid sequence of the CDR through substitution, deletion and/or addition of one or more amino acids .
  • amino acids For example 1-30, 1-20 or 1-10, and for example 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid substitutions, deletions and/or or insertions; homologues thereof, which may be at least about 85% (e.g., at least about 85%, about 90%, about 91%, about 92%, Amino acid sequences having about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) sequence homology.
  • the isolated antigen binding proteins described herein are defined by the Kabat coding system.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody can specifically bind PD-L1 protein
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody Can specifically bind PD-1 protein
  • the HCDR3 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:76.
  • the HCDR3 sequence of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR2 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:70.
  • the HCDR2 sequence of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:61.
  • the HCDR1 sequence of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:61; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:70 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:76.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibody 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM or have the same HCDR3 (e.g., have the same HCDR1-3) antigen-binding fragments.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise a heavy chain variable region, and the heavy chain variable region may comprise the amino acid sequence shown in SEQ ID NO:122 .
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody comprises VH.
  • the VH has one or more amino acids selected from the group consisting of Amino acid substitutions (eg, conservative amino acid substitutions, etc.): X 5 , X 7 , X 10 , X 11 , X 12 , X 16 , X 20 , X 37 , X 38 , X 40 , X 46 , X 48 , X 67 , X 68 , X 69 , X 75 , X 81 , X 86 , X 90 , X 115 and X 116 .
  • Amino acid substitutions eg, conservative amino acid substitutions, etc.
  • the heavy chain variable region of the first targeting portion in the first polypeptide chain of the bispecific antibody may comprise amino acids shown in any one of SEQ ID NO:95 to SEQ ID NO:104 sequence.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise at least one CDR in the VL of the light chain variable region, and the VL may comprise the CDR shown in SEQ ID NO: 123. amino acid sequence.
  • the VL in the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111.
  • the LCDR of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be divided in any form, as long as VL is consistent with any one of SEQ ID NO:105 to SEQ ID NO:111
  • the amino acid sequences shown are the same, and the LCDR obtained by dividing in any form can fall within the scope of protection of the present application.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise a light chain variable region VL, and the VL may comprise at least one, at least two, of LCDR1, LCDR2 and LCDR3 or at least three.
  • the LCDR3 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:94.
  • the LCDR3 of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • LCDR2 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:87.
  • LCDR2 of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:82.
  • LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:82; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:87 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:94.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibody 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM or have the same LCDR3 (e.g., Antigen-binding fragments having the same LCDR1-3) as it.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the light chain variable region VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:123.
  • the VL of the first targeting moiety in the first polypeptide chain of the bispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (e.g., conservative amino acid substitutions, etc.): X7 , X8 , X15 , X22 , X41 , X42 , X43 , X44 , X46 , X60 , X71 , X72 , X77 , X79 , X 80 , X 83 , X 87 and X 104 .
  • DIQMTQX 7 X 8 SSLSASX 15 GDRVTIX 22 CRASQDISKYLNWYQQKPX 41 X 42 X 43 X 44 KX 46 LIYYTSRLHSGVPX 60 RFSGSGTDX 71 X 72 LTISX 77 LX 79 X 80 EDX 83 ATYX 87 CQQGDTLPWTFGGGTKX 104 EIK(SEQ ID NO:123), ⁇ ,X 7 ⁇ is S or T, X 8 can be P or T, X 15 can be L or V, X 22 can be S or T, X 41 can be D or G, X 42 can be G or K, X 43 can be A or T, X 44 can be P or V, X 46 can be F or L, X 60 can be A or S, X 71 can be F or Y, X 72 can be F or T, X 77 can be N or S , X 79 can be E or Q, X 80
  • the light chain variable region of the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise amino acids shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111 sequence.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise a light chain constant region, which may include a constant region derived from Ig ⁇ or a constant region derived from Ig ⁇ . district.
  • the light chain constant region may comprise a constant region derived from Ig ⁇ .
  • the light chain constant region of the first targeting moiety in the first polypeptide chain of the bispecific antibody comprises the amino acid sequence shown in any one of SEQ ID NO:114.
  • the first polypeptide chain may comprise the amino acid sequence shown in any one of SEQ ID NO: 134 to 140, SEQ ID NO: 144 to 153.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:51.
  • the HCDR3 sequence of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR3 of the second targeting part in the second polypeptide chain of the bispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (eg, conservative amino acid substitutions, etc.): X 1 .
  • X 1 HYGTSPFVY (SEQ ID NO: 51), wherein, wherein, X 1 can be D or E.
  • the HCDR3 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:9 and SEQ ID NO:10.
  • the HCDR3 sequence of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR2 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:6.
  • the HCDR2 sequence of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3.
  • the HCDR1 sequence of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:6 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:9.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibodies 19D4F1, hu19D4-25, 19D4-25-1A3, 19D4-25-1B3, 19D4-25-1C2, 19D4-25 - 1E4, 19D4-25-2E10 or an antigen-binding fragment thereof having the same HCDR3 (eg, having the same HCDR1-3).
  • the HCDR1 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:6 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:10.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-3C11, 19D4-25-1C2-3C11 or have the same HCDR3 (eg, have the same HCDR1- 3) The antigen-binding fragment.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise a heavy chain variable region, and the heavy chain variable region may comprise the amino acid sequence shown in SEQ ID NO:52 .
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody comprises VH, and compared with the sequence shown in SEQ ID NO:52, the VH has one or more amino acids selected from the group consisting of Amino acid substitutions (eg, conservative amino acid substitutions, etc.): X 1 , X 5 , X 13 , X 16 , X 17 , X 20 , X 37 , X 48 , X 67 , X 68 , X 73 , X 76 , X 79 , X 82 , X 83 , X 85 , X 86 , X 87 , X 88 , X 92 , X 98 and X 118 .
  • the heavy chain variable region of the second targeting portion in the second polypeptide chain of the bispecific antibody may comprise amino acids shown in any one of SEQ ID NO:29 to SEQ ID NO:31 sequence.
  • the second polypeptide chain comprises the amino acid sequence shown in any one of SEQ ID NO:39 and SEQ ID NO:40.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise at least one CDR in the VL of the light chain variable region of the antibody, and the VL may comprise SEQ ID NO:58 amino acid sequence.
  • the VL may comprise the amino acid sequence shown in any one of SEQ ID NO:32 to SEQ ID NO:38.
  • the LCDR of the second targeting moiety in the second polypeptide chain of the isolated bispecific antibody can be divided in any form, as long as VL is related to any one of SEQ ID NO:32 to SEQ ID NO:38
  • the amino acid sequences shown in the items are the same, and the LCDR obtained by dividing in any form can fall within the protection scope of the present application.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise a light chain variable region VL, and the VL may comprise at least one, at least two, of LCDR1, LCDR2 and LCDR3 or at least three.
  • the LCDR3 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:57.
  • the LCDR3 of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR3 of the second targeting part in the second polypeptide chain of the bispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (eg, conservative amino acid substitutions, etc.): X 1 , X 4 , X 5 , X 7 and X 9 .
  • X 1 QSX 4 X 5 VX 7 WX 9 (SEQ ID NO: 57), wherein, X 1 can be Q or S, X 4 can be K, L or S, X 5 can be E, H, K or R, X 7 can be N or P, and X 9 can be S or T.
  • the LCDR3 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:21 to SEQ ID NO:26.
  • the LCDR3 of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR2 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:18.
  • LCDR2 of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:15.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:21.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 19D4F1, hu19D4-25, 19D4-25-3C11 or an antibody having the same LCDR3 (e.g., having the same LCDR1-3) Antigen-binding fragments.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:22.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-1A3 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:23.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-1B3 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:24.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-1C2, 19D4-25-1C2-3C11 or have the same LCDR3 (e.g., have the same LCDR1-3 ) antigen-binding fragment.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 25.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-1E4 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:26.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-2E10 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise the light chain variable region VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:58.
  • the VL of the second targeting moiety in the second polypeptide chain of the bispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (e.g., conservative amino acid substitutions, etc.): X 7 , X 9 , X 12 , X 14 , X 15 , X 18 , X 20 , X 41 , X 49 , X 64 , X 76 , X 78 , X 80 , X 81 , X 82 , X 84 , X 85 , X 87 , X 88 , X 89 , X 93 , X 96 , X 97 , X 99 , X
  • DIVLTQX 7 PX 9 SLX 12 VX 14 X 15 GQX 18 AX 20 ISCRASESVDNYGISFMNWFX 41 QKPGQPP X 49 LLIYAASNQGSGVPX 64 RFSGSGSGTDFX 76 LX 78 IX 80 X 81 X 82 EX 84 X 85 DX 8X S9 V9 V9 X 93 X 93 X FC WX 101 FGGGTKX 108 EIK (SEQ ID NO: 58), wherein, X 7 can be S or T, X 9 can be A or L, X 12 can be A or S, X 14 can be S or T, X 15 can be is L or P, X 18 can be P or R, X 20 can be S or T, X 41 can be L or Q, X 49 can be K or Q, X 64 can be A or D, X 76 can be S Or T, X 78 can be K or N, X 80 can be H or
  • the light chain variable region of the second targeting portion in the second polypeptide chain of the bispecific antibody may comprise amino acids shown in any one of SEQ ID NO:32 to SEQ ID NO:38 sequence.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise a heavy chain constant region, which may comprise a constant region derived from IgG or a constant region derived from IgY. district.
  • the heavy chain constant region of the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequences shown in SEQ ID NO: 112 to SEQ ID NO: 113.
  • the second polypeptide chain may comprise the amino acid sequence shown in any one of SEQ ID NO:39 to SEQ ID NO:40, SEQ ID NO:154 to SEQ ID NO:160.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise any one of SEQ ID NO: 95 to SEQ ID NO: 104, SEQ ID NO: 105 to SEQ ID NO: 111.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise any one of SEQ ID NO:29 to SEQ ID NO:31, SEQ ID NO:32 to SEQ ID NO:38 Amino acid sequence shown.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 97
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 98
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 100
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 102
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 103
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 97
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 98
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 100
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 102
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 103
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:146
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:40.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:147
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:40.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:149
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:40.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:151
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:40.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:152
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:40.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:146
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:158.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:147
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:158.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:149
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:158.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:151
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:158.
  • the bispecific antibody can comprise a first polypeptide chain and a second polypeptide chain.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:152
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:158.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody can specifically bind to the PD-1 protein
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody Some can specifically bind PD-L1 protein.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:51.
  • the HCDR3 sequence of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR3 of the first targeting part in the first polypeptide chain of the bispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (eg, conservative amino acid substitutions, etc.): X 1 .
  • X 1 HYGTSPFVY (SEQ ID NO: 51), wherein X 1 can be D or E.
  • the HCDR3 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:9 and SEQ ID NO:10.
  • the HCDR3 sequence of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR2 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:6.
  • the HCDR2 sequence of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3.
  • the HCDR1 sequence of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:6 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:9.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibodies 19D4F1, hu19D4-25, 19D4-25-1A3, 19D4-25-1B3, 19D4-25-1C2, 19D4-25 - 1E4, 19D4-25-2E10 or an antigen-binding fragment thereof having the same HCDR3 (eg, having the same HCDR1-3).
  • the HCDR1 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:6 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:10.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-3C11, 19D4-25-1C2-3C11 or have the same HCDR3 (eg, have the same HCDR1- 3) The antigen-binding fragment.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise a heavy chain variable region, and the heavy chain variable region may comprise the amino acid sequence shown in SEQ ID NO:52 .
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody comprises VH.
  • the VH has one or more amino acids selected from the group consisting of Amino acid substitutions (eg, conservative amino acid substitutions, etc.): X 1 , X 5 , X 13 , X 16 , X 17 , X 20 , X 37 , X 48 , X 67 , X 68 , X 73 , X 76 , X 79 , X 82 , X 83 , X 85 , X 86 , X 87 , X 88 , X 92 , X 98 and X 118 .
  • Amino acid substitutions eg, conservative amino acid substitutions, etc.
  • the heavy chain variable region of the first targeting portion in the first polypeptide chain of the bispecific antibody may comprise amino acids shown in any one of SEQ ID NO:29 to SEQ ID NO:31 sequence.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise at least one CDR in the antibody light chain variable region VL, and the VL may comprise SEQ ID NO:58 amino acid sequence.
  • the VL of the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:32 to SEQ ID NO:38.
  • the LCDR of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be divided in any form, as long as VL is consistent with any one of SEQ ID NO:32 to SEQ ID NO:38
  • the amino acid sequences shown are the same, and the LCDR obtained by dividing in any form can fall within the scope of protection of the present application.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise a light chain variable region VL, and the VL may comprise at least one, at least two, of LCDR1, LCDR2 and LCDR3 or at least three.
  • the LCDR3 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:57.
  • the LCDR3 of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR3 of the first targeting part in the first polypeptide chain of the bispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (eg, conservative amino acid substitutions, etc.): X 1 , X 4 , X 5 , X 7 and X 9 .
  • X 1 QSX 4 X 5 VX 7 WX 9 (SEQ ID NO: 57), wherein, X 1 can be Q or S, X 4 can be K, L or S, X 5 can be E, H, K or R, X 7 can be N or P, and X 9 can be S or T.
  • the LCDR3 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:21 to SEQ ID NO:26.
  • the LCDR3 of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR2 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:18.
  • LCDR2 of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • LCDR1 of the first targeting part in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:15.
  • LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:21.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibodies 19D4F1, hu19D4-25, 19D4-25-3C11 or antibodies having the same LCDR3 (eg, having the same LCDR1-3) Antigen-binding fragments.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:22.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-1A3 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:23.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-1B3 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:24.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-1C2, 19D4-25-1C2-3C11 or have the same LCDR3 (e.g., have the same LCDR1-3 ) antigen-binding fragment.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:25.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-1E4 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO: 15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 18. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:26.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise antibody 19D4-25-2E10 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the light chain variable region VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:58.
  • the VL of the first targeting moiety in the first polypeptide chain of the bispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (e.g., conservative amino acid substitutions, etc.): X 7 , X 9 , X 12 , X 14 , X 15 , X 18 , X 20 , X 41 , X 49 , X 64 , X 76 , X 78 , X 80 , X 81 , X 82 , X 84 , X 85 , X 87 , X 88 , X 89 , X 93 , X 96 , X 97 , X 99 , X
  • DIVLTQX 7 PX 9 SLX 12 VX 14 X 15 GQX 18 AX 20 ISCRASESVDNYGISFMNWFX 41 QKPGQPPX 49 LLIYAASNQGSGVPX 64 RFSGSGSGTDFX 76 LX 78 IX 80 X 81 X 82 EX 84 X 85 DX 87 X 88 X 89 YFCX 93 QSX 96 X 97 VX 99 WX 101 FGGGTKX 108 EIK (SEQ ID NO:58), wherein, X 7 can be S or T, X 9 can be A or L, X 12 can be A or S, X 14 can be S or T, X 15 can be L Or P, X 18 can be P or R, X 20 can be S or T, X 41 can be L or Q, X 49 can be K or Q, X 64 can be A or D, X 76 can be S or T , X 78 can be K or N,
  • the light chain variable region of the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise amino acids shown in any one of SEQ ID NO:32 to SEQ ID NO:38 sequence.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise a light chain constant region, which may include a constant region derived from Ig ⁇ or a constant region derived from Ig ⁇ . district.
  • the light chain constant region may comprise a constant region derived from Ig ⁇ .
  • the light chain constant region of the first targeting moiety in the first polypeptide chain of the bispecific antibody comprises the amino acid sequence shown in SEQ ID NO:114.
  • the first polypeptide chain comprises the amino acid sequence shown in any one of SEQ ID NO:141 to 143, SEQ ID NO:41 to SEQ ID NO:46.
  • the HCDR3 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:76.
  • the HCDR3 sequence of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR2 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:70.
  • the HCDR2 sequence of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:61.
  • the HCDR1 sequence of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:61; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:70 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:76.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM or have the same HCDR3 (e.g., have the same HCDR1-3) antigen-binding fragments.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise a heavy chain variable region, and the heavy chain variable region may comprise the amino acid sequence shown in SEQ ID NO:122 .
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody comprises VH, and compared with the sequence shown in SEQ ID NO: 122, the VH has one or more amino acids selected from the group consisting of Amino acid substitutions (eg, conservative amino acid substitutions, etc.): X 5 , X 7 , X 10 , X 11 , X 12 , X 16 , X 20 , X 37 , X 38 , X 40 , X 46 , X 48 , X 67 , X 68 , X 69 , X 75 , X 81 , X 86 , X 90 , X 115 and X 116 .
  • the heavy chain variable region of the second targeting portion in the second polypeptide chain of the bispecific antibody may comprise amino acids shown in any one of SEQ ID NO:95 to SEQ ID NO:104 sequence.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise at least one CDR in the VL of the light chain variable region of the antibody, and the VL may comprise SEQ ID NO: 123 amino acid sequence.
  • the VL in the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111.
  • the LCDR of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be divided in any form, as long as VL is consistent with any one of SEQ ID NO:105 to SEQ ID NO:111
  • the amino acid sequences shown are the same, and the LCDR obtained by dividing in any form can fall within the scope of protection of the present application.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise a light chain variable region VL, and the VL may comprise at least one, at least two, of LCDR1, LCDR2 and LCDR3 or at least three.
  • the LCDR3 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:94.
  • the LCDR3 of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR2 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:87.
  • LCDR2 of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the second targeting part in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:82.
  • LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the bispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:82; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:87. Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:94.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise antibody 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM or have the same LCDR3 (e.g., Antigen-binding fragments having the same LCDR1-3) as it.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise the light chain variable region VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:123.
  • the VL of the second targeting moiety in the second polypeptide chain of the bispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (e.g., conservative amino acid substitutions, etc.): X7 , X8 , X15 , X22 , X41 , X42 , X43 , X44 , X46 , X60 , X71 , X72 , X77 , X79 , X 80 , X 83 , X 87 and X 104 .
  • DIQMTQX 7 X 8 SSLSASX 15 GDRVTIX 22 CRASQDISKYLNWYQQKPX 41 X 42 X 43 X 44 KX 46 LIYYTSRLHSGVPX 60 RFSGSGTDX 71 X 72 LTISX 77 LX 79 X 80 EDX 83 ATYX 87 CQQGDTLPWTFGGGTKX 104 EIK(SEQ ID NO:123), ⁇ ,X 7 ⁇ is S or T, X 8 can be P or T, X 15 can be L or V, X 22 can be S or T, X 41 can be D or G, X 42 can be G or K, X 43 can be A or T, X 44 can be P or V, X 46 can be F or L, X 60 can be A or S, X 71 can be F or Y, X 72 can be F or T, X 77 can be N or S , X 79 can be E or Q, X 80
  • the light chain variable region of the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise amino acids shown in any one of SEQ ID NO:105 to SEQ ID NO:111 sequence.
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise a heavy chain constant region, which may comprise a constant region derived from IgG or a constant region derived from IgY. district.
  • the heavy chain constant region of the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise the amino acid sequences shown in SEQ ID NO: 112 to SEQ ID NO: 113.
  • the second polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 124 to 133, SEQ ID NO: 161 to SEQ ID NO: 167.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise any one of SEQ ID NO:29 to SEQ ID NO:31, SEQ ID NO:32 to SEQ ID NO:38.
  • the amino acid sequence shown, the second targeting moiety in the second polypeptide chain of the bispecific antibody may comprise any of SEQ ID NO:95 to SEQ ID NO:104, SEQ ID NO:105 to SEQ ID NO:111 Amino acid sequence shown in one item.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:97.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:98.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:100.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:102.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:103.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:97.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:98.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:100.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:102.
  • the bispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the bispecific antibody and a second targeting moiety in the second polypeptide chain of the bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:103.
  • the bispecific antibody may comprise the two aforementioned first polypeptide chains and the two aforementioned second polypeptide chains.
  • the two aforementioned first polypeptide chains may be linked by a disulfide bond, and the two aforementioned first polypeptide chains and the two aforementioned second polypeptide chains may form an IgG-like antibody.
  • the bispecific antibody may be a homodimer.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:143
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:126.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:143
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:127.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:143
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:129.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:143
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:131.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:143
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:132.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:44
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:126.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:44
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:127.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:44
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:129.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:44
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:131.
  • the bispecific antibody may comprise two first and second polypeptide chains.
  • the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:44
  • the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:132.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody can specifically bind PD-1 protein
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody can specifically bind Sexually binds CD28 or CD16a protein
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the bispecific antibody
  • the direction part may comprise the amino acid sequence shown in SEQ ID NO: 176 or SEQ ID NO: 168.
  • the bispecific antibody may comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond
  • the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody can specifically bind CD28 or CD16a protein
  • the second targeting moiety in the second polypeptide chain of the bispecific antibody can specifically bind Sexually binds to PD-1 protein
  • the first targeting moiety in the first polypeptide chain of the bispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 176 or SEQ ID NO: 168
  • the bispecific antibody The second targeting moiety in the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:31.
  • the bispecific antibody may comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond
  • the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the application provides one or more multispecific antibodies comprising a first polypeptide chain, a second polypeptide chain, the first polypeptide chain comprising a first targeting moiety, the second The polypeptide chain comprises a second targeting moiety, the first targeting moiety and the second targeting moiety independently bind immune cell-associated antigens, the first polypeptide chain and the second polypeptide chain pass through Disulfide linkage.
  • the immune cells may include T cells, macrophages, dendritic cells and/or NK cells.
  • the immune cell-associated antigens may include PD-1, PD-L1, CD3, CD16a and/or CD28.
  • the first targeting moiety of the multispecific antibody may be the same as the first targeting moiety of the aforementioned bispecific antibody.
  • the second targeting moiety of the multispecific antibody may be the same as the second targeting moiety of the aforementioned bispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind to PD-L1 protein
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody Can specifically bind PD-1 protein
  • the HCDR3 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:76.
  • the HCDR3 sequence of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR2 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:70.
  • the HCDR2 sequence of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:61.
  • the HCDR1 sequence of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the first targeting portion in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:61; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:70 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:76.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise antibody 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM or have the same HCDR3 (e.g., have the same HCDR1-3) antigen-binding fragments.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise a heavy chain variable region, and the heavy chain variable region may comprise the amino acid sequence shown in SEQ ID NO:122 .
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody comprises VH, and compared with the sequence shown in SEQ ID NO: 122, the VH has one or more amino acids selected from the group consisting of Amino acid substitutions (eg, conservative amino acid substitutions, etc.): X 5 , X 7 , X 10 , X 11 , X 12 , X 16 , X 20 , X 37 , X 38 , X 40 , X 46 , X 48 , X 67 , X 68 , X 69 , X 75 , X 81 , X 86 , X 90 , X 115 and X 116 .
  • the heavy chain variable region of the first targeting portion in the first polypeptide chain of the multispecific antibody may comprise amino acids shown in any one of SEQ ID NO:95 to SEQ ID NO:104 sequence.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise at least one CDR in the VL of the light chain variable region, and the VL may comprise the CDR shown in SEQ ID NO: 123. amino acid sequence.
  • the VL in the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111.
  • the LCDR of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be divided in any form, as long as VL is related to any one of SEQ ID NO:105 to SEQ ID NO:111.
  • the amino acid sequences shown are the same, and the LCDR obtained by dividing in any form can fall within the scope of protection of the present application.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may include a light chain variable region VL, and the VL may include at least one of LCDR1, LCDR2 and LCDR3, at least two or at least three.
  • the LCDR3 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:94.
  • the LCDR3 of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR2 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:87.
  • LCDR2 of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:82.
  • LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:82; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:87 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:94.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise antibody 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM, or have the same LCDR3 (e.g., Antigen-binding fragments having the same LCDR1-3) as it.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the light chain variable region VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:123.
  • the VL of the first targeting moiety in the first polypeptide chain of the multispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (e.g., conservative amino acid substitutions, etc.): X7 , X8 , X15 , X22 , X41 , X42 , X43 , X44 , X46 , X60 , X71 , X72 , X77 , X79 , X 80 , X 83 , X 87 and X 104 .
  • DIQMTQX 7 X 8 SSLSASX 15 GDRVTIX 22 CRASQDISKYLNWYQQKPX 41 X 42 X 43 X 44 KX 46 LIYYTSRLHSGVPX 60 RFSGSGTDX 71 X 72 LTISX 77 LX 79 X 80 EDX 83 ATYX 87 CQQGDTLPWTFGGGTKX 104 EIK(SEQ ID NO:123), ⁇ ,X 7 ⁇ is S or T, X 8 can be P or T, X 15 can be L or V, X 22 can be S or T, X 41 can be D or G, X 42 can be G or K, X 43 can be A or T, X 44 can be P or V, X 46 can be F or L, X 60 can be A or S, X 71 can be F or Y, X 72 can be F or T, X 77 can be N or S , X 79 can be E or Q, X 80
  • the light chain variable region of the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise amino acids shown in any one of SEQ ID NO:105 to SEQ ID NO:111 sequence.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise a light chain constant region, which may comprise a constant region derived from Ig ⁇ or a constant region derived from Ig ⁇ . district.
  • the light chain constant region may comprise a constant region derived from Ig ⁇ .
  • the light chain constant region of the first targeting moiety in the first polypeptide chain of the multispecific antibody comprises the amino acid sequence shown in any one of SEQ ID NO:114.
  • the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 134 to 140, SEQ ID NO: 144 to 153.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:51.
  • the HCDR3 sequence of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR3 of the second targeting part in the second polypeptide chain of the multispecific antibody has an amino acid substitution at one or more amino acids selected from the group (eg, conservative amino acid substitutions, etc.): X 1 .
  • X 1 HYGTSPFVY (SEQ ID NO: 51), wherein, wherein, X 1 can be D or E.
  • the HCDR3 of the second targeting part in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:9 and SEQ ID NO:10.
  • the HCDR3 sequence of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR2 of the second targeting part in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:6.
  • the HCDR2 sequence of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3.
  • the HCDR1 sequence of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:6 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:9.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can include antibodies 19D4F1, hu19D4-25, 19D4-25-1A3, 19D4-25-1B3, 19D4-25-1C2, 19D4-25 - 1E4, 19D4-25-2E10 or an antigen-binding fragment thereof having the same HCDR3 (eg, having the same HCDR1-3).
  • the HCDR1 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:6 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:10.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise antibody 19D4-25-3C11, 19D4-25-1C2-3C11 or have the same HCDR3 (e.g., have the same HCDR1- 3) The antigen-binding fragment.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise a heavy chain variable region, and the heavy chain variable region may comprise the amino acid sequence shown in SEQ ID NO:52 .
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody comprises VH, and compared with the sequence shown in SEQ ID NO:52, the VH has one or more amino acids selected from the group consisting of Amino acid substitutions (eg, conservative amino acid substitutions, etc.): X 1 , X 5 , X 13 , X 16 , X 17 , X 20 , X 37 , X 48 , X 67 , X 68 , X 73 , X 76 , X 79 , X 82 , X 83 , X 85 , X 86 , X 87 , X 88 , X 92 , X 98 and X 118 .
  • the heavy chain variable region of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise amino acids shown in any one of SEQ ID NO:29 to SEQ ID NO:31 sequence.
  • the second polypeptide chain of the multispecific antibody comprises the amino acid sequence shown in any one of SEQ ID NO:39 and SEQ ID NO:40.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise at least one CDR in the VL of the light chain variable region of the antibody, and the VL may comprise SEQ ID NO:58 amino acid sequence.
  • the VL may comprise the amino acid sequence shown in any one of SEQ ID NO:32 to SEQ ID NO:38.
  • the LCDR of the second targeting moiety in the second polypeptide chain of the isolated multispecific antibody can be divided in any form, as long as VL is related to any one of SEQ ID NO:32 to SEQ ID NO:38
  • the amino acid sequences shown in the items are the same, and the LCDR obtained by dividing in any form can fall within the protection scope of the present application.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may include a light chain variable region VL, and the VL may include at least one of LCDR1, LCDR2 and LCDR3, at least two or at least three.
  • the LCDR3 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:57.
  • the LCDR3 of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR3 of the second targeting portion in the second polypeptide chain of the multispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (eg, conservative amino acid substitutions, etc.): X 1 , X 4 , X 5 , X 7 and X 9 .
  • X 1 QSX 4 X 5 VX 7 WX 9 (SEQ ID NO: 57), wherein, X 1 can be Q or S, X 4 can be K, L or S, X 5 can be E, H, K or R, X 7 can be N or P, and X 9 can be S or T.
  • the LCDR3 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:21 to SEQ ID NO:26.
  • the LCDR3 of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR2 of the second targeting part in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:18.
  • LCDR2 of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:15.
  • LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:21.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can comprise antibody 19D4F1, hu19D4-25, 19D4-25-3C11 or an antibody having the same LCDR3 (e.g., having the same LCDR1-3) Antigen-binding fragments.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:22.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can comprise antibody 19D4-25-1A3 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:23.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can comprise antibody 19D4-25-1B3 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:24.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise antibody 19D4-25-1C2, 19D4-25-1C2-3C11 or have the same LCDR3 (e.g., have the same LCDR1-3 ) antigen-binding fragment.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:25.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can comprise antibody 19D4-25-1E4 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:26.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise antibody 19D4-25-2E10 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise the light chain variable region VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:58.
  • the VL of the second targeting moiety in the second polypeptide chain of the multispecific antibody has an amino acid substitution at one or more amino acids selected from the group (e.g., conservative amino acid substitutions, etc.): X 7 , X 9 , X 12 , X 14 , X 15 , X 18 , X 20 , X 41 , X 49 , X 64 , X 76 , X 78 , X 80 , X 81 , X 82 , X 84 , X 85 , X 87 , X 88 , X 89 , X 93 , X 96 , X 97 , X 99 , X 101 and
  • DIVLTQX 7 PX 9 SLX 12 VX 14 X 15 GQX 18 AX 20 ISCRASESVDNYGISFMNWFX 41 QKPGQPPX 49 LLIYAASNQGSGVPX 64 RFSGSGSGTDFX 76 LX 78 IX 80 X 81 X 82 EX 84 X 85 DX 87 X 88 X 89 YFCX 93 QSX 96 X 97 VX 99 WX 101 FGGGTKX 108 EIK (SEQ ID NO:58), wherein, X 7 can be S or T, X 9 can be A or L, X 12 can be A or S, X 14 can be S or T, X 15 can be L Or P, X 18 can be P or R, X 20 can be S or T, X 41 can be L or Q, X 49 can be K or Q, X 64 can be A or D, X 76 can be S or T , X 78 can be K or N,
  • the light chain variable region of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise amino acids shown in any one of SEQ ID NO:32 to SEQ ID NO:38 sequence.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise a heavy chain constant region, which may comprise a constant region derived from IgG or a constant region derived from IgY. district.
  • the heavy chain constant region of the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequences shown in SEQ ID NO: 112 to SEQ ID NO: 113.
  • the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:39 to SEQ ID NO:40, SEQ ID NO:154 to SEQ ID NO:160.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise any one of SEQ ID NO:95 to SEQ ID NO:104, SEQ ID NO:105 to SEQ ID NO:111 Amino acid sequence
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise any one of SEQ ID NO:29 to SEQ ID NO:31, SEQ ID NO:32 to SEQ ID NO:38 Amino acid sequence shown.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 97
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 98
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 100
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 102
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 103
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:31.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 97
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 98
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 100
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 102
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 103
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:36.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind to the PD-1 protein
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody Some can specifically bind PD-L1 protein.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:51.
  • the HCDR3 sequence of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR3 of the first targeting part in the first polypeptide chain of the multispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (eg, conservative amino acid substitutions, etc.): X 1 .
  • X 1 HYGTSPFVY (SEQ ID NO: 51), wherein X 1 can be D or E.
  • the HCDR3 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:9 and SEQ ID NO:10.
  • the HCDR3 sequence of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR2 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:6.
  • the HCDR2 sequence of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3.
  • the HCDR1 sequence of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the first targeting portion in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:6 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:9.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can include antibodies 19D4F1, hu19D4-25, 19D4-25-1A3, 19D4-25-1B3, 19D4-25-1C2, 19D4-25 - 1E4, 19D4-25-2E10 or an antigen-binding fragment thereof having the same HCDR3 (eg, having the same HCDR1-3).
  • the HCDR1 of the first targeting portion in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:3; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:6 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:10.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise antibody 19D4-25-3C11, 19D4-25-1C2-3C11 or have the same HCDR3 (eg, have the same HCDR1- 3) The antigen-binding fragment.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise a heavy chain variable region, and the heavy chain variable region may comprise the amino acid sequence shown in SEQ ID NO:52 .
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody comprises VH, and compared with the sequence shown in SEQ ID NO:52, the VH has one or more amino acids selected from the group consisting of Amino acid substitutions (eg, conservative amino acid substitutions, etc.): X 1 , X 5 , X 13 , X 16 , X 17 , X 20 , X 37 , X 48 , X 67 , X 68 , X 73 , X 76 , X 79 , X 82 , X 83 , X 85 , X 86 , X 87 , X 88 , X 92 , X 98 and X 118 .
  • the heavy chain variable region of the first targeting portion in the first polypeptide chain of the multispecific antibody may comprise amino acids shown in any one of SEQ ID NO:29 to SEQ ID NO:31 sequence.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise at least one CDR in the antibody light chain variable region VL, and the VL may comprise SEQ ID NO:58 amino acid sequence.
  • the VL of the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:32 to SEQ ID NO:38.
  • the LCDR of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be divided in any form, as long as VL and any one of SEQ ID NO:32 to SEQ ID NO:38 The amino acid sequences shown are the same, and the LCDR obtained by dividing in any form can fall within the scope of protection of the present application.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may include a light chain variable region VL, and the VL may include at least one of LCDR1, LCDR2 and LCDR3, at least two or at least three.
  • the LCDR3 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:57.
  • the LCDR3 of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR3 of the first targeting part in the first polypeptide chain of the multispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (eg, conservative amino acid substitutions, etc.): X 1 , X 4 , X 5 , X 7 and X 9 .
  • X 1 QSX 4 X 5 VX 7 WX 9 (SEQ ID NO: 57), wherein, X 1 can be Q or S, X 4 can be K, L or S, X 5 can be E, H, K or R, X 7 can be N or P, and X 9 can be S or T.
  • the LCDR3 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:21 to SEQ ID NO:26.
  • the LCDR3 of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR2 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:18.
  • LCDR2 of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the first targeting part in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:15.
  • LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:21.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise antibody 19D4F1, hu19D4-25, 19D4-25-3C11 or an antibody having the same LCDR3 (e.g., having the same LCDR1-3) Antigen-binding fragments.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:22.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can comprise antibody 19D4-25-1A3 or an antigen-binding fragment having the same LCDR3 therewith (eg, having the same LCDR1-3 as it).
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 23.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can comprise antibody 19D4-25-1B3 or an antigen-binding fragment having the same LCDR3 therewith (eg, having the same LCDR1-3 as it).
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:24.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise antibody 19D4-25-1C2, 19D4-25-1C2-3C11 or have the same LCDR3 (e.g., have the same LCDR1-3 ) antigen-binding fragment.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:25.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can comprise antibody 19D4-25-1E4 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the LCDR1 of the first targeting moiety in the first polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:15; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:18 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:26.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can comprise antibody 19D4-25-2E10 or an antigen-binding fragment having the same LCDR3 (eg, having the same LCDR1-3) therewith.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the light chain variable region VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:58.
  • the VL of the first targeting moiety in the first polypeptide chain of the multispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (e.g., conservative amino acid substitutions, etc.): X 7 , X 9 , X 12 , X 14 , X 15 , X 18 , X 20 , X 41 , X 49 , X 64 , X 76 , X 78 , X 80 , X 81 , X 82 , X 84 , X 85 , X 87 , X 88 , X 89 , X 93 , X 96 , X 97 , X 99 , X
  • DIVLTQX 7 PX 9 SLX 12 VX 14 X 15 GQX 18 AX 20 ISCRASESVDNYGISFMNWFX 41 QKPGQPP X 49 LLIYAASNQGSGVPX 64 RFSGSGSGTDFX 76 LX 78 IX 80 X 81 X 82 EX 84 X 85 DX 87 X 88 X 89 YFCX 93 QSX 96 X 97 VX 99 WX 101 FGGGTKX 108 EIK (SEQ ID NO:58), wherein, X 7 can be S or T, X 9 can be A or L, X 12 can be A or S, X 14 can be S or T, X 15 can be L or P, X 18 can be P or R, X 20 can be S or T, X 41 can be L or Q, X 49 can be K or Q, X 64 can be A or D, X 76 can be S or T, X 78 can be K or N,
  • the light chain variable region of the first targeting portion in the first polypeptide chain of the multispecific antibody may comprise amino acids shown in any one of SEQ ID NO:32 to SEQ ID NO:38 sequence.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise a light chain constant region, which may comprise a constant region derived from Ig ⁇ or a constant region derived from Ig ⁇ . district.
  • the light chain constant region may comprise a constant region derived from Ig ⁇ .
  • the light chain constant region of the first targeting moiety in the first polypeptide chain of the multispecific antibody comprises the amino acid sequence shown in SEQ ID NO:114.
  • the HCDR3 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:76.
  • the HCDR3 sequence of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR2 of the second targeting part in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:70.
  • the HCDR2 sequence of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the second targeting part in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:61.
  • the HCDR1 sequence of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat coding system.
  • the HCDR1 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:61; the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:70 and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:76.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can comprise antibody 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM, or have the same HCDR3 (e.g., have the same HCDR1-3) antigen-binding fragments.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise a heavy chain variable region, and the heavy chain variable region may comprise the amino acid sequence shown in SEQ ID NO:122 .
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody comprises VH, compared with the sequence shown in SEQ ID NO: 122, the VH has one or more amino acids selected from the group consisting of Amino acid substitutions (eg, conservative amino acid substitutions, etc.): X 5 , X 7 , X 10 , X 11 , X 12 , X 16 , X 20 , X 37 , X 38 , X 40 , X 46 , X 48 , X 67 , X 68 , X 69 , X 75 , X 81 , X 86 , X 90 , X 115 and X 116 .
  • X 5 can be Q or V
  • X 7 can be P or S
  • X 10 can be D or E
  • X 11 can be L or V
  • X 12 can be K or V
  • X 16 can be A or S
  • X 20 can be L or V
  • X 37 can be D
  • X 38 can be K or R
  • X 40 can be A or R
  • X 46 can be D or E
  • X 48 can be I Or M
  • X 67 can be A or
  • the heavy chain variable region of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise amino acids shown in any one of SEQ ID NO:95 to SEQ ID NO:104 sequence.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise at least one CDR in the VL of the light chain variable region of the antibody, and the VL may comprise SEQ ID NO: 123 amino acid sequence.
  • the VL in the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 105 to SEQ ID NO: 111.
  • the LCDR of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be divided in any form, as long as VL is related to any one of SEQ ID NO:105 to SEQ ID NO:111.
  • the amino acid sequences shown are the same, and the LCDR obtained by dividing in any form can fall within the scope of protection of the present application.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may include a light chain variable region VL, and the VL may include at least one of LCDR1, LCDR2 and LCDR3, at least two or at least three.
  • the LCDR3 of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:94.
  • the LCDR3 of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR2 of the second targeting part in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:87.
  • LCDR2 of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the second targeting part in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO:82.
  • LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody can be defined according to the Kabat numbering system.
  • the LCDR1 of the second targeting moiety in the second polypeptide chain of the multispecific antibody described in the present application may comprise the amino acid sequence shown in SEQ ID NO:82; the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:87 Amino acid sequence; and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:94.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can comprise antibody 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM, or have the same LCDR3 (e.g., Antigen-binding fragments having the same LCDR1-3) as it.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise the light chain variable region VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:123.
  • the VL of the second targeting moiety in the second polypeptide chain of the multispecific antibody has an amino acid substitution at one or more amino acids selected from the following group (e.g., conservative amino acid substitutions, etc.): X7 , X8 , X15 , X22 , X41 , X42 , X43 , X44 , X46 , X60 , X71 , X72 , X77 , X79 , X 80 , X 83 , X 87 and X 104 .
  • DIQMTQX 7 X 8 SSLSASX 15 GDRVTIX 22 CRASQDISKYLNWYQQKPX 41 X 42 X 43 X 44 KX 46 L IYYTSRLHSGVPX 60 RFSGSGSGTDX 71 X 72 LTISX 77 LX 79 X 80 EDX 83 ATYX 87 CQQGDTLPWTF GGGTKX 104 EIK(SEQ ID NO:123), ⁇ ,X 7 can be S or T, X 8 can be P or T, X 15 can be L or V, X 22 can be S or T, X 41 can be D or G, X 42 can be G or K, X 43 can is A or T, X 44 can be P or V, X 46 can be F or L, X 60 can be A or S, X 71 can be F or Y, X 72 can be F or T, X 77 can be N Or S, X 79 can be E or Q, X 80
  • the light chain variable region of the second targeting portion in the second polypeptide chain of the multispecific antibody may comprise amino acids shown in any one of SEQ ID NO:105 to SEQ ID NO:111 sequence.
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise a heavy chain constant region, which may comprise a constant region derived from IgG or a constant region derived from IgY. district.
  • the heavy chain constant region of the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise the amino acid sequences shown in SEQ ID NO: 112 to SEQ ID NO: 113.
  • the multispecific antibody may comprise a first targeting moiety in the first polypeptide chain of the multispecific antibody and a second targeting moiety in the second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise any one of SEQ ID NO: 29 to SEQ ID NO: 31, SEQ ID NO: 32 to SEQ ID NO: 38.
  • the amino acid sequence shown, the second targeting moiety in the second polypeptide chain of the multispecific antibody may comprise any of SEQ ID NO:95 to SEQ ID NO:104, SEQ ID NO:105 to SEQ ID NO:111 Amino acid sequence shown in one item.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:97.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:98.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:100.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:102.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:103.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:97.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:98.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:100.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:102.
  • the multispecific antibody can comprise a first targeting moiety in a first polypeptide chain of the multispecific antibody and a second targeting moiety in a second polypeptide chain of the multispecific antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 36
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence shown in SEQ ID NO:103.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind PD-1 protein
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can specifically bind sexually binds CD28 or CD16a protein
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in SEQ ID NO: 31, and the second targeting moiety in the second polypeptide chain of the multispecific antibody
  • the direction part may comprise the amino acid sequence shown in SEQ ID NO: 176 or SEQ ID NO: 168.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind CD28 or CD16a protein
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can specifically bind Sexually binds to PD-1 protein.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 176 or SEQ ID NO: 168
  • the second targeting moiety in the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:31.
  • the first polypeptide chain of the multispecific antibody may further comprise a third targeting moiety.
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody can be directly or indirectly linked to the C-terminus of the first targeting moiety in the first polypeptide chain of the multispecific antibody.
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody can be connected to the C-terminus of the first targeting moiety in the first polypeptide chain of the multispecific antibody through a linker.
  • the linker may be a linker commonly used in the art.
  • the linker can be a flexible linker.
  • the linker may be a G4S linker.
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind to an immune cell-associated antigen.
  • the immune cell-associated antigens may include PD-1, PD-L1, CD3, CD16a and/or CD28.
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind CD3 or CD16a protein.
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind to an antigen associated with tumorigenesis.
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind EGFR and/or cMet.
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody can specifically bind to a tumor-associated antigen.
  • the tumor-associated antigens may include PD-L1, HER2, CD47, CD19 and/or CD20.
  • the second polypeptide chain of the multispecific antibody may further comprise a fourth targeting moiety.
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody can be directly or indirectly linked to the C-terminus of the second targeting moiety in the second polypeptide chain of the multispecific antibody.
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody can be linked to the C-terminus of the second targeting moiety in the second polypeptide chain of the multispecific antibody through a linker.
  • the linker may be a linker commonly used in the art.
  • the linker can be a flexible linker.
  • the linker may be a G4S linker.
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody can specifically bind to an immune cell-associated antigen.
  • the immune cell-associated antigens may include PD-1, PD-L1, CD3, CD16a and/or CD28.
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody can specifically bind CD3 or CD16a protein.
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody can specifically bind to an antigen associated with tumorigenesis.
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody can specifically bind EGFR and/or cMet.
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody can specifically bind to a tumor-associated antigen.
  • the tumor-associated antigens may include PD-L1, HER2, CD47, CD19 and/or CD20.
  • the multispecific antibody may comprise two aforementioned first polypeptide chains and two aforementioned second polypeptide chains.
  • the two aforementioned first polypeptide chains may be linked by a disulfide bond, and the two aforementioned first polypeptide chains and the two aforementioned second polypeptide chains may form an IgG-like antibody.
  • the multispecific antibody can be a homodimer.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-L1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target Towards PD-L1
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody may target PD-1, CD3 or CD16a.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 105-111; the second polypeptide chain of the multispecific antibody The second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:95-104; And the 4th targeting moiety in the second polypeptide chain can comprise SEQ ID NO:29-31 The amino acid sequence of the VH shown in any one of , 168 and 172 and the amino acid sequence of the VL shown in any one of SEQ ID NO: 32-38, 169 and 173.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target Towards PD-1
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody may target PD-L1, CD3 or CD16a.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 32-38;
  • the second polypeptide chain of the multispecific antibody The second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:29-31;
  • the 4th targeting moiety in the second polypeptide chain can comprise SEQ ID NO:95-104
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-L1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target For PD-1
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody may target CD3 or CD16a.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:95-104 and SEQ ID NO:105-111;
  • the second targeting moiety in the second polypeptide chain of the specific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:29-31 and SEQ ID NO:32-38; and the first polypeptide chain
  • the third targeting moiety in may comprise the amino acid sequence of the VH shown in any one of SEQ ID NOs: 168 and 172 and the amino acid sequence of the VL shown in any one of SEQ ID NOs: 169 and 173.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody targets PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody targets PD-1 -L1
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody targets CD3 or CD16a.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:29-31 and SEQ ID NO:32-38;
  • the second targeting moiety in the second polypeptide chain of the specific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO:95-104 and SEQ ID NO:105-111; and the first polypeptide chain
  • the third targeting moiety in may comprise the amino acid sequence of the VH shown in any one of SEQ ID NOs: 168 and 172 and the amino acid sequence of the VL shown in any one of SEQ ID NOs: 169 and 173.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target CD28 or CD16a
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target Towards PD-1
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody may target PD-L1, HER2, CD47, CD19 and/or CD20.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 168 or SEQ ID NO: 176;
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody targets PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody targets CD28 or CD16a
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody targets PD-L1, HER2, CD47, CD19 and/or CD20.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 29-31; the second polypeptide chain of the multispecific antibody The second targeting moiety in may comprise the amino acid sequence shown in any one of SEQ ID NO: 168 or SEQ ID NO: 176; and the fourth targeting moiety in the second polypeptide chain may comprise SEQ ID NO The amino acid sequence of the VH shown in any one of: 95-104, 170, 174 and 178 and the amino acid sequence of the VL shown in any one of SEQ ID NO: 105-111, 171, 175 and 179.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target CD28 or CD16a
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target PD-1
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody targets EGFR or cMET
  • the fourth targeting moiety in the second polypeptide chain of the multispecific antibody targets PD- L1, HER2, CD47, CD19 and/or CD20.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 168 or SEQ ID NO: 176;
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target To CD28 or CD16a
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody may target PD-L1, HER2, CD47, CD19 and/or CD20
  • the second polypeptide of the multispecific antibody A fourth targeting moiety in the chain can target EGFR or cMET.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 29-31; the second polypeptide chain of the multispecific antibody The second targeting moiety in may comprise the amino acid sequence shown in any one of SEQ ID NO: 168 or SEQ ID NO: 176; and the third targeting moiety in the first polypeptide chain of the multispecific antibody may be Comprising the amino acid sequence of the VH shown in any one of SEQ ID NO: 95-104, 170, 174 and 178 and the amino acid sequence of the VL shown in any one of SEQ ID NO: 105-111, 171, 175 and 179 .
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be linked by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target PD-1
  • the C-terminus of the second polypeptide chain of the multispecific antibody may comprise IL-2 variants, IFN ⁇ -2b or IL-15.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 32-38; the second polypeptide chain of the multispecific antibody The second targeting moiety in may comprise the amino acid sequence shown in any one of SEQ ID NO: 29-31; and the cytokine in the second polypeptide chain of the multispecific antibody may comprise SEQ ID NO: 180 or Amino acid sequence shown in SEQ ID NO: 181.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-L1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target Towards PD-L1
  • the C-terminus of the second polypeptide chain of the multispecific antibody may comprise IL-2 variants, IFN ⁇ -2b or IL-15.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 105-111; the second polypeptide chain of the multispecific antibody The second targeting moiety in may comprise the amino acid sequence shown in any one of SEQ ID NO: 95-104; and the cytokine in the second polypeptide chain of the multispecific antibody may comprise SEQ ID NO: 180 or Amino acid sequence shown in SEQ ID NO: 181.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target Towards PD-L1
  • the C-terminus of the first polypeptide chain of the multispecific antibody may comprise IL-2, IFN ⁇ -2b or IL-15
  • the fourth target in the second polypeptide chain of the multispecific antibody may comprise CD3 or CD16a.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 29-31; the second polypeptide chain of the multispecific antibody
  • the second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:95-104;
  • the cytokine in the second polypeptide chain of described multispecific antibody can comprise SEQ ID NO:180 or SEQ ID NO:180 or SEQ ID NO:104;
  • the fourth targeting part in the second polypeptide chain can comprise the amino acid sequence of VH shown in any one of SEQ ID NO:168 and 172 and SEQ ID NO: Amino acid sequence of VL shown in any one of 169 and 173.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-L1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target
  • the C-terminus of the first polypeptide chain of the multispecific antibody may contain IL-2, IFN ⁇ -2b or IL-15
  • the fourth targeting moiety may contain CD3 or CD16a.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 95-104;
  • the second polypeptide chain of the multispecific antibody The second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:29-31;
  • the cytokine in the second polypeptide chain of described multispecific antibody can comprise SEQ ID NO:180 or SEQ ID NO:180 or SEQ The amino acid sequence shown in ID NO:181;
  • the fourth targeting part in the second polypeptide chain can comprise the amino acid sequence of VH shown in any one of SEQ ID NO:168 and 172 and SEQ ID NO: Amino acid sequence of VL shown in any one of 169 and 173.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-L1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target
  • the C-terminus of the first polypeptide chain of the multispecific antibody may contain IL-2, IFN ⁇ -2b or IL-15.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 95-104; the second polypeptide chain of the multispecific antibody The second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:29-31;
  • the cytokine in the second polypeptide chain of described multispecific antibody can comprise SEQ ID NO:180 or SEQ ID NO:180 or SEQ Amino acid sequence shown in ID NO:181.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target
  • the C-terminus of the first polypeptide chain of the multispecific antibody may contain IL-2, IFN ⁇ -2b or IL-15.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 29-31; the second polypeptide chain of the multispecific antibody The second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:95-104;
  • the cytokine in the second polypeptide chain of described multispecific antibody can comprise SEQ ID NO:180 or SEQ ID NO:180 or SEQ ID NO:104; Amino acid sequence shown in ID NO:181.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target Towards PD-1
  • the C-terminus of the first polypeptide chain of the multispecific antibody may contain IL-2, IFN ⁇ -2b or IL-15
  • the fourth target in the second polypeptide chain of the multispecific antibody Some can target PD-L1.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 32-38;
  • the second polypeptide chain of the multispecific antibody The second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:29-31;
  • the cytokine in the second polypeptide chain of described multispecific antibody can comprise SEQ ID NO:180 or SEQ ID NO:180 or SEQ The amino acid sequence shown in ID NO:181;
  • the fourth targeting part in the second polypeptide chain can comprise the amino acid sequence of VH shown in any one of SEQ ID NO:95-104 and SEQ ID NO: The amino acid sequence of the VL shown in any one of 105-111.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-L1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target Towards PD-L1
  • the C-terminus of the first polypeptide chain of the multispecific antibody may contain IL-2, IFN ⁇ -2b or IL-15
  • the fourth target in the second polypeptide chain of the multispecific antibody Partially targets PD-1.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 105-111; the second polypeptide chain of the multispecific antibody
  • the second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:95-104;
  • the cytokine in the second polypeptide chain of described multispecific antibody can comprise SEQ ID NO:180 or SEQ ID NO:180 or SEQ ID NO:104;
  • the fourth targeting part in the second polypeptide chain can comprise the amino acid sequence of VH shown in any one of SEQ ID NO:29-31 and SEQ ID NO: The amino acid sequence of the VL shown in any one of 32-38.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target To PD-L1
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody may target CD3 or CD16a
  • the C-terminus of the second polypeptide chain of the multispecific antibody may contain IL- 2. IFN ⁇ -2b or IL-15.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 29-31; the second polypeptide chain of the multispecific antibody The second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:95-104;
  • the third targeting moiety in the first polypeptide chain can comprise SEQ ID NO:168 and 172
  • the amino acid sequence of VH shown in any one and the amino acid sequence of VL shown in any one of SEQ ID NO: 169 and 173; and the cytokine in the second polypeptide chain of the multispecific antibody may comprise SEQ ID The amino acid sequence shown in NO:180 or SEQ ID NO:181.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody can target PD-L1
  • the second targeting moiety in the second polypeptide chain of the multispecific antibody can target To PD-1
  • the third targeting moiety in the first polypeptide chain of the multispecific antibody targets CD3 or CD16a
  • the C-terminus of the second polypeptide chain of the multispecific antibody comprises IL-2, IFN ⁇ -2b or IL-15.
  • the first targeting moiety in the first polypeptide chain of the multispecific antibody may comprise the amino acid sequence shown in any one of SEQ ID NO: 95-104;
  • the second polypeptide chain of the multispecific antibody The second targeting moiety in can comprise the amino acid sequence shown in any one of SEQ ID NO:29-31;
  • the third targeting moiety in the first polypeptide chain can comprise SEQ ID NO:168 and 172
  • the amino acid sequence of VH shown in any one and the amino acid sequence of VL shown in any one of SEQ ID NO: 169 and 173; and the cytokine in the second polypeptide chain of the multispecific antibody may comprise SEQ ID The amino acid sequence shown in NO:180 or SEQ ID NO:181.
  • the multispecific antibody can comprise two first polypeptide chains and two second polypeptide chains.
  • two first polypeptide chains can be connected by a disulfide bond, and the two first polypeptide chains and two second polypeptide chains can form an IgG-like antibody.
  • the application provides one or more polypeptides, which may comprise an isolated antigen binding protein of the application.
  • the polypeptide can include a fusion protein.
  • the polypeptide can include a bispecific antibody.
  • the application provides one or more immunoconjugates, which may comprise an isolated antigen binding protein of the application.
  • the immunoconjugate may further comprise a pharmaceutically acceptable therapeutic agent, label and/or detection agent.
  • the present application also provides one or more isolated nucleic acid molecules that encode the isolated antigen-binding protein described herein.
  • each of the one or more nucleic acid molecules may encode the entirety of the antigen binding protein, or may encode a portion thereof (e.g., HCDR1-3, one of the heavy chain variable regions, or variety).
  • the products encoded by the nucleic acid molecules together can form a functional (for example, binding to PD-L1 and PD-1) isolated antigen-binding protein of the present application. protein.
  • the nucleic acid molecules described herein can be isolated. For example, it may be produced or synthesized by (i) amplified in vitro, such as by polymerase chain reaction (PCR) amplification, (ii) recombinantly produced by cloning, (iii) purified (iv) synthetic, for example by chemical synthesis.
  • the isolated nucleic acid can be a nucleic acid molecule prepared by recombinant DNA techniques.
  • nucleic acid encoding the isolated antigen-binding protein can be prepared by various methods known in the art, including but not limited to, using reverse transcription PCR and PCR to obtain the isolated antigen-binding protein described in the application. protein nucleic acid molecule.
  • the present application provides one or more vectors comprising one or more nucleic acid molecules described herein.
  • Each vector may contain one or more such nucleic acid molecules.
  • other genes may be included in the vector, such as marker genes that allow selection of the vector in appropriate host cells and under appropriate conditions.
  • the vector may also contain expression control elements that permit proper expression of the coding region in an appropriate host.
  • control elements are well known to those skilled in the art, and may include, for example, promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation, and the like.
  • the expression control sequences are regulatable elements.
  • the specific structure of the expression control sequence may vary depending on the function of the species or cell type, but generally includes 5' non-transcribed sequences and 5' and 3' non-translated sequences involved in the initiation of transcription and translation, respectively, such as TATA box, plus Cap sequence, CAAT sequence, etc.
  • the 5' non-transcribed expression control sequence may comprise a promoter region which may comprise a promoter sequence for transcriptional control of the functionally linked nucleic acid.
  • the expression control sequences may also include enhancer sequences or upstream activator sequences.
  • suitable promoters may include, for example, promoters for SP6, T3, and T7 polymerases, human U6 RNA promoters, CMV promoters, and artificial hybrid promoters thereof (such as CMV), wherein the promoter's Portions may be fused to portions of gene promoters of other cellular proteins (eg, human GAPDH, glyceraldehyde-3-phosphate dehydrogenase), which may or may not contain additional introns.
  • One or more nucleic acid molecules described herein can be operably linked to the expression control element.
  • Such vectors may include, for example, plasmids, cosmids, viruses, phages, or other vectors commonly used, for example, in genetic engineering.
  • the vector may be an expression vector.
  • the vector can be a viral vector.
  • Viral vectors may be administered directly to the patient (in vivo) or may be indirect, for example, in vitro by treating cells with virus and then administering the treated cells to the patient (ex vivo).
  • Viral vector technology is well known in the art and described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other handbooks of virology and molecular biology.
  • Lentiviral vectors are retroviral vectors capable of transducing or infecting non-dividing cells and typically producing higher viral titers.
  • Lentiviral vectors may contain long terminal repeat 5'LTR and truncated 3'LTR, RRE, rev response element (cPPT), central termination sequence (CTS) and/or post-translational regulatory element (WPRE).
  • the vectors described herein can be introduced into cells.
  • the present application provides a cell.
  • the cells may comprise the isolated antigen binding protein described herein, the polypeptide, the immunoconjugate, one or more nucleic acid molecules and/or one or more carriers described herein .
  • each or each cell may comprise one or more of the nucleic acid molecules or vectors described herein.
  • each or each cell may contain multiple (eg, 2 or more) or multiple (eg, 2 or more) nucleic acid molecules or vectors described herein.
  • the vectors described herein can be introduced into said host cells, such as prokaryotic cells (e.g., bacterial cells), CHO cells, NS/0 cells, HEK293T cells, 293F cells or HEK293A cells, or other eukaryotic cells, Such as cells from plants, fungal or yeast cells, etc.
  • the vectors described in this application can be introduced into the host cells by methods known in the art, such as electroporation, lipofectine transfection, lipofectamin transfection and the like.
  • the cells can include yeast cells.
  • the cells may include E. coli cells.
  • the cells can include mammalian cells.
  • the cells can include immune cells.
  • the cells may include immune cells.
  • the cells can include immune cells.
  • the cells may include T cells, B cells, natural killer (NK) cells, macrophages, NKT cells, monocytes, dendritic cells, granulocytes, lymphocytes, leukocytes, and/or peripheral blood mononuclear cells cell.
  • NK natural killer
  • the present application provides a pharmaceutical composition.
  • the pharmaceutical composition may comprise the isolated antigen binding protein described herein, the polypeptide, the immunoconjugate, the isolated nucleic acid molecule, the carrier, the cell, and/or Or pharmaceutically acceptable adjuvants and/or excipients.
  • the pharmaceutically acceptable adjuvants may include buffers, antioxidants, preservatives, low molecular weight polypeptides, proteins, hydrophilic polymers, amino acids, sugars, chelating agents, counter ions, metal complexes and /or nonionic surfactants. Unless incompatible with the cells described herein, any conventional media or reagents are contemplated for use in the pharmaceutical compositions of the present application.
  • the pharmaceutically acceptable excipients may include additives other than the main drug in the pharmaceutical preparation, and may also be referred to as auxiliary materials.
  • the excipients may include binders, fillers, disintegrants, lubricants in tablets.
  • the excipients may include wine, vinegar, medicinal juice, etc. in traditional Chinese medicine pills.
  • the excipient may comprise the base part of a semi-solid formulation ointment, cream.
  • the excipients may include preservatives, antioxidants, flavoring agents, fragrances, solubilizers, emulsifiers, solubilizers, osmotic pressure regulators, colorants in liquid formulations.
  • the present application provides a method for modulating an immune response, comprising administering to a subject in need an effective amount of the isolated antigen-binding protein, the polypeptide, the immunoconjugate, Said isolated nucleic acid molecule, said carrier, said cell and/or said pharmaceutical composition, and/or a pharmaceutically acceptable therapeutic agent.
  • the method for modulating immune response may include in vitro method, ex vivo method, non-diagnostic or non-therapeutic method.
  • the present application provides a method for regulating immune response, which comprises administering an effective amount of the drug combination, and/or a pharmaceutically acceptable therapeutic agent to a subject in need.
  • the method for modulating immune response may include in vitro method, ex vivo method, non-diagnostic or non-therapeutic method.
  • the application provides the isolated antigen-binding protein, the polypeptide, the immunoconjugate, the isolated nucleic acid molecule, the carrier, and the pharmaceutical composition for preventing, alleviating and/or treat a disease or condition.
  • the disease or condition may include tumors.
  • the tumor can include a non-solid tumor.
  • the tumor can include a tumor associated with expression of PD-L1.
  • the term "tumor associated with the expression of PD-L1" generally refers to a tumor formed due to changes in the expression of PD-L1 leading to disease progression or escape from immune surveillance.
  • the "tumor associated with the expression of PD-L1" may be a tumor formed by the upregulation of PD-L1 expression leading to disease progression or escape from immune surveillance.
  • the tumor associated with the protein expression of PD-L1 may be a PD-L1 positive tumor.
  • the protein expression of PD-L1 on the surface of tumor cells or in the tumor microenvironment is about 1%, 5%, 10%, 15%, 20%, 25% higher , 30%, 35%, 40%, 50%, 60%, 70%, 80% or higher.
  • the application provides a kind of said isolated antigen binding protein, said polypeptide, said immunoconjugate, said isolated nucleic acid molecule, said carrier, said cell and /or the use of the pharmaceutical composition in the preparation of medicaments for preventing, alleviating and/or treating diseases or conditions.
  • the disease or condition may include tumors.
  • the tumor can include a solid tumor.
  • the tumor can include a non-solid tumor.
  • the tumor can include a tumor associated with expression of PD-L1.
  • the term "tumor associated with the expression of PD-L1" generally refers to a tumor formed due to changes in the expression of PD-L1 leading to disease progression or escape from immune surveillance.
  • the "tumor associated with the expression of PD-L1" may be a tumor formed by the upregulation of PD-L1 expression leading to disease progression or escape from immune surveillance.
  • the tumor associated with the protein expression of PD-L1 may be a PD-L1 positive tumor.
  • the protein expression of PD-L1 on the surface of tumor cells or in the tumor microenvironment is about 1%, 5%, 10%, 15%, 20%, 25% higher , 30%, 35%, 40%, 50%, 60%, 70%, 80% or higher.
  • the present application provides a method for preventing and/or treating a disease or disorder, comprising administering the isolated antigen-binding protein, the isolated nucleic acid molecule, the The carrier, the cell, the pharmaceutical composition.
  • the disease or condition may include tumors.
  • the tumor can include a non-solid tumor.
  • the tumor can include a tumor associated with expression of PD-L1.
  • the term "tumor associated with the expression of PD-L1" generally refers to a tumor formed due to changes in the expression of PD-L1 leading to disease progression or escape from immune surveillance.
  • the "tumor associated with the expression of PD-L1" may be a tumor formed by the upregulation of PD-L1 expression leading to disease progression or escape from immune surveillance.
  • the tumor associated with the protein expression of PD-L1 may be a PD-L1 positive tumor.
  • the protein expression of PD-L1 on the surface of tumor cells or in the tumor microenvironment is about 1%, 5%, 10%, 15%, 20%, 25% higher , 30%, 35%, 40%, 50%, 60%, 70%, 80% or higher.
  • the pharmaceutical compositions and methods described herein can be used in conjunction with other types of cancer therapy, such as chemotherapy, surgery, radiation, gene therapy, and the like.
  • the pharmaceutical compositions and methods described in this application can be used in other disease conditions that depend on immune responses, such as inflammation, immune diseases and infectious diseases.
  • the subject may include humans or non-human animals.
  • the non-human animal can be selected from the group consisting of monkeys, chickens, geese, cats, dogs, mice and rats.
  • non-human animals may also include any animal species other than humans, such as livestock animals, or rodents, or primates, or domestic animals, or poultry animals.
  • the human can be Caucasian, African, Asian, Semitic, or other ethnicity, or a hybrid of various ethnicities.
  • the human can be elderly, adult, adolescent, child or infant.
  • the effective amount in humans can be inferred from the effective amount in experimental animals.
  • Freireich et al. describe the correlation of doses in animals and humans (based on milligrams per square meter of body surface) (Freiheim et al., Cancer Chemother. Rep. 50, 219 (1966)).
  • Body surface area can be approximately determined from the patient's height and weight. See, eg, Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 537 (1970).
  • the antigen-binding proteins 13H6D3 and 19D4F1 were obtained by hybridoma technology. Afterwards, humanized antibodies to 13H6D3, hu13H6D3, 5BM, AH00228, AH00229, AH00230, AH00231, AH00232, AH00233, CBM, and humanized antibodies to 19D4F1, hu19D4-25, 19D4-25- 1A3, 19D4-25-1B3, 19D4-25-1C2, 19D4-25-1E4, 19D4-25-2E10, 19D4-25-3C11, 19D4-25-1C2-3C11.
  • the preparation method of hybridoma and the method of humanized design can be carried out according to the methods published in many documents in this field.
  • a 417bp fragment was amplified from the antibody 5BM heavy chain vector pCP-5BM-H-agYTE (agYTE represents the YTE mutation and the N297A mutation).
  • PCR enzyme and system according to Takara Bio HS (Premix) kit configuration and use. After the fragments are amplified, they are gel-recovered and purified for use.
  • a 350bp light chain Kappa constant region sequence was amplified from the vector containing the Kappa light chain constant region using PCP-CK1-S+PCP-CK1-AS primers. After the fragments are amplified, they are gel-recovered and purified for use.
  • the light chain expression vector pCP-L was digested with KpnI+NotI (KpnI and NotI were from Takara Bio), and the vector fragment of about 5.5Kb was recovered by gel cutting.
  • the three fragments were constructed by homologous recombination using the ClonExpress Ultra One Step Cloning Kit (Vazyme). 10 positive clones were picked from the LB plate for sequencing identification, and one of the correctly constructed plasmids was selected to enter the subsequent Lh vector amplification preparation process.
  • a 411bp fragment was amplified from the antibody 19D4-25-3C11VH template (agYTE represents YTE mutation and N297A mutation).
  • PCR enzyme and system according to Takara Bio HS (Premix) kit configuration and use. After the fragments are amplified, they are gel-recovered and purified for use.
  • the light chain expression vector pCP-H-agYTE vector was digested with KpnI+NheI (KpnI and NheI were from Takara Bio), and the vector fragment of about 6.5Kb was recovered by gel cutting.
  • ClonExpress Ultra One Step Cloning Kit Vazyme
  • the sequence of the anti-PDL1 antibody 5BMVH region (SEQ ID NO:97) was connected to the N-terminal of the human IgG1kappa chain constant region (CL), and the sequence of the anti-PD1 antibody 19D4-25-3C11VH region (SEQ ID NO: :31) to the N-terminus of the first constant region (CH1) of the human IgG1 heavy chain.
  • HEK293 cells were transfected with the plasmid expressing the bispecific antibody and cultured, and then the culture medium was separated and the antibody was purified.
  • the expression level of 2xVH double antibody (5BMVH-3C11VH, also called Lh5BM-3C11) is the same as that of general antibodies.
  • the anti-PD1 antibody could dose-dependently reduce the binding of PD1 to the coated PDL-1.
  • the bispecific antibody dose-dependently increases the HRP signal, interpreted as the bispecific anti-PDL-1 binds coated PDL1, and the anti-PD1 arm binds PD1-biotin bound by HRP-avidin, thus, the bispecific antibody Dose-dependently increased HRP signaling.
  • the sequence of the anti-PDL1 antibody 5BMVH region (SEQ ID NO:97) was connected to the N-terminal of the human IgG1kappa chain constant region (CL), and the sequence of the anti-PD1 antibody 19D4-25-3C11VH region (SEQ ID NO: :31) to the N-terminus of the first constant region (CH1) of the human IgG1 heavy chain.
  • the VH (SEQ ID NO: 168) and VL (SEQ ID NO: 169) of the anti-CD16a antibody were connected with a linker (GGGGS)3 and the N-terminal of the VH was connected to the C-terminal of the Fc with a linker.
  • a trispecific antibody against PD1/PDL1/CD16a was constructed. Staining was performed with HEK293 cells expressing PD1, PDL1, CD16a or wild type. The results showed that the third antibody could specifically stain the cells with high expression of PD1, PDL1 or CD16a, but did not stain the wild-type HEK293.
  • Biacore experiments showed that the chip was coated with trispecific antibodies, and the peaks were observed to increase sequentially after adding PD1, PDL-1 or CD16a in sequence, indicating that this The molecule can simultaneously bind PD1, PDL-1 and CD16a.
  • the sequence (SEQ ID NO:97) of the anti-PDL-1 antibody 5BMVH region was connected to the N-terminal of the human IgG1kappa chain constant region (CL), and the sequence of the anti-PD1 antibody 19D4-25-3C11VH region (SEQ ID NO:97) ID NO: 31) was linked to the N-terminus of the first constant region (CH1) of the human IgG1 heavy chain.
  • the IL-2 (SEQ ID NO: 180) expression gene was connected to the C-terminal of the Fc with a linker (GGGGS) 3.
  • Biacore experiments showed that the chip was coated with anti-PD1/PDL1/IL-2 bispecific antibody, and the peaks were observed to increase sequentially after adding PD1, PDL-1 or IL-2R in sequence, indicating that this molecule can bind PD1 at the same time, PDL-1 and IL-2R.
  • the sequence of the anti-PDL-1 antibody 5BM VH region (SEQ ID NO: 97) was connected to the N-terminal of the human IgG1kappa chain constant region (CL), and the sequence of the anti-PD1 antibody 19D4-25-3C11 VH region ( SEQ ID NO: 31) is linked to the N-terminus of the first constant region (CH1) of the human IgG1 heavy chain.
  • the IFN- ⁇ (SEQ ID NO: 181) expression gene was connected to the C-terminal of the Fc with a linker (GGGGS)3.
  • the anti-PD1/PDL1/IFN- ⁇ bispecific antibody immunocytokines (Immunocytokines) are constructed.
  • Biacore experiments showed that the chip was coated with anti-PD1/PDL1/IFN- ⁇ bispecific antibody, and the peaks were observed to increase sequentially after adding PD1, PDL-1 or IFNR in sequence, indicating that this molecule can simultaneously bind PD1, PDL- 1 and IFNR.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供了一种靶向PD-L1/PD-1的抗体及其应用,所述抗体包含第一多肽链、第二多肽链,所述第一多肽链包含第一靶向部分,所述第二多肽链包含第二靶向部分,所述第一靶向部分和所述第二靶向部分各自独立地结合免疫细胞相关抗原,所述第一多肽链与所述第二多肽链通过二硫键连接。所述抗体还可带有细胞因子,或者所述抗体可结合肿瘤相关抗原(TAA)。还提供了包含所述抗体的免疫缀合物、制备所述抗体的方法及其用途。

Description

靶向PD-L1/PD-1的抗体及其应用 技术领域
本申请涉及生物医药领域,具体的涉及一种靶向PD-L1/PD-1的抗体及其应用。
背景技术
程序性死亡受体配体1(PD-L1),也称为分化簇274(CD274)或B7同源蛋白1(B7-H1),是一个40KDa的I型跨膜蛋白,一般在活化的T细胞、B细胞、单核细胞、树突状细胞、巨噬细胞及许多非造血细胞上表达。
PD-L1能与程序性死亡受体1(PD-1)和B7-1(CD80)结合。其中PD-L1/PD-1信号通路是免疫反应中非常重要的共抑制信号途径,负调节T细胞免疫应答,抑制T细胞活性,减弱细胞因子的分泌。研究发现PD-L1能在许多肿瘤组织中表达,包括胃癌、肺癌、乳腺癌、胰腺癌、卵巢癌、结肠癌、肥大细胞性肿瘤以及恶性黑色素瘤等,以及在浸润肿瘤微环境的骨髓细胞中表达,保护肿瘤细胞逃避免疫攻击。
目前,抗PD-L1抗体和抗PD-1抗体能使很多癌症患者获益,但仍有部分患者对单药治疗不做应答。能够结合PD-1蛋白和PD-L1蛋白的多特异性抗体有望增强抗肿瘤活性。因此,亟需开发具备阻断PD-L1/PD-1信号通路能力的PD1/PD-L1双特异性抗体。
发明内容
本申请提供了一种分离的抗原结合蛋白,其具有下述性质的一种或多种:1)既能结合PD-1蛋白又能结合PD-L1蛋白;2)第一多肽链和第二多肽链自然配对不需要非自然的工程化配对,克服了一般多特异性抗体生产过程中的错配问题,降低成本;3)相比一般多特异性抗体,覆盖抗原的面积大30%;和4)能够高效杀伤肿瘤细胞。
在某些实施方式中,所述抗原结合蛋白包含第一多肽链、第二多 肽链,所述第一多肽链包括第一靶向部分,所述第二多肽链包含第二靶向部分,所述第一靶向部分和所述第二靶向部分各自独立地结合免疫细胞相关抗原,所述第一多肽链与所述第二多肽链通过二硫键连接。
在某些实施方式中,所述免疫细胞包括T细胞、巨噬细胞、树突状细胞和/或NK细胞。
在某些实施方式中,所述免疫细胞相关抗原包括PD-1、PD-L1、CD3、CD16a和/或CD28。
在某些实施方式中,所述第一靶向部分和第二靶向部分结合相同的免疫细胞相关抗原。
在某些实施方式中,所述第一靶向部分和第二靶向部分均结合PD-1蛋白或PD-L1蛋白。
在某些实施方式中,所述第一靶向部分特异性结合PD-1蛋白,且所述第二靶向部分特异性结合PD-L1蛋白。
在某些实施方式中,所述第一靶向部分特异性结合PD-L1蛋白,所述第二靶向部分特异性结合PD-1蛋白。
在某些实施方式中,所述第一靶向部分特异性结合PD-1蛋白,且所述第二靶向部分特异性结合CD28或CD16a蛋白。
在某些实施方式中,所述第一靶向部分特异性结合CD28或CD16a蛋白,且所述第二靶向部分特异性结合PD-1蛋白。
在某些实施方式中,所述第一多肽链还包含第三靶向部分。
在某些实施方式中,所述第一多肽链中第三靶向部分与所述第一靶向部分的C端直接或间接地连接。
在某些实施方式中,所述第一多肽链中第三靶向部分与所述第一靶向部分的C端通过连接子连接。
在某些实施方式中,所述第三靶向部分靶向免疫细胞相关抗原。
在某些实施方式中,所述免疫细胞相关抗原包括PD-1、PD-L1、CD3、CD16a和/或CD28。
在某些实施方式中,所述第三靶向部分靶向CD3或CD16a蛋白。
在某些实施方式中,所述第三靶向部分靶向肿瘤发生相关抗原。
在某些实施方式中,所述第三靶向部分靶向EGFR和/或cMet。
在某些实施方式中,所述第三靶向部分靶向肿瘤相关抗原。
在某些实施方式中,所述肿瘤相关抗原包括PD-L1、HER2、CD47、CD19和/或CD20。
在某些实施方式中,所述第二多肽链还包含第四靶向部分。
在某些实施方式中,所述第二多肽链中第四靶向部分与所述第二靶向部分的C端直接或间接地连接。
在某些实施方式中,所述第二多肽链中第四靶向部分与所述第二靶向部分的C端通过连接子连接。
在某些实施方式中,所述第四靶向部分靶向免疫细胞相关抗原。
在某些实施方式中,所述免疫细胞相关抗原包括PD-1、PD-L1、CD3、CD16a和/或CD28。
在某些实施方式中,所述第四靶向部分靶向肿瘤发生相关抗原。
在某些实施方式中,所述第四靶向部分靶向EGFR和/或cMet。
在某些实施方式中,所述第四靶向部分靶向肿瘤相关抗原。
在某些实施方式中,所述肿瘤相关抗原包括PD-L1、HER2、CD47、CD19和/或CD20。
在某些实施方式中,所述第一多肽链包含细胞因子。
在某些实施方式中,所述细胞因子包括IL-2、IFNa、IFNb和/或IL-15。
在某些实施方式中,所述第二多肽链包含细胞因子。
在某些实施方式中,所述细胞因子包括IL-2、IFNa、IFNb和/或IL-15。
在某些实施方式中,所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-L1,所述第四靶向部分靶向PD-1、CD3或CD16a。
在某些实施方式中,所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-1,所述第四靶向部分靶向PD-L1、CD3或CD16a。
在某些实施方式中,所述第一靶向部分靶向PD-L1,所述第二靶 向部分靶向PD-1,所述第三靶向部分靶向CD3或CD16a。
在某些实施方式中,所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-L1,所述第三靶向部分靶向CD3或CD16a。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向CD28或CD16a,所述第二靶向部分靶向PD-1,所述第四靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向CD28或CD16a,所述第四靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向CD28或CD16a,所述第二靶向部分靶向PD-1,所述第三靶向部分靶向EGFR或cMET,所述第四靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向CD28或CD16a,所述第三靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20,所述第四靶向部分靶向EGFR或cMET。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-1,且所述第二多肽链包含IL-2或IL-15。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-L1,且所述第二多肽链包含IL-2或IL-15。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-L1,所述第一多肽链包含IL-2或IL-15,第四靶向部分包含CD3或CD16a。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-1,所述第一多肽链包含IL-2或IL-15,第四靶向部分包含CD3或CD16a。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-1,所述第一多肽链包含IL-2或IL-15。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-L1,所述第一多肽链包含IL-2或IL-15。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-1,所述第一多肽链包含IL-2或IL-15,且第四靶向部分靶向PD-L1。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-L1,所述第一多肽链包含IL-2或IL-15,且第四靶向部分靶向PD-1。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-L1,第三靶向部分靶向CD3或CD16a,且所述第二多肽链包含IL-2或IL-15。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-1,第三靶向部分靶向CD3或CD16a,且所述第二多肽链包含IL-2或IL-15。
在某些实施方式中,所述第一靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:51所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含HCDR2,所述HCDR2包含SEQ ID NO:6所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含HCDR1,所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含SEQ ID NO:52所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
在某些实施方式中,所述第一靶向部分包含SEQ ID NO:29至SEQ  ID NO:31中任一项所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
在某些实施方式中,所述第一靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:51所示的氨基酸序列;所述HCDR2包含SEQ ID NO:6所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列;所述HCDR2包含SEQ ID NO:6所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的HCDR1、HCDR2和HCDR3包含选自下述任意一组的氨基酸序列:
a)HCDR1:SEQ ID NO:3,HCDR2:SEQ ID NO:6和HCDR3:SEQ ID NO:9;和
b)HCDR1:SEQ ID NO:3,HCDR2:SEQ ID NO:6和HCDR3:SEQ ID NO:10。
在某些实施方式中,所述第一靶向部分包含H-FR1,所述H-FR1的C末端与所述HCDR1的N末端直接或间接地相连,且所述H-FR1包含SEQ ID NO:47所示的氨基酸序列。
在某些实施方式中,所述H-FR1包含SEQ ID NO:1和SEQ ID NO:2中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR2,所述H-FR2位于所述HCDR1与所述HCDR2之间,且所述H-FR2包含SEQ ID NO:48所示的氨基酸序列。
在某些实施方式中,所述H-FR2包含SEQ ID NO:4和SEQ ID NO:5中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR3,所述H-FR3位于所述HCDR2与所述HCDR3之间,且所述H-FR3包含SEQ ID NO:49所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述H-FR3包含SEQ ID NO:7和SEQ ID NO:8中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR4,所述H-FR4的N末端与所述HCDR3的C末端直接或间接地相连,且所述H-FR4包含SEQ ID NO:50所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述H-FR4包含SEQ ID NO:11和SEQ ID NO:12中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:47所示的氨基酸序列;所述H-FR2包含SEQ ID NO:48所示的氨基酸序列;所述H-FR3包含SEQ ID NO:49所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:50所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:1和SEQ ID NO:2中任一项所示的氨基酸序列;所述H-FR2包含SEQ ID NO:4和SEQ ID NO:5中任一项所示的氨基酸序列;所述H-FR3包含SEQ ID NO:7和SEQ ID NO:8中任一项所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:11和SEQ ID NO:12中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述H-FR1、H-FR2、H-FR3和H-FR4包含选自下述任意一组的氨基酸序列:
a)H-FR1:SEQ ID NO:1,H-FR2:SEQ ID NO:4,H-FR3:SEQ ID NO:7和H-FR4:SEQ ID NO:11;和
b)H-FR1:SEQ ID NO:2,H-FR2:SEQ ID NO:5,H-FR3:SEQ ID NO:8和H-FR4:SEQ ID NO:12。
在某些实施方式中,所述第一靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:52所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:57所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含LCDR2,所述LCDR2包含SEQ ID NO:18所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含LCDR1,所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含SEQ ID NO:58所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
在某些实施方式中,所述第一靶向部分包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
在某些实施方式中,所述第一靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:57所示的氨基酸序列;所述LCDR2包含SEQ ID NO:18所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列;所述LCDR2包含SEQ ID NO:18所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中所述LCDR1、LCDR2和LCDR3包含选自下述任意一组的氨基酸序列:
a)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:21;
b)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:22;
c)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:23;
d)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:24;
e)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:25;和
f)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:26。
在某些实施方式中,所述第一靶向部分包含L-FR1,所述L-FR1的C末端与所述LCDR1的N末端直接或间接地相连,且所述L-FR1包含SEQ ID NO:53所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR1包含SEQ ID NO:13和SEQ ID NO:14中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR2,所述L-FR2位于所述LCDR1与所述LCDR2之间,且所述L-FR2包含SEQ ID NO:54所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR2包含SEQ ID NO:16和SEQ ID NO:17中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR3,所述L-FR3位于所述LCDR2与所述LCDR3之间,且所述L-FR3包含SEQ ID NO:55所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR3包含SEQ ID NO:19和SEQ ID NO:20中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR4,所述L-FR4的N末端与所述LCDR3的C末端直接或间接地相连,且所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR4包含SEQ ID NO:27和SEQ ID NO:28中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:53所示的氨基酸序列;所述L-FR2包含SEQ ID NO:54所示的氨基酸序列;所述L-FR3包含SEQ ID  NO:55所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:13和SEQ ID NO:14中任一项所示的氨基酸序列;所述L-FR2包含SEQ ID NO:16和SEQ ID NO:17中任一项所示的氨基酸序列;所述L-FR3包含SEQ ID NO:19和SEQ ID NO:20中任一项所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:27和SEQ ID NO:28中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR1、L-FR2、L-FR3和L-FR4包含选自下述任意一组的氨基酸序列:
a)L-FR1:SEQ ID NO:13,L-FR2:SEQ ID NO:16,L-FR3:SEQ ID NO:19和L-FR4:SEQ ID NO:27;和
b)L-FR1:SEQ ID NO:14,L-FR2:SEQ ID NO:17,L-FR3:SEQ ID NO:20和L-FR4:SEQ ID NO:28。
在某些实施方式中,所述第一靶向部分包括VL,所述VL包含SEQ ID NO:58中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述VL包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:76所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含HCDR2,所述HCDR2包含SEQ ID NO:70所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含HCDR1,所述HCDR1包含SEQ ID NO:61所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含SEQ ID NO:122所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
在某些实施方式中,所述第一靶向部分包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
在某些实施方式中,所述第一靶向部分包括重链可变区VH,所述 VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:76所示的氨基酸序列;所述HCDR2包含SEQ ID NO:70所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:61所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR1,所述H-FR1的C末端与所述HCDR1的N末端直接或间接地相连,且所述H-FR1包含SEQ ID NO:115所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述H-FR1包含SEQ ID NO:59至SEQ ID NO:60中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR2,所述H-FR2位于所述HCDR1与所述HCDR2之间,且所述H-FR2包含SEQ ID NO:116所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述H-FR2包含SEQ ID NO:62至SEQ ID NO:69中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR3,所述H-FR3位于所述HCDR2与所述HCDR3之间,且所述H-FR3包含SEQ ID NO:117所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述H-FR3包含SEQ ID NO:71至SEQ ID NO:75中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR4,所述H-FR4的N末端与所述HCDR3的C末端直接或间接地相连,且所述H-FR4包含SEQ ID NO:118所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述H-FR4包含SEQ ID NO:77至SEQ ID NO:78中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:115所示的氨基酸序列;所述H-FR2包含SEQ ID NO:116所示的氨基酸序列;所述H-FR3包含SEQ ID NO:117所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:118所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含H-FR1,H-FR2,H-FR3 和H-FR4,所述H-FR1包含SEQ ID NO:59至SEQ ID NO:60中任一项所示的氨基酸序列;所述H-FR2包含SEQ ID NO:62至SEQ ID NO:69中任一项所示的氨基酸序列;所述H-FR3包含SEQ ID NO:71至SEQ ID NO:75中任一项所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:77至SEQ ID NO:78中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述H-FR1、H-FR2、H-FR3和H-FR4包含选自下述任意一组的氨基酸序列:
a)H-FR1:SEQ ID NO:59,H-FR2:SEQ ID NO:62,H-FR3:SEQ ID NO:71和H-FR4:SEQ ID NO:77;
b)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:63,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
c)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:64,H-FR3:SEQ ID NO:73和H-FR4:SEQ ID NO:78;
d)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:65,H-FR3:SEQ ID NO:74和H-FR4:SEQ ID NO:78;
e)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:66,H-FR3:SEQ ID NO:75和H-FR4:SEQ ID NO:78;
f)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:67,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
g)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:65,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
h)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:64,H-FR3:SEQ ID NO:74和H-FR4:SEQ ID NO:78;
i)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:68,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;和
j)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:69,H-FR3:SEQ ID NO:73和H-FR4:SEQ ID NO:78。
在某些实施方式中,所述第一靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:122所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的VH包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:94所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含LCDR2,所述LCDR2包含SEQ ID NO:87所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含LCDR1,所述LCDR1包含SEQ ID NO:82所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含SEQ ID NO:123中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
在某些实施方式中,所述第一靶向部分包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
在某些实施方式中,所述第一靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:94所示的氨基酸序列;所述LCDR2包含SEQ ID NO:87所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:82所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR1,所述L-FR1的C末端与所述LCDR1的N末端直接或间接地相连,且所述L-FR1包含SEQ ID NO:119所示的氨基酸序列。
在某些实施方式中,所述L-FR1包含SEQ ID NO:79至SEQ ID NO:81中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR2,所述L-FR2位于所述LCDR1与所述LCDR2之间,且所述L-FR2包含SEQ ID NO:120所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR2包含SEQ ID NO:83至SEQ ID NO:86中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR3,所述L-FR3位于所述LCDR2与所述LCDR3之间,且所述L-FR3包含SEQ ID NO:121 所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR3包含SEQ ID NO:88至SEQ ID NO:93中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR4,所述L-FR4的N末端与所述LCDR3的C末端直接或间接地相连,且所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR4包含SEQ ID NO:27至SEQ ID NO:28中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:119所示的氨基酸序列;所述L-FR2包含SEQ ID NO:120所示的氨基酸序列;所述L-FR3包含SEQ ID NO:121所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:79至SEQ ID NO:81中任一项所示的氨基酸序列;所述L-FR2包含SEQ ID NO:83至SEQ ID NO:86中任一项所示的氨基酸序列;所述L-FR3包含SEQ ID NO:88至SEQ ID NO:93中任一项所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:27至SEQ ID NO:28中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述L-FR1、L-FR2、L-FR3和L-FR4包含选自下述任意一组的氨基酸序列:
a)L-FR1:SEQ ID NO:79,L-FR2:SEQ ID NO:83,L-FR3:SEQ ID NO:88和L-FR4:SEQ ID NO:27;
b)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:84,L-FR3:SEQ ID NO:89和L-FR4:SEQ ID NO:28;
c)L-FR1:SEQ ID NO:81,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:90和L-FR4:SEQ ID NO:28;
d)L-FR1:SEQ ID NO:81,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:91和L-FR4:SEQ ID NO:28;
e)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:90和L-FR4:SEQ ID NO:28;
f)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:92和L-FR4:SEQ ID NO:28;和
g)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:86,L-FR3:SEQ ID NO:93和L-FR4:SEQ ID NO:28。
在某些实施方式中,所述第一靶向部分包括VL,所述VL包含SEQ ID NO:123所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分中的所述VL包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向CD28,所述第一靶向部分包含VH,所述VH包含SEQ ID NO:176所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第一靶向部分靶向CD16a,所述第一靶向部分包含VH,所述VH包含SEQ ID NO:168所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:51所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含HCDR2,所述HCDR2包含SEQ ID NO:6所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含HCDR1,所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含SEQ ID NO:52所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
在某些实施方式中,所述第二靶向部分包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
在某些实施方式中,所述第二靶向部分包括重链可变区VH,所述 VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:51所示的氨基酸序列;所述HCDR2包含SEQ ID NO:6所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列;所述HCDR2包含SEQ ID NO:6所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述HCDR1、HCDR2和HCDR3包含选自下述任意一组的氨基酸序列:
a)HCDR1:SEQ ID NO:3,HCDR2:SEQ ID NO:6和HCDR3:SEQ ID NO:9;和
b)HCDR1:SEQ ID NO:3,HCDR2:SEQ ID NO:6和HCDR3:SEQ ID NO:10。
在某些实施方式中,所述第二靶向部分包含H-FR1,所述H-FR1的C末端与所述HCDR1的N末端直接或间接地相连,且所述H-FR1包含SEQ ID NO:47所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR1包含SEQ ID NO:1和SEQ ID NO:2中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR2,所述H-FR2位于所述HCDR1与所述HCDR2之间,且所述H-FR2包含SEQ ID NO:48所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR2包含SEQ ID NO:4和SEQ ID NO:5中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR3,所述H-FR3位于所述HCDR2与所述HCDR3之间,且所述H-FR3包含SEQ ID NO:49所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR3包含SEQ ID NO:7和SEQ ID NO:8中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR4,所述H-FR4的N末端与所述HCDR3的C末端直接或间接地相连,且所述H-FR4包含SEQ ID NO:50所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR4包含SEQ ID NO:11和SEQ ID NO:12中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:47所示的氨基酸序列;所述H-FR2包含SEQ ID NO:48所示的氨基酸序列;所述H-FR3包含SEQ ID NO:49所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:50所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:1和SEQ ID NO:2中任一项所示的氨基酸序列;所述H-FR2包含SEQ ID NO:4和SEQ ID NO:5中任一项所示的氨基酸序列;所述H-FR3包含SEQ ID NO:7和SEQ ID NO:8中任一项所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:11和SEQ ID NO:12中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR1、H-FR2、H-FR3和H-FR4包含选自下述任意一组的氨基酸序列:
a)H-FR1:SEQ ID NO:1,H-FR2:SEQ ID NO:4,H-FR3:SEQ ID NO:7和H-FR4:SEQ ID NO:11;和
b)H-FR1:SEQ ID NO:2,H-FR2:SEQ ID NO:5,H-FR3:SEQ ID NO:8和H-FR4:SEQ ID NO:12。
在某些实施方式中,所述第二靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:52所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:57所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含LCDR2,所述LCDR2包含SEQ ID NO:18所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含LCDR1,所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含SEQ ID NO:58所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
在某些实施方式中,所述第二靶向部分包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
在某些实施方式中,所述第二靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:57所示的氨基酸序列;所述LCDR2包含SEQ ID NO:18所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列;所述LCDR2包含SEQ ID NO:18所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述LCDR1、LCDR2和LCDR3包含选自下述任意一组的氨基酸序列:
a)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:21;
b)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:22;
c)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:23;
d)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:24;
e)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:25;和
f)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:26。
在某些实施方式中,所述第二靶向部分包含L-FR1,所述L-FR1的C末端与所述LCDR1的N末端直接或间接地相连,且所述L-FR1包含SEQ ID NO:53所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR1包含SEQ ID NO:13和SEQ ID NO:14中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR2,所述L-FR2位于所述LCDR1与所述LCDR2之间,且所述L-FR2包含SEQ ID NO:54所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR2包含SEQ ID NO:16和SEQ ID NO:17中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR3,所述L-FR3位于所述LCDR2与所述LCDR3之间,且所述L-FR3包含SEQ ID NO:55所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR3包含SEQ ID NO:19和SEQ ID NO:20中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR4,所述L-FR4的N末端与所述LCDR3的C末端直接或间接地相连,且所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR4包含SEQ ID NO:27和SEQ ID NO:28中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:53所示的氨基酸序列;所述L-FR2包含SEQ ID NO:54所示的氨基酸序列;所述L-FR3包含SEQ ID NO:55所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:13和SEQ ID NO:14中任一项所示的氨基酸序列;所述L-FR2包含SEQ ID NO:16和SEQ ID NO:17中任一项所示的氨基酸序列;所述L-FR3包含SEQ ID NO:19和SEQ ID NO:20中任一项所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:27和SEQ ID NO:28中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR1、L-FR2、L-FR3和L-FR4包含选自下述任意一组的氨基酸序列:
a)L-FR1:SEQ ID NO:13,L-FR2:SEQ ID NO:16,L-FR3:SEQ ID NO:19和L-FR4:SEQ ID NO:27;和
b)L-FR1:SEQ ID NO:14,L-FR2:SEQ ID NO:17,L-FR3:SEQ ID NO:20和L-FR4:SEQ ID NO:28。
在某些实施方式中,所述第二靶向部分包括VL,所述VL包含SEQ ID NO:58中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述VL包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:76所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含HCDR2,所述HCDR2包含SEQ ID NO:70所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含HCDR1,所述HCDR1包含SEQ ID NO:61所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含SEQ ID NO:122所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
在某些实施方式中,所述第二靶向部分包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
在某些实施方式中,所述第二靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:76所示的氨基酸序列;所述HCDR2包含SEQ ID NO:70所示的氨基酸序 列;以及所述HCDR1包含SEQ ID NO:61所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR1,所述H-FR1的C末端与所述HCDR1的N末端直接或间接地相连,且所述H-FR1包含SEQ ID NO:115所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR1包含SEQ ID NO:59至SEQ ID NO:60中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR2,所述H-FR2位于所述HCDR1与所述HCDR2之间,且所述H-FR2包含SEQ ID NO:116所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR2包含SEQ ID NO:62至SEQ ID NO:69中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR3,所述H-FR3位于所述HCDR2与所述HCDR3之间,且所述H-FR3包含SEQ ID NO:117所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR3包含SEQ ID NO:71至SEQ ID NO:75中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR4,所述H-FR4的N末端与所述HCDR3的C末端直接或间接地相连,且所述H-FR4包含SEQ ID NO:118所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR4包含SEQ ID NO:77至SEQ ID NO:78中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:115所示的氨基酸序列;所述H-FR2包含SEQ ID NO:116所示的氨基酸序列;所述H-FR3包含SEQ ID NO:117所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:118所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:59至SEQ ID NO:60中任一项所示的氨基酸序列;所述H-FR2包含SEQ ID NO:62至SEQ ID NO: 69中任一项所示的氨基酸序列;所述H-FR3包含SEQ ID NO:71至SEQ ID NO:75中任一项所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:77至SEQ ID NO:78中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述H-FR1、H-FR2、H-FR3和H-FR4包含选自下述任意一组的氨基酸序列:
a)H-FR1:SEQ ID NO:59,H-FR2:SEQ ID NO:62,H-FR3:SEQ ID NO:71和H-FR4:SEQ ID NO:77;
b)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:63,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
c)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:64,H-FR3:SEQ ID NO:73和H-FR4:SEQ ID NO:78;
d)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:65,H-FR3:SEQ ID NO:74和H-FR4:SEQ ID NO:78;
e)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:66,H-FR3:SEQ ID NO:75和H-FR4:SEQ ID NO:78;
f)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:67,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
g)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:65,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
h)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:64,H-FR3:SEQ ID NO:74和H-FR4:SEQ ID NO:78;
i)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:68,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;和
j)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:69,H-FR3:SEQ ID NO:73和H-FR4:SEQ ID NO:78。
在某些实施方式中,所述第二靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:122所示的氨基酸序列。
在某些实施方式中,所述VH包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:94所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含LCDR2,所述LCDR2包含SEQ ID NO:87所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含LCDR1,所述LCDR1包含SEQ ID NO:82所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含SEQ ID NO:123中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
在某些实施方式中,所述第二靶向部分包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
在某些实施方式中,所述第二靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:94所示的氨基酸序列;所述LCDR2包含SEQ ID NO:87所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:82所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR1,所述L-FR1的C末端与所述LCDR1的N末端直接或间接地相连,且所述L-FR1包含SEQ ID NO:119所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR1包含SEQ ID NO:79至SEQ ID NO:81中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR2,所述L-FR2位于所述LCDR1与所述LCDR2之间,且所述L-FR2包含SEQ ID NO:120所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR2包含SEQ ID NO:83至SEQ ID NO:86中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR3,所述L-FR3位于所述LCDR2与所述LCDR3之间,且所述L-FR3包含SEQ ID NO:121所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR3包含SEQ  ID NO:88至SEQ ID NO:93中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR4,所述L-FR4的N末端与所述LCDR3的C末端直接或间接地相连,且所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中的所述L-FR4包含SEQ ID NO:27至SEQ ID NO:28中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:119所示的氨基酸序列;所述L-FR2包含SEQ ID NO:120所示的氨基酸序列;所述L-FR3包含SEQ ID NO:121所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:79至SEQ ID NO:81中任一项所示的氨基酸序列;所述L-FR2包含SEQ ID NO:83至SEQ ID NO:86中任一项所示的氨基酸序列;所述L-FR3包含SEQ ID NO:88至SEQ ID NO:93中任一项所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:27至SEQ ID NO:28中任一项所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分中所述L-FR1、L-FR2、L-FR3和L-FR4包含选自下述任意一组的氨基酸序列:
a)L-FR1:SEQ ID NO:79,L-FR2:SEQ ID NO:83,L-FR3:SEQ ID NO:88和L-FR4:SEQ ID NO:27;
b)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:84,L-FR3:SEQ ID NO:89和L-FR4:SEQ ID NO:28;
c)L-FR1:SEQ ID NO:81,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:90和L-FR4:SEQ ID NO:28;
d)L-FR1:SEQ ID NO:81,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:91和L-FR4:SEQ ID NO:28;
e)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:90和L-FR4:SEQ ID NO:28;
f)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:92和L-FR4:SEQ ID NO:28;和
g)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:86,L-FR3:SEQ ID NO:93和L-FR4:SEQ ID NO:28。
在某些实施方式中,所述第二靶向部分包括VL,所述VL包含SEQ ID NO:123所示的氨基酸序列。
在某些实施方式中,所述第二靶向部分的VL包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第二靶向部分靶向CD28,所述第二靶向部分包含VH,所述VH包含SEQ ID NO:176所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第二靶向部分靶向CD16a,所述第二靶向部分包含VH,所述VH包含SEQ ID NO:168所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白包括第一靶向部分和第二靶向部分,所述第一靶向部分包含SEQ ID NO:29至SEQ ID NO:31、SEQ ID NO:32至SEQ ID NO:38、SEQ ID NO:95至SEQ ID NO:104和SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列;所述第二靶向部分包含SEQ ID NO:29至SEQ ID NO:31、SEQ ID NO:32至SEQ ID NO:38、SEQ ID NO:95至SEQ ID NO:104和SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
在某些实施方式中,所述第一靶向部分和第二靶向部分包含选自下述任意一组的氨基酸序列:
a)第一靶向部分:SEQ ID NO:97和第二靶向部分:SEQ ID NO:31;
b)第一靶向部分:SEQ ID NO:98和第二靶向部分:SEQ ID NO:31;
c)第一靶向部分:SEQ ID NO:100和第二靶向部分:SEQ ID NO:31;
d)第一靶向部分:SEQ ID NO:102和第二靶向部分:SEQ ID NO:31;
e)第一靶向部分:SEQ ID NO:103和第二靶向部分:SEQ ID NO:31;
f)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:97;
g)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:98;
h)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:100;
i)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:102;
j)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:103;
k)第一靶向部分:SEQ ID NO:97和第二靶向部分:SEQ ID NO:36;
l)第一靶向部分:SEQ ID NO:98和第二靶向部分:SEQ ID NO:36;
m)第一靶向部分:SEQ ID NO:100和第二靶向部分:SEQ ID NO:36;
n)第一靶向部分:SEQ ID NO:102和第二靶向部分:SEQ ID NO:36;
o)第一靶向部分:SEQ ID NO:103和第二靶向部分:SEQ ID NO:36;
p)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:97;
q)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:98;
r)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO: 100;
s)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:102;
t)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:103;
u)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:176;
v)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:168;
w)第一靶向部分:SEQ ID NO:176和第二靶向部分:SEQ ID NO:31;
x)第一靶向部分:SEQ ID NO:168和第二靶向部分:SEQ ID NO:31。
在某些实施方式中,所述第二多肽链包含重链恒定区,且所述重链恒定区包括源自IgG的恒定区或源自IgY的恒定区。
在某些实施方式中,所述第二多肽链中所述重链恒定区包括源自IgG的恒定区。
在某些实施方式中,所述第二多肽链中所述重链恒定区包括源自IgG1、IgG2、IgG3或IgG4的恒定区。
在某些实施方式中,所述第二多肽链中所述重链恒定区包括源自IgG1的Fc区。
在某些实施方式中,所述第二多肽链中所述重链恒定区中的Fc区包含N297A突变,残基根据Kabat系统进行编号。
在某些实施方式中,所述重链恒定区中的Fc区包含M252Y、S254T和T256E突变,残基根据Kabat系统进行编号。
在某些实施方式中,所述第二多肽链中所述重链恒定区包含SEQ ID NO:112至SEQ ID NO:113所示的氨基酸序列。
在某些实施方式中,所述第一多肽链包含轻链恒定区,且所述轻链恒定区包括源自Igκ的恒定区或源自Igλ的恒定区。
在某些实施方式中,所述轻链恒定区包括源自人Igκ的恒定区。
在某些实施方式中,所述轻链恒定区包含SEQ ID NO:114所示 的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第三靶向部分包含VH,所述VH包含SEQ ID NO:168、170、172、174、176和178中任一项所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第三靶向部分包含VL,所述VL包含SEQ ID NO:169、171、173、175、177和179中任一项所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第三靶向部分包括抗体或抗原结合片段。
在某些实施方式中,所述分离的抗原结合蛋白中所述抗原结合片段选自下组:Fab,Fab’,F(ab)2,Fv片段,F(ab’)2,scFv,di-scFv,VHH和dAb。
在某些实施方式中,所述分离的抗原结合蛋白中所述第三靶向部分为scFv。
在某些实施方式中,所述分离的抗原结合蛋白中所述第三靶向部分中VH的C端与所述VL的N端直接或间接地连接。
在某些实施方式中,所述分离的抗原结合蛋白中所述第三靶向部分中VL的C端与所述VH的N端直接或间接地连接。
在某些实施方式中,所述分离的抗原结合蛋白中所述第四靶向部分包含VH,所述VH包含SEQ ID NO:29-31、95-104、168、170、172、174、176和178中任一项所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第四靶向部分包含VL,所述VL包含SEQ ID NO:32-38、105-111、169、171、173、175、177和179中任一项所示的氨基酸序列。
在某些实施方式中,所述分离的抗原结合蛋白中所述第四靶向部分包括抗体或抗原结合片段。
在某些实施方式中,所述分离的抗原结合蛋白中所述抗原结合片段选自下组:Fab,Fab’,F(ab)2,Fv片段,F(ab’)2,scFv,di-scFv,VHH和dAb。
在某些实施方式中,所述分离的抗原结合蛋白中所述第四靶向部分为scFv。
在某些实施方式中,所述分离的抗原结合蛋白中所述第四靶向部分中VH的C端与所述VL的N端直接或间接地连接。
在某些实施方式中,所述分离的抗原结合蛋白中所述第四靶向部分中VL的C端与所述VH的N端直接或间接地连接。
在某些实施方式中,所述抗原结合蛋白包含两条第一多肽链和两条第二多肽链,所述两条第一多肽链之间通过二硫键连接,所述两条第一多肽链和两条第二多肽链形成IgG样的抗体。
在某些实施方式中,所述抗原结合蛋白包括单克隆抗体、单链抗体、嵌合抗体、人源化抗体、多特异性抗体、双特异性抗体和/或全人源抗体。
另一方面,本申请提供了一种或多种多肽,其包含所述分离的抗原结合蛋白。
另一方面,本申请提供了一种或多种免疫缀合物,其包含所述分离的抗原结合蛋白或所述的多肽。
另一方面,本申请提供了一种或多种分离的核酸分子,其编码所述分离的抗原结合蛋白,或者所述的多肽。
另一方面,本申请提供了一种或多种载体,其包含所述分离的核酸分子。
另一方面,本申请提供了一种或多种细胞,其包含所述分离的抗原结合蛋白,所述的多肽,所述的免疫缀合物,所述分离的核酸分子和/或所述的载体。
另一方面,本申请提供了一种制备所述分离的抗原结合蛋白或所述的多肽的方法,所述方法包括再使得所述分离的抗原结合蛋白或所述的多肽表达的条件下,培养所述的细胞。
另一方面,本申请提供了一种或多种药物组合物,其包含所述分离的抗原结合蛋白,所述的多肽,所述的免疫缀合物,所述分离的核酸分子,所述的载体,所述的细胞,和/或药学上可接受的佐剂和/ 或赋形剂。
另一方面,本申请提供了一种抑制PD-1与PD-L1相互作用的方法,其包括向有需要的受试者施用有效量的所述分离的抗原结合蛋白,所述的多肽,所述的免疫缀合物,所述分离的核酸分子,所述的载体,和/或所述的细胞。
另一方面,本申请提供了所述分离的抗原结合蛋白,所述的多肽,所述的免疫缀合物,所述分离的核酸分子,所述的载体,所述的细胞和/或所述的药物组合物在制备预防和/或治疗疾病或病症的药物中的用途。
在某些实施方式中,所述疾病或病症包括肿瘤。
在某些实施方式中,所述肿瘤包括实体瘤。
在某些实施方式中,所述肿瘤包括非实体瘤。
在某些实施方式中,所述肿瘤包括乳腺癌、肺癌、胃癌、肠癌、肾癌、黑色素瘤、非小细胞肺癌、结肠癌、膀胱癌、卵巢癌、胰腺癌和/或肝癌。
另一方面,本申请提供了所述分离的抗原结合蛋白,所述的多肽,所述的免疫缀合物,所述分离的核酸分子,所述的载体,所述的细胞和/或所述的药物组合物,其用于预防、缓解和/或治疗疾病或病症。
在某些实施方式中,所述疾病或病症包括肿瘤。
在某些实施方式中,所述肿瘤包括实体瘤。
在某些实施方式中,所述肿瘤包括非实体瘤。
在某些实施方式中,所述肿瘤包括乳腺癌、肺癌、胃癌、肠癌、肾癌、黑色素瘤、非小细胞肺癌、结肠癌、膀胱癌、卵巢癌、胰腺癌和/或肝癌。
另一方面,本申请提供了一种预防和/或治疗疾病或病症的方法,其包括向有需要的受试者施用有效量的所述分离的抗原结合蛋白,所述的多肽,所述的免疫缀合物,所述分离的核酸分子,所述的载体,和/或所述的细胞。
在某些实施方式中,所述疾病或病症包括肿瘤。
在某些实施方式中,所述肿瘤包括实体瘤。
在某些实施方式中,所述肿瘤包括非实体瘤。
在某些实施方式中,所述肿瘤包括乳腺癌、肺癌、胃癌、肠癌、肾癌、黑色素瘤、非小细胞肺癌、结肠癌、膀胱癌、卵巢癌、胰腺癌和/或肝癌。
本领域技术人员能够从下文的详细描述中容易地洞察到本申请的其它方面和优势。下文的详细描述中仅显示和描述了本申请的示例性实施方式。如本领域技术人员将认识到的,本申请的内容使得本领域技术人员能够对所公开的具体实施方式进行改动而不脱离本申请所涉及发明的精神和范围。相应地,本申请的附图和说明书中的描述仅仅是示例性的,而非为限制性的。
附图说明
本申请所涉及的发明的具体特征如所附权利要求书所显示。通过参考下文中详细描述的示例性实施方式和附图能够更好地理解本申请所涉及发明的特点和优势。对附图简要说明如下:
图1A-1B显示的是本申请所述示例性的抗原结合蛋白的结构示意图。
图2显示的是本申请所述示例性的双特异性抗体与PD-1高表达、PDL1高表达或野生型的HEK293细胞的结合结果。
图3显示的是本申请所述示例性的双特异性抗体的ELISA实验结果。
具体实施方式
以下由特定的具体实施例说明本申请发明的实施方式,熟悉此技术的人士可由本说明书所公开的内容容易地了解本申请发明的其他优点及效果。
术语定义
在本申请中,术语“分离的”通常指从天然状态下经人工手段获得的。如果自然界中出现某一种“分离”的物质或成分,那么可能是其所处的天然环境发生了改变,或从天然环境下分离出该物质,或二者情况均有发生。例如,某一活体动物体内天然存在某种未被分离的多聚核苷酸或多肽,而从这种天然状态下分离出来的高纯度的相同的多聚核苷酸或多肽即称之为分离的。术语“分离的”不排除混有人工或合成的物质,也不排除存在不影响物质活性的其它不纯物质。
在本申请中,术语“抗原结合蛋白”通常是指一种能够特异性识别和/或中和特定抗原的多肽分子。例如,在本申请中,术语“抗原结合蛋白”可包括“抗体”或“抗原结合片段”。例如,所述抗体可包含通过二硫键相互连接的至少两条重(H)链和两条轻(L)链组成的免疫球蛋白,并且可包括任何包含其抗原结合部分的分子。术语“抗体”可包括单克隆抗体、抗体片段或抗体衍生物,包括但不限于鼠源抗体、人抗体(全人源抗体)、人源化抗体、嵌合抗体、双特异性抗体、多特异性抗体、单链抗体(例如,scFv),以及与抗原结合的抗体片段(例如,Fab、Fab’,VHH和(Fab)2片段)。术语“抗体”还可包括抗体的所有重组体形式,例如在原核细胞中表达的抗体、未糖基化的抗体以及本文所述的任何与抗原结合的抗体片段及其衍生物。每条重链可由重链可变区(VH)和重链恒定区构成。每条轻链可由轻链可变区(VL)和轻链恒定区构成。VH和VL区可进一步被区分为称为互补决定区(CDR)的高变区,它们散布在称为构架区(FR)的更保守的区域中。每个VH和VL可由三个CDR和四个FR区构成,它们从氨基端至羧基端可按以下顺序排列:FR1、CDR1、FR2、CDR2、FR3、CDR3和FR4。重链和轻链的可变区含有与抗原(例如,人PD-L1)相互作用的结合结构域。抗体的恒定区可介导该免疫球蛋白与宿主组织或因子的结合,所述宿主组织或因子包括免疫系统的多种细胞(例如,效应细胞)和经典补体系统的第一成分(Clq)。所述CDRs的确 切边界已根据不同系统不同地限定。由Kabat(Kabat等人,Sequences of Proteins of Immunological Interest(National Institutes of Health,Bethesda,Md.(1987)和(1991))描述的系统,不仅提供了可应用于抗原结合片段的任何可变区的明确残基编号系统,还提供了限定CDRs的精确残基边界。这些CDRs可以被称为Kabat CDRs。Chothia和同事(Chothia和Lesk,J.Mol.Biol.196:901-917(1987)以及Chothia等人,Nature 342:877-883(1989))发现尽管在氨基酸序列水平上具有大的多样性,但是Kabat CDRs内的某些亚部分采取几乎相同的肽主链构象。这些亚部分命名为L1、L2和L3或H1、H2和H3,其中“L”和“H”分别指轻链和重链区域。这些区域可以被称为Chothia CDRs,所述Chothia CDRs具有与Kabat CDRs重叠的边界。与Kabat CDRs重叠的限定CDRs的其他边界已由Padlan(FASEB J.9:133-139(1995))和MacCallum(J Mol Biol 262(5):732-45(1996))描述。另外,其他的CDR边界定义可能不严格地遵循上述系统之一,但仍将与Kabat CDRs重叠,尽管按照特定残基或残基组或甚至整个CDRs并不显著影响抗原结合的预测或实验发现,它们可以缩短或加长。在本申请中,所述CDR可通过使用的是Kabat编号系统定义。
在本申请中,术语“抗原结合片段”通常是指抗体中发挥特异性结合抗原功能的一个或多个片段。抗体的抗原结合功能可通过抗体的全长片段来实现。抗体的抗原结合功能也可通过以下来实现:包括Fv、ScFv、dsFv、Fab、Fab’或F(ab’)2的片段的重链,或者,包括Fv、scFv、dsFv、Fab、Fab’或F(ab’)2的片段的轻链。(1)Fab片段,通常为由VL、VH、CL和CH结构域组成的一价片段;(2)F(ab’)2片段,包含通过铰链区处的二硫键连接的两个Fab片段的二价片段;(3)由VH和CH结构域组成的Fd片段;(4)由抗体单臂的VL和VH结构域组成的Fv片段;(5)由VH结构域组成的dAb片段(Ward等,(1989)Nature 341:544-546);(6)分离的互补决定区(CDR)和(7)可任选地通过接头连接的两个或以上分离的CDR的组合。例如,还可包括由VL和VH配对形成的一价单链分子Fv (scFv)(参见Bird等(1988)Science 242:423-426;以及Huston等(1988)Proc.Natl.Acad.Sci.85:5879-5883)。例如,还可包括缺失抗体轻链而只有重链可变区的一类抗体VHH(例如,可参见康晓圳等,生物工程学报,2018,34(12):1974-1984)。所述“抗原结合部分”还可包括免疫球蛋白融合蛋白,所述融合蛋白包含选自以下的结合结构域:(1)与免疫球蛋白铰链区多肽融合的结合结构域多肽;(2)与铰链区融合的免疫球蛋白重链CH2恒定区;和(3)与CH2恒定区融合的免疫球蛋白重链CH3恒定区。
在本申请中,术语“单克隆抗体”通常是指一群基本同源的抗体,即包含该群的各个抗体除了可能的以微量存在的天然发生的突变之外是相同的。单克隆抗体是高度特异性的,直接针对单个抗原性位点。例如,所述单克隆抗体可以通过杂交瘤技术制备或者通过使用重组DNA方法在细菌、真核动物或植物细胞中产生。单克隆抗体也可以得自噬菌体抗体文库,使用例如Clackson etal.,Nature,352:624-628(1991)和Marks et al.,Mol.Biol.,222:581-597(1991)所述的技术进行。
在本申请中,术语“嵌合抗体”通常是指这样的抗体,其中每个重链或轻链氨基酸序列的一部分与来自特定物种的抗体中相应氨基酸序列同源,或者属于特定的类别,而该链的其余区段则与另一物种中的相应序列同源。例如,轻链和重链的可变区均来自一个动物物种(如小鼠、大鼠等)的抗体的可变区,而恒定部分则与来自另一物种(如人)的抗体序列同源。例如,为获得嵌合抗体,可利用非人源的B细胞或杂交瘤细胞产生可变区,而与其组合的恒定区则来自人。所述可变区具有易于制备的优点,并且其特异性不受与其组合的恒定区的来源的影响。同时,由于嵌合抗体的恒定区可来源于人类,因此嵌合在注射时抗体引发免疫应答的可能性会低于使用恒定区为非人来源的抗体。
在本申请中,术语“人源化抗体”通常是指一种嵌合抗体,其含有较少的来自非人免疫球蛋白的序列,从而降低异种抗体引入到人类 中时的免疫原性,同时保持抗体的完全抗原结合亲和力和特异性。例如,可以使用CDR移植(Jones et al.,Nature 321:522(1986))及其变体;包括“重塑”(reshaping),(Verhoeyen,et al.,1988 Science 239:1534-1536;Riechmann,et al.,1988 Nature 332:323-337;Tempest,et al.,Bio/Technol 1991 9:266-271),“高度加成”(hyperchimerization),(Queen,et al.,1989 Proc Natl Acad Sci USA 86:10029-10033;Co,et al.,1991 Proc Natl Acad Sci USA 88:2869-2873;Co,et al.,1992 J Immunol 148:1149-1154)和“贴面”(veneering),(Mark,et al.,“Derivation of therapeutically active humanized and veneered anti-CD18 antibodies.”In:Metcalf B W,Dalton B J,eds.Cellular adhesion:molecular definition to therapeutic potential.New York:Plenum Press,1994:291-312)、表面重建(美国专利US5639641)等技术手段,对非人源的结合域进行人源化。如果其他区域,例如铰链区和恒定区结构域也源自非人来源,则这些区域也可以被人源化。
在本申请中,术语“鼠源抗体”通常是指可变区框架和CDR区得自小鼠种系免疫球蛋白序列的抗体。此外,如果抗体包含恒定区,其也得自小鼠种系免疫球蛋白序列。本申请的鼠源抗体可以包含不由小鼠种系免疫球蛋白序列编码的氨基酸残基,例如可以包括通过体外随机突变或点突变或通过体内体细胞突变而导入的突变。
在本申请中,术语“双特异性抗体”通常是指含有两种特异性抗原结合位点的抗体或抗原结合片段。在本申请中,双特异性抗体可以是同二聚体或者异二聚体。例如,在本申请中,所述双特异性抗体可以结合PD-1蛋白和PD-L1蛋白,能够有效抑制PD-L1和PD-1活化,进而治疗PD1/PD-L1相关的疾病(例如,肿瘤)。
在本申请中,术语“PD-L1”通常是指程序性死亡配体1蛋白、其功能变体和/或其功能活性片段。PD-L1也称为分化簇274(CD274)或B7同源物1(B7-H1),并且是由(人类中)CD274基因编码的蛋 白。PD-L1结合其受体,例如程序性死亡1(PD-1),所述PD-1在活化的T细胞、B细胞和巨噬细胞中表达(Ishida et al.,1992 EMBO J,11:3887-3395;Okazaki et al.,Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.Science,2001;291:319-22)。PD-L1和PD-1的络合通过抑制T细胞增殖和产生细胞因子IL-2和IFN-γ发挥免疫抑制作用(Freeman et al.,Engagement of PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation,J.Exp.Med.2000,192:1027-1034;Carter et al.,PD-1:PD-L inhibitory pathway affects both CD4(+)and CD8(+)T cells and is overcome by IL-2.Eur.J.Immunol.2002,32:634–643)。术语“PD-L1”涵盖任何脊椎动物来源的任何天然PD-L1,所述任何脊椎动物来源包括哺乳动物,诸如灵长类(例如,人)和啮齿类(例如,小鼠和大鼠)。所述术语涵盖“全长”、未加工的PD-L1以及由细胞中的加工所产生的任何形式的PD-L1。PD-L1可作为跨膜蛋白或作为可溶性蛋白存在。所述术语还涵盖天然存在的PD-L1的变体,例如剪接变体或等位基因变体。示例性的全长人PD-L1蛋白的氨基酸序列可在UniProt登录号Q9NZQ7下找到。例如,所述“功能活性片段”可以包括保留至少一种天然存在的蛋白质的内源功能(例如,与本申请所述的抗原结合蛋白结合)的片段。例如,所述“功能活性片段”可以包括与本申请的抗原结合蛋白结合的结构域。
在本申请中,术语“PD-1蛋白”,“PD-1”或“PD-1抗原”可以互换使用,并且包括PD-1的任何功能活性片段、变体和同源物,其由细胞天然表达或在用PD-1基因转染的细胞上表达。在本申请中,PD-1可以为人PD-1,其在UniProt/Swiss-Prot中的登录号为Q15116。例如,PD-1可以为人PD-1的功能活性片段。例如,所述“功能活性片段”可以包括保留至少一种天然存在的蛋白质的内源功能(例如,与本申请所述的抗原结合蛋白结合)的片段。例如,所述“功能活性片段”可以包括与本申请的抗原结合蛋白结合的结构域。
除了本文提到的特定蛋白质和核苷酸之外,本申请还可包括其功能活性片段、衍生物、类似物、同源物及其片段。
术语“功能活性片段”指与天然存在序列具有基本上同一的氨基酸序列或由基本上同一的核苷酸序列编码并能够具有天然存在序列的一种或多种活性的多肽。在本申请的上下文中,任何给定序列的功能活性片段是指其中残基的特定序列(无论是氨基酸或核苷酸残基)已经经过修饰而使得所述多肽或多核苷酸基本上保留至少一种内源功能的序列。可以通过天然存在的蛋白质和/或多核苷酸中存在的至少一个氨基酸残基和/或核苷酸残基的添加、缺失、取代、修饰、替换和/或变异来获得编码功能活性片段的序列,只要保持原来的功能活性即可。
在本申请中,术语“衍生物”通常是指对本申请的多肽或多核苷酸的一个(或多个)氨基酸残基(或核苷酸)的任何取代、变异、修饰、替换、缺失和/或添加,只要所得的多肽或多核苷酸基本上保留其至少一种内源功能。
在本申请中,术语“类似物”通常对多肽或多核苷酸而言,包括多肽或多核苷酸的任何模拟物,即拥有该模拟物模拟的多肽或多核苷酸的至少一种内源功能的化学化合物。
通常,可以进行氨基酸取代,例如至少1个(例如,1、2、3、4、5、6、7、8、9、10或20个以上)氨基酸取代,只要经修饰的序列基本上保持需要的活性或能力。氨基酸取代可包括使用非天然存在的类似物。
在本申请中,术语“同源物”通常是指与天然存在序列具有一定同源性的氨基酸序列或核苷酸序列。术语“同源性”可以等同于序列“同一性”。同源序列可以包括可以与主题序列是至少80%、85%、90%、99.1%、99.2%、99.3%、99.4%、99.5%、99.6%、99.7%、99.8%或99.9%相同的氨基酸序列。通常,同源物将包含与主题氨基酸序列相同的活性位点等。同源性可以根据相似性(即具有相似化学性质/功能的氨基酸残基)来考虑,也可以在序列同一性方面表达同源性。 在本申请中,提及的氨基酸序列或核苷酸序列的SEQ ID NO中的任一项具有百分比同一性的序列是指在所提及的SEQ ID NO的整个长度上具有所述百分比同一性的序列。为了确定序列同一性,可进行序列比对,其可通过本领域技术人员了解的各种方式进行,例如,使用BLAST、BLAST-2、ALIGN、NEEDLE或Megalign(DNASTAR)软件等。本领域技术人员能够确定用于比对的适当参数,包括在所比较的全长序列中实现最优比对所需要的任何算法。
用于本申请的蛋白质或多肽也可以具有氨基酸残基的缺失、插入或取代,所述氨基酸残基产生沉默的变化并导致功能上等同的蛋白质。可以根据残基的极性、电荷、溶解性、疏水性、亲水性和/或两性性质的相似性进行有意的氨基酸取代,只要保留内源性功能即可。例如,带负电荷的氨基酸包括天冬氨酸和谷氨酸;带正电荷的氨基酸包括赖氨酸和精氨酸;并且含具有相似亲水性值的不带电极性头基的氨基酸包括天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸和酪氨酸。
在本申请中,术语“肿瘤”通常是指在各种致瘤因子作用下,局部组织细胞增生所形成的赘生物。例如,所述肿瘤可包括实体瘤。例如,所述肿瘤可包括非实体瘤。例如,所述肿瘤可包括与PD-L1的表达相关的肿瘤。术语“与PD-L1的表达相关的肿瘤”通常是指PD-L1表达改变导致疾病进展或逃避免疫监视而形成的肿瘤。例如,所述“与PD-L1的表达相关的肿瘤”可以是PD-L1表达量上调导致疾病进展或逃避免疫监视而形成的肿瘤。所述与PD-L1的蛋白表达相关的肿瘤可以是PD-L1阳性的肿瘤。在PD-L1阳性的肿瘤中,与正常细胞相比,肿瘤细胞表面或肿瘤微环境中的PD-L1的蛋白表达量高约1%,5%,10%,15%,20%,25%,30%,35%,40%,50%,60%,70%,80%或更高。
在本申请中,术语“实体瘤”通常是指可通过临床检测(例如,X线射片,CT扫描,B超或触诊)到的有形肿块。例如,所述实体瘤可包括乳腺癌、肺癌、胃癌、肠癌、肾癌、黑色素瘤、非小细胞肺癌、结肠癌、膀胱癌、卵巢癌、胰腺癌和/或肝癌。
在本申请中,术语“非实体瘤”通常是指X线射片、CT扫描、B 超以及触诊无法看到或扪及到的肿瘤。例如,所述非实体瘤可以包括白血病。例如,所述非实体瘤可以包括淋巴瘤。例如,所述非实体瘤可包括多发性骨髓瘤。
在本申请中,术语“肿瘤相关抗原”通常是指在肿瘤细胞或正常细胞上存在的抗原分子。在本申请中,所述肿瘤相关抗原可微量存在于正常细胞,而在肿瘤细胞中高度表达。例如,所述肿瘤相关抗原可包括但不限于胚胎性蛋白、糖蛋白抗原和/或鳞状细胞抗原。例如,所述肿瘤相关抗原可以包括CD19、CD20、CD47、HER2、EGFR、CD22和/或PD-L1。
在本申请中,术语“免疫细胞相关抗原”通常是指免疫细胞上存在的抗原分子。例如,所述免疫细胞相关抗原可以包括与免疫抑制相关的抗原(例如,PD-1抗原)。例如,所述免疫细胞相关抗原可以包括T细胞或NK细胞抗原(例如,CD3,CD16a等)。
在本申请中,术语“细胞因子”通常是指由免疫细胞和某些非免疫细胞(例如,内皮细胞、表皮细胞、纤维母细胞等)经刺激而合成、分泌的一类具有广泛生物学活性的小分子蛋白质。例如,所述细胞因子可以通过结合相应受体调节细胞生长、分化和效应,调控免疫应答。例如,所述细胞因子可包括但不限于白细胞介素(例如,IL-2、IL-7、IL-15等)、干扰素(例如,IFNa、IFNb)、肿瘤坏死因子超家族、集落刺激因子、趋化因子、生长因子等。例如,所述细胞因子可包括白细胞介素的变体(例如,IL-2变体R38A,I80F,R81D,L85V,I86V,I92F,其可与IL-2βγ受体结合而和IL-2α受体结合力较弱)。例如,所述细胞因子可包括干扰素变体(例如,IFNα变体R144A突变体,其与IFNAR2受体的结合显著减弱,可减少INFα的毒副作用)。
在本申请中,术语“免疫缀合物”通常是指所述其他治疗剂与所述分离的抗原结合蛋白缀合(例如,通过连接分子共价相连)而形成的缀合物,该缀合物可以通过所述分离的抗原结合蛋白与靶细胞上的抗原的特异性结合,将所述其他治疗剂递送至靶细胞(例如,肿瘤细胞)。此外,所述抗原也可以由所述靶细胞分泌,并位于所述靶细胞 外的间隙。
在本申请中,术语“受试者”通常指人类或非人类动物,包括但不限于猫、狗、马、猪、奶牛、羊、兔、小鼠、大鼠或猴。
在本申请中,术语“核酸分子”通常是指从其天然环境中分离的或人工合成的任何长度的分离形式的核苷酸、脱氧核糖核苷酸或核糖核苷酸或其类似物。
在本申请中,术语“载体”通常是指一种核酸分子,该种核酸分子能够转运与其连接的另一核酸。所述载体可将插入的核酸分子转移到细胞中和/或细胞之间。所述载体可包括主要用于将DNA或RNA插入细胞中的载体、主要用于复制DNA或RNA的载体,以及主要用于DNA或RNA的转录和/或翻译的表达的载体。所述载体可以是当引入合适的细胞时能够转录并翻译成多肽的多核苷酸。通常,通过培养包含所述载体的合适的细胞,所述载体可以产生期望的表达产物。在本申请中,所述载体可包含慢病毒载体。
在本申请中,术语“细胞”通常是指可以或已经含有包括本申请所述的核酸分子的质粒或载体,或者能够表达本申请所述的多肽或本申请所述的抗原结合蛋白的个体细胞,细胞系或细胞培养物。所述细胞可以包括单个细胞的子代。由于天然的,意外的或故意的突变,子代细胞与原始亲本细胞在形态上或在基因组上可能不一定完全相同,但能够表达本申请所述的多肽或抗原结合蛋白即可。所述细胞可以通过使用本申请所述的载体体外转染细胞而得到。所述细胞可以是原核细胞(例如大肠杆菌),也可以是真核细胞(例如酵母细胞,例如COS细胞,中国仓鼠卵巢(CHO)细胞,HeLa细胞,HEK293细胞,COS-1细胞,NS0细胞或骨髓瘤细胞)。在一些实施方式中,所述细胞可以是免疫细胞。例如,所述免疫细胞可以选自下组:T细胞、B细胞、天然杀伤细胞(NK细胞)、巨噬细胞、NKT细胞、单核细胞、树突状细胞、粒细胞、淋巴细胞、白细胞和/或外周血单个核细胞。
在本申请中,术语“治疗”通常是指:(i)预防可能易患疾病、病症和/或病状、但尚未诊断出患病的患者出现该疾病、病症或病状; (ii)抑制该疾病、病症或病状,亦即遏制其发展;以及(iii)缓解该疾病、病症或病状,亦即使得该疾病、病症和/或病状和/或与该疾病、病症和/或病状相关联的症状消退。
在本申请中,术语“多肽”、“肽”、“蛋白”和“蛋白质”可互换地使用,通常是指具有任何长度的氨基酸的聚合物。该聚合物可以是直链或支链的,它可以包含修饰的氨基酸,并且可以被非氨基酸中断。这些术语还涵盖已经被修饰的氨基酸聚合物。这些修饰可以包含:二硫键形成、糖基化、脂化(lipidation)、乙酰化、磷酸化、或任何其他操纵(如与标记组分结合)。术语“氨基酸”包括天然的和/或非天然的或者合成的氨基酸,包括甘氨酸以及D和L旋光异构体、以及氨基酸类似物和肽模拟物。
在本申请中,术语“多核苷酸”、“核苷酸”、“核苷酸序列”、“核酸”和“寡核苷酸”可互换地使用,通常是指具有任何长度的核苷酸的聚合形式,如脱氧核糖核苷酸或核糖核苷酸、或其类似物。多核苷酸可具有任何三维结构,并且可以执行已知或未知的任何功能。以下是多核苷酸的非限制性实例:基因或基因片段的编码区或非编码区、根据连接分析定义的多个座位(一个座位)、外显子、内含子、信使RNA(mRNA)、转运RNA、核糖体RNA、短干扰RNA(siRNA)、短发夹RNA(shRNA)、micro-RNA(miRNA)、核酶、cDNA、重组多核苷酸、分支多核苷酸、质粒、载体、任何序列的分离的DNA、任何序列的分离的RNA、核酸探针、和引物。多核苷酸可以包含一个或多个经修饰的核苷酸,如甲基化的核苷酸和核苷酸类似物。如果存在,可以在聚合物组装之前或之后进行核苷酸结构的修饰。核苷酸的序列可以被非核苷酸组分中断。多核苷酸可以在聚合后,如通过与标记的组分缀合来进一步修饰。
在本申请中,术语“K D”(同样地,“K D”或“K D”)通常指“亲和常数”或“平衡解离常数”,并指在滴定测量中在平衡时、或者通过将解离速率常数(kd)除以结合速率常数(ka)所获得的值。使用结合速率常数(ka)、解离速率常数(kd)和平衡解离常数(K D)表 示结合蛋白(例如本申请所述的分离的抗原结合蛋白)对抗原(例如,PD-L1蛋白、PD-1蛋白)的结合亲和力。确定结合和解离速率常数的方法为本领域熟知。使用基于荧光的技术提供了高灵敏度以及在生理缓冲液中在平衡时检查样品的能力。例如,可以通过Biacore(生物分子相互作用分析)测定(例如,可以从BIAcoreInternationalAB,aGEHealthcarecompany,Uppsala,瑞典获得的仪器)所述K D值,也可以使用其他实验途径和仪器例如Octet检测。另外,也可以使用可以从SapidyneInstruments(Boise,Idaho)获得的KinExA(动态排阻测定(KineticExclusionAssay))测定所述K D值,或者使用表面等离子共振仪(SPR)测定所述K D值。例如,也可以通过胺偶联试剂盒测定所述K D值。
在本申请中,术语“和/或”应理解为意指可选项中的任一项或可选项的两项。
在本申请中,术语“包含”通常是指包括明确指定的特征,但不排除其他要素。在某些情形中,“包含”也涵盖仅包括指定的组分的情况。例如,包含也表示为也表示“由……组成”的含义。
在本申请中,术语“约”通常是指在指定数值以上或以下0.5%-10%的范围内变动,例如在指定数值以上或以下0.5%、1%、1.5%、2%、2.5%、3%、3.5%、4%、4.5%、5%、5.5%、6%、6.5%、7%、7.5%、8%、8.5%、9%、9.5%、或10%的范围内变动。
在本申请中,术语“包括”通常是指包含、总括、含有或包涵的含义。在某些情况下,也表示“为”、“由……组成”的含义。
发明详述
本申请所述分离的抗原结合蛋白
一方面,本申请提供一种分离的抗原结合蛋白,其可包含第一多肽链、第二多肽链,所述第一多肽链包括第一靶向部分,所述第二多肽链包含第二靶向部分,所述第一靶向部分和所述第二靶向部分各自 独立地结合PD-1蛋白或PD-L1蛋白,所述第一靶向部分和第二靶向部分结合的蛋白不同,所述第一多肽链与所述第二多肽链通过二硫键连接。
例如,所述抗原结合蛋白可包含如图1A-1B所示的示例性结构。
双特异性抗体
在本申请中,抗体的CDR又称互补决定区,是可变区的一部分。该区域的氨基酸残基可以与抗原或抗原表位接触。抗体CDR可以通过多种编码系统来确定,如CCG、Kabat、Chothia、IMGT、AbM、综合考虑Kabat/Chothia等。这些编码系统为本领域内已知,具体可参见,例如,http://www.bioinf.org.uk/abs/index.html#kabatnum。本领域技术人员可以根据抗体的序列和结构,用不同的编码系统确定出CDR区。使用不同的编码系统,CDR区可能存在差别。在本申请中,所述CDR涵盖根据任何CDR划分方式划分得到的CDR序列;也涵盖其变体,所述变体包括所述CDR的氨基酸序列经过取代、缺失和/或添加一个或多个氨基酸。例如1-30个、1-20个或1-10个,又例如1个、2个、3个、4个、5个、6个、7个、8个或9个氨基酸取代、缺失和/或插入;也涵盖其同源物,所述同源物可以为与所述CDR的氨基酸序列具有至少约85%(例如,具有至少约85%、约90%、约91%、约92%、约93%、约94%、约95%、约96%、约97%、约98%、约99%或更高的)序列同源性的氨基酸序列。在某些实施方式中,本申请所述分离的抗原结合蛋白通过Kabat编码系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可特异性结合PD-L1蛋白,所述双特异性抗体第二多肽链中的第二靶向部分可特异性结合PD-1蛋白。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR3可包含SEQ ID NO:76所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR3序列可根据Kabat编码系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的 HCDR2可包含SEQ ID NO:70所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR2序列可根据Kabat编码系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:61所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR1序列可根据Kabat编码系统定义。
例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:61所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:70所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:76所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体13H6D3、hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可包含重链可变区,所述重链可变区可包含SEQ ID NO:122所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分包含VH,所述VH与SEQ ID NO:122所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 5,X 7,X 10,X 11,X 12,X 16,X 20,X 37,X 38,X 40,X 46,X 48,X 67,X 68,X 69,X 75,X 81,X 86,X 90,X 115和X 116
QVQLX 5QX 7GAX 10X 11X 12KPGX 16SVKX 20SCKASGYTFTSNWMHWX 37X 38QX 40PGQGLX 4 6WX 48GMIHPNSAIKYNEKFKSRX 67X 68X 69TADKSX 75STAYMX 81LSSLX 86SEDX 90AVYYCARSYYGSSPYFFDYWGQGTX 115X 116TVSS(SEQ ID NO:122),其中,X 5可以是Q或V,X 7可以是P或S,X 10可以是D或E,X 11可以是L或V,X 12可以是K或V,X 16可以是A或S,X 20可以是L或V,X 37可以是D,M或V,X 38可以是K或R,X 40可以是A或R,X 46可以是D或E,X 48可以是I或M,X 67可以是A或V,X 68可以是S或T,X 69可以是I或L,X 75可以是S或T,X 81可以是E或Q,X 86可以是R或T,X 90可以是S或T, X 115可以是M或T,X 116可以是L或V。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的重链可变区可包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可以包含轻链可变区VL中的至少一个CDR,所述VL可以包含SEQ ID NO:123所示的氨基酸序列。
例如,所述双特异性抗体第一多肽链中的第一靶向部分中的VL可以包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR可以通过任何形式划分,只要VL与SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列相同,以任何形式划分得到的LCDR都可落入本申请的保护范围内。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可包括轻链可变区VL,所述VL可包含LCDR1、LCDR2和LCDR3中的至少一个,至少两个或至少三个。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR3可包含SEQ ID NO:94所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR3可根据Kabat编号系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR2可包含SEQ ID NO:87所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR2可根据Kabat编号系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:82所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可根据Kabat编号系统定义。
例如,本申请所述双特异性抗体第一多肽链中的第一靶向部分的 LCDR1可包含SEQ ID NO:82所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:87所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:94所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体13H6D3、hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可包含轻链可变区VL,所述VL可包含SEQ ID NO:123所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的VL与SEQ ID NO:123所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 7,X 8,X 15,X 22,X 41,X 42,X 43,X 44,X 46,X 60,X 71,X 72,X 77,X 79,X 80,X 83,X 87和X 104
DIQMTQX 7X 8SSLSASX 15GDRVTIX 22CRASQDISKYLNWYQQKPX 41X 42X 43X 44KX 46LIYYTSRLHSGVPX 60RFSGSGSGTDX 71X 72LTISX 77LX 79X 80EDX 83ATYX 87CQQGDTLPWTFGGGTKX 104EIK(SEQ ID NO:123),其中,X 7可以是S或T,X 8可以是P或T,X 15可以是L或V,X 22可以是S或T,X 41可以是D或G,X 42可以是G或K,X 43可以是A或T,X 44可以是P或V,X 46可以是F或L,X 60可以是A或S,X 71可以是F或Y,X 72可以是F或T,X 77可以是N或S,X 79可以是E或Q,X 80可以是P或Q,X 83可以是F或V,X 87可以是F或Y,X 104可以是L或V。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的轻链可变区可包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可包含轻链恒定区,所述轻链恒定区可包括源自Igκ的恒定区或源自Igλ的恒定区。
例如,所述轻链恒定区可包括源自Igκ的恒定区。
例如,所述双特异性抗体第一多肽链中的第一靶向部分的轻链恒定区包含SEQ ID NO:114中任一项所示的氨基酸序列。
例如,所述第一多肽链可包含SEQ ID NO:134至140、SEQ ID NO:144至153中任一项所示的氨基酸序列。
例如,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:51所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR3序列可根据Kabat编码系统定义。
例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR3与SEQ ID NO:51所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1
X 1HYGTSPFVY(SEQ ID NO:51),其中,其中,X 1可以是D或E。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR3可包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR3序列可根据Kabat编码系统定义。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR2可包含SEQ ID NO:6所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR2序列可根据Kabat编码系统定义。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR1序列可根据Kabat编码系统定义。
例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:6所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:9所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4F1、hu19D4-25、19D4-25-1A3、19D4-25-1B3、19D4-25-1C2、19D4-25-1E4、19D4-25-2E10或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR1 可包含SEQ ID NO:3所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:6所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:10所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-3C11、19D4-25-1C2-3C11或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可包含重链可变区,所述重链可变区可包SEQ ID NO:52所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分包含VH,所述VH与SEQ ID NO:52所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1,X 5,X 13,X 16,X 17,X 20,X 37,X 48,X 67,X 68,X 73,X 76,X 79,X 82,X 83,X 85,X 86,X 87,X 88,X 92,X 98和X 118
X 1VQLX 5ESGPGLVX 13PSX 16X 17LSX 20TCTVSGFSLTSYAISWX 37RQPPGKGLEWX 48GVIWTGGGTNYNSALKSRX 67X 68ISKDX 73SKX 76QVX 79LKX 82X 83SX 85X 86X 87X 88DTAX 92YYC ARX 98HYGTSPFVYWGQGTLVTVSX 118(SEQ ID NO:52),其中,X 1可以是E或Q,X 5可以是K或Q,X 13可以是A或K,X 16可以是E或Q,X 17可以是S或T,X 20可以是I或L,X 37可以是I或V,X 48可以是I或L,X 67可以是L或V,X 68可以是S或T,X 73可以是N或T,X 76可以是N或S,X 79可以是F或S,X 82可以是L或M,X 83可以是N或S,X 85可以是L或V,X 86可以是Q或T,X 87可以是A或T,X 88可以是A或E,X 92可以是S或V,X 98可以是D或E,X 118可以是A或S。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的重链可变区可包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的氨基酸序列。
例如,所述第二多肽链包含SEQ ID NO:39和SEQ ID NO:40中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可以包含抗体轻链可变区VL中的至少一个CDR,所述VL可以包含SEQ ID NO:58所示的氨基酸序列。
例如,所述VL可以包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。在本申请中,所述分离的双特异性抗体第二多肽链中的第二靶向部分的LCDR可以通过任何形式划分,只要VL与SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列相同,以任何形式划分得到的LCDR都可落入本申请的保护范围内。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可包括轻链可变区VL,所述VL可包含LCDR1、LCDR2和LCDR3中的至少一个,至少两个或至少三个。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR3可包含SEQ ID NO:57所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR3可根据Kabat编号系统定义。
例如,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR3与SEQ ID NO:57所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1,X 4,X 5,X 7和X 9
X 1QSX 4X 5VX 7WX 9(SEQ ID NO:57),其中,X 1可以是Q或S,X 4可以是K,L或S,X 5可以是E,H,K或R,X 7可以是N或P,X 9可以是S或T。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR3可包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR3可根据Kabat编号系统定义。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR2可包含SEQ ID NO:18所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR2可根据Kabat编号系统定义。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列。例如,所述双特异 性抗体第二多肽链中的第二靶向部分的LCDR1可根据Kabat编号系统定义。
例如,本申请所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:21所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4F1、hu19D4-25、19D4-25-3C11或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:22所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-1A3或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:23所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-1B3或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:24所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-1C2、19D4-25-1C2-3C11或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO: 25所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-1E4或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:26所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-2E10或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可包含轻链可变区VL,所述VL可包含SEQ ID NO:58所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的VL与SEQ ID NO:58所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 7,X 9,X 12,X 14,X 15,X 18,X 20,X 41,X 49,X 64,X 76,X 78,X 80,X 81,X 82,X 84,X 85,X 87,X 88,X 89,X 93,X 96,X 97,X 99,X 101和X 108
DIVLTQX 7PX 9SLX 12VX 14X 15GQX 18AX 20ISCRASESVDNYGISFMNWFX 41QKPGQPP X 49LLIYAASNQGSGVPX 64RFSGSGSGTDFX 76LX 78IX 80X 81X 82EX 84X 85DX 87X 88X 89YFCX 93Q SX 96X 97VX 99WX 101FGGGTKX 108EIK(SEQ ID NO:58),其中,X 7可以是S或T,X 9可以是A或L,X 12可以是A或S,X 14可以是S或T,X 15可以是L或P,X 18可以是P或R,X 20可以是S或T,X 41可以是L或Q,X 49可以是K或Q,X 64可以是A或D,X 76可以是S或T,X 78可以是K或N,X 80可以是H或S,X 81可以是P或R,X 82可以是M或V,X 84可以是A或E,X 85可以是D或E,X 87可以是T或V,X 88可以是A或G,X 89可以是M或V,X 93可以是Q或S,X 96可以是K,L或S,X 97可以是E,H,K或R,X 99可以是N或P,X 101可以是S或T,X 108可以是L或V。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的轻链可变区可包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可包含重链恒定区,所述重链恒定区可包括源自IgG的恒定区或源自IgY的恒定区。
例如,所述双特异性抗体第二多肽链中的第二靶向部分的重链恒定区可包含SEQ ID NO:112至SEQ ID NO:113所示的氨基酸序列。
例如,所述第二多肽链可以包含SEQ ID NO:39至SEQ ID NO:40、SEQ ID NO:154至SEQ ID NO:160中任一项所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:95至SEQ ID NO:104、SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29至SEQ ID NO:31、SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:97所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:98所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:100所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:102所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:103所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:97所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:98所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:100所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:102所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包 含SEQ ID NO:36所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:103所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:146所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:40所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:147所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:40所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:149所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:40所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:151所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:40所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:152所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:40所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:146所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:158所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:147所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:158所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:149所示的氨基酸序列,所述第二多 肽链可包含SEQ ID NO:158所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:151所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:158所示的氨基酸序列。
例如,所述双特异性抗体可包含第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:152所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:158所示的氨基酸序列。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可特异性结合PD-1蛋白,且所述双特异性抗体第二多肽链中的第二靶向部分可特异性结合PD-L1蛋白。
例如,所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:51所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR3序列可根据Kabat编码系统定义。
例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR3与SEQ ID NO:51所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1
X 1HYGTSPFVY(SEQ ID NO:51),其中,X 1可以是D或E。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR3可包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR3序列可根据Kabat编码系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR2可包含SEQ ID NO:6所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR2序列可根据Kabat编码系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR1序列可根据Kabat编码系统定义。
例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:6所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:9所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4F1、hu19D4-25、19D4-25-1A3、19D4-25-1B3、19D4-25-1C2、19D4-25-1E4、19D4-25-2E10或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
例如,所述双特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:6所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:10所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-3C11、19D4-25-1C2-3C11或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可包含重链可变区,所述重链可变区可包SEQ ID NO:52所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分包含VH,所述VH与SEQ ID NO:52所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1,X 5,X 13,X 16,X 17,X 20,X 37,X 48,X 67,X 68,X 73,X 76,X 79,X 82,X 83,X 85,X 86,X 87,X 88,X 92,X 98和X 118
X 1VQLX 5ESGPGLVX 13PSX 16X 17LSX 20TCTVSGFSLTSYAISWX 37RQPPGKGLEWX 48GVIWTGGGTNYNSALKSRX 67X 68ISKDX 73SKX 76QVX 79LKX 82X 83SX 85X 86X 87X 88DTAX 92YYCARX 98HYGTSPFVYWGQGTLVTVSX 118(SEQ ID NO:52),其中,X 1可以是E或Q,X 5可以是K或Q,X 13可以是A或K,X 16可以是E或Q,X 17可以是S或T,X 20可以是I或L,X 37可以是I或V,X 48可以是I或L,X 67可以是L或V,X 68可以是S或T,X 73可以是N或T,X 76可以是N或S,X 79可以是F或S,X 82可以是L或M,X 83可以是N或S,X 85可以是L或V,X 86可以是Q或T,X 87可以是A或T,X 88可以是A或E,X 92可以是S或V,X 98可以是D或E,X 118可以是A或S。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的重链可变区可包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可以包含抗体轻链可变区VL中的至少一个CDR,所述VL可以包含SEQ ID NO:58所示的氨基酸序列。
例如,所述双特异性抗体第一多肽链中的第一靶向部分的VL可以包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR可以通过任何形式划分,只要VL与SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列相同,以任何形式划分得到的LCDR都可落入本申请的保护范围内。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可包括轻链可变区VL,所述VL可包含LCDR1、LCDR2和LCDR3中的至少一个,至少两个或至少三个。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR3可包含SEQ ID NO:57所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR3可根据Kabat编号系统定义。
例如,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR3与SEQ ID NO:57所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1,X 4,X 5,X 7和X 9
X 1QSX 4X 5VX 7WX 9(SEQ ID NO:57),其中,X 1可以是Q或S,X 4可以是K,L或S,X 5可以是E,H,K或R,X 7可以是N或P,X 9可以是S或T。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR3可包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的 LCDR3可根据Kabat编号系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR2可包含SEQ ID NO:18所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR2可根据Kabat编号系统定义。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可根据Kabat编号系统定义。
例如,本申请所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:21所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4F1、hu19D4-25、19D4-25-3C11或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:22所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-1A3或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:23所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-1B3或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含 SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:24所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-1C2、19D4-25-1C2-3C11或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:25所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-1E4或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述双特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:26所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-2E10或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可包含轻链可变区VL,所述VL可包含SEQ ID NO:58所示的氨基酸序列。例如,所述双特异性抗体第一多肽链中的第一靶向部分的VL与SEQ ID NO:58所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 7,X 9,X 12,X 14,X 15,X 18,X 20,X 41,X 49,X 64,X 76,X 78,X 80,X 81,X 82,X 84,X 85,X 87,X 88,X 89,X 93,X 96,X 97,X 99,X 101和X 108
DIVLTQX 7PX 9SLX 12VX 14X 15GQX 18AX 20ISCRASESVDNYGISFMNWFX 41QKPGQPPX 49LLIYAASNQGSGVPX 64RFSGSGSGTDFX 76LX 78IX 80X 81X 82EX 84X 85DX 87X 88X 89YFCX 93QSX 96X 97VX 99WX 101FGGGTKX 108EIK(SEQ ID NO:58),其中,X 7可以是S或T,X 9可以是A或L,X 12可以是A或S,X 14可以是S或T,X 15可以是L或P,X 18可以是P或R,X 20可以是S或T,X 41可以是L或Q,X 49可以是K或Q,X 64可以是A或D,X 76可以是S或T,X 78可以是K或N,X 80 可以是H或S,X 81可以是P或R,X 82可以是M或V,X 84可以是A或E,X 85可以是D或E,X 87可以是T或V,X 88可以是A或G,X 89可以是M或V,X 93可以是Q或S,X 96可以是K,L或S,X 97可以是E,H,K或R,X 99可以是N或P,X 101可以是S或T,X 108可以是L或V。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分的轻链可变区可包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体第一多肽链中的第一靶向部分可包含轻链恒定区,所述轻链恒定区可包括源自Igκ的恒定区或源自Igλ的恒定区。
例如,所述轻链恒定区可包括源自Igκ的恒定区。
例如,所述双特异性抗体第一多肽链中的第一靶向部分的轻链恒定区包含SEQ ID NO:114所示的氨基酸序列。
例如,所述第一多肽链包含SEQ ID NO:141至143、SEQ ID NO:41至SEQ ID NO:46中任一项所示的氨基酸序列。在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR3可包含SEQ ID NO:76所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR3序列可根据Kabat编码系统定义。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR2可包含SEQ ID NO:70所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR2序列可根据Kabat编码系统定义。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:61所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR1序列可根据Kabat编码系统定义。
例如,所述双特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:61所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:70所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:76所 示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体13H6D3、hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可包含重链可变区,所述重链可变区可包含SEQ ID NO:122所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分包含VH,所述VH与SEQ ID NO:122所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 5,X 7,X 10,X 11,X 12,X 16,X 20,X 37,X 38,X 40,X 46,X 48,X 67,X 68,X 69,X 75,X 81,X 86,X 90,X 115和X 116
QVQLX 5QX 7GAX 10X 11X 12KPGX 16SVKX 20SCKASGYTFTSNWMHWX 37X 38QX 40PGQGLX 4 6WX 48GMIHPNSAIKYNEKFKSRX 67X 68X 69TADKSX 75STAYMX 81LSSLX 86SEDX 90AVYYCARSYYGSSPYFFDYWGQGTX 115X 116TVSS(SEQ ID NO:122),其中,X 5可以是Q或V,X 7可以是P或S,X 10可以是D或E,X 11可以是L或V,X 12可以是K或V,X 16可以是A或S,X 20可以是L或V,X 37可以是D,M或V,X 38可以是K或R,X 40可以是A或R,X 46可以是D或E,X 48可以是I或M,X 67可以是A或V,X 68可以是S或T,X 69可以是I或L,X 75可以是S或T,X 81可以是E或Q,X 86可以是R或T,X 90可以是S或T,X 115可以是M或T,X 116可以是L或V。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的重链可变区可包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可以包含抗体轻链可变区VL中的至少一个CDR,所述VL可以包含SEQ ID NO:123所示的氨基酸序列。
例如,所述双特异性抗体第二多肽链中的第二靶向部分中的VL可以包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分 的LCDR可以通过任何形式划分,只要VL与SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列相同,以任何形式划分得到的LCDR都可落入本申请的保护范围内。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可包括轻链可变区VL,所述VL可包含LCDR1、LCDR2和LCDR3中的至少一个,至少两个或至少三个。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR3可包含SEQ ID NO:94所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR3可根据Kabat编号系统定义。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR2可包含SEQ ID NO:87所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR2可根据Kabat编号系统定义。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:82所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可根据Kabat编号系统定义。
例如,本申请所述双特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:82所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:87所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:94所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分可包括抗体13H6D3、hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可包含轻链可变区VL,所述VL可包含SEQ ID NO:123所示的氨基酸序列。例如,所述双特异性抗体第二多肽链中的第二靶向部分的VL与SEQ ID NO:123所示的序列相比,在选自下组的一个或多个氨基 酸处存在氨基酸取代(例如,保守氨基酸取代等):X 7,X 8,X 15,X 22,X 41,X 42,X 43,X 44,X 46,X 60,X 71,X 72,X 77,X 79,X 80,X 83,X 87和X 104
DIQMTQX 7X 8SSLSASX 15GDRVTIX 22CRASQDISKYLNWYQQKPX 41X 42X 43X 44KX 46LIYYTSRLHSGVPX 60RFSGSGSGTDX 71X 72LTISX 77LX 79X 80EDX 83ATYX 87CQQGDTLPWTFGGGTKX 104EIK(SEQ ID NO:123),其中,X 7可以是S或T,X 8可以是P或T,X 15可以是L或V,X 22可以是S或T,X 41可以是D或G,X 42可以是G或K,X 43可以是A或T,X 44可以是P或V,X 46可以是F或L,X 60可以是A或S,X 71可以是F或Y,X 72可以是F或T,X 77可以是N或S,X 79可以是E或Q,X 80可以是P或Q,X 83可以是F或V,X 87可以是F或Y,X 104可以是L或V。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分的轻链可变区可包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体第二多肽链中的第二靶向部分可包含重链恒定区,所述重链恒定区可包括源自IgG的恒定区或源自IgY的恒定区。
例如,所述双特异性抗体第二多肽链中的第二靶向部分的重链恒定区可包含SEQ ID NO:112至SEQ ID NO:113所示的氨基酸序列。
例如,所述双特异性抗体的第二多肽链可包含SEQ ID NO:124至133、SEQ ID NO:161至SEQ ID NO:167中任一项所示的氨基酸序列。
在本申请中,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:29至SEQ ID NO:31、SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95至SEQ ID NO:104、SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第 一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:97所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:98所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:100所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:102所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:103所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:97所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:98所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:100所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:102所示的氨基酸序列。
例如,所述双特异性抗体可包含双特异性抗体第一多肽链中的第一靶向部分和双特异性抗体第二多肽链中的第二靶向部分。所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:103所示的氨基酸序列。
在本申请中,所述双特异性抗体可包含两条前述第一多肽链和两条前述第二多肽链。例如,两条前述第一多肽链之间可通过二硫键连接,所述两条前述第一多肽链和两条前述第二多肽链可形成IgG样的抗体。例如,所述双特异性抗体可为同二聚体。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:143所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:126所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:143所示的氨基酸序列,所述第 二多肽链可包含SEQ ID NO:127所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:143所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:129所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:143所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:131所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:143所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:132所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:44所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:126所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:44所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:127所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:44所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:129所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:44所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:131所示的氨基酸序列。
例如,所述双特异性抗体可包含两条第一多肽链和第二多肽链。所述第一多肽链可包含SEQ ID NO:44所示的氨基酸序列,所述第二多肽链可包含SEQ ID NO:132所示的氨基酸序列。
例如,所述双特异性抗体第一多肽链中的第一靶向部分可特异性结合PD-1蛋白,且所述双特异性抗体第二多肽链中的第二靶向部分可特异性结合CD28或CD16a蛋白。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,且 所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:176或SEQ ID NO:168所示的氨基酸序列。例如,所述双特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
例如,所述双特异性抗体第一多肽链中的第一靶向部分可特异性结合CD28或CD16a蛋白,且所述双特异性抗体第二多肽链中的第二靶向部分可特异性结合PD-1蛋白。例如,所述双特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:176或SEQ ID NO:168中任一项所示的氨基酸序列,且所述双特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。例如,所述双特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
多特异性抗体
另一方面,本申请提供了一种或多种多特异性抗体,其包含第一多肽链、第二多肽链,所述第一多肽链包含第一靶向部分,所述第二多肽链包含第二靶向部分,所述第一靶向部分和所述第二靶向部分各自独立地结合免疫细胞相关抗原,所述第一多肽链与所述第二多肽链通过二硫键连接。
例如,所述免疫细胞可包括T细胞、巨噬细胞、树突状细胞和/或NK细胞。例如,所述免疫细胞相关抗原可包括PD-1、PD-L1、CD3、CD16a和/或CD28。
在本申请中,所述多特异性抗体的第一靶向部分可与前述双特异性抗体的第一靶向部分相同。在本申请中,所述多特异性抗体的第二靶向部分可与前述双特异性抗体的第二靶向部分相同。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可特异性结合PD-L1蛋白,所述多特异性抗体第二多肽链中的第二靶向部分可特异性结合PD-1蛋白。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR3可包含SEQ ID NO:76所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR3序列可根据Kabat编码系统定义。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR2可包含SEQ ID NO:70所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR2序列可根据Kabat编码系统定义。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:61所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR1序列可根据Kabat编码系统定义。
例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:61所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:70所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:76所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体13H6D3、hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可包含重链可变区,所述重链可变区可包含SEQ ID NO:122所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分包含VH,所述VH与SEQ ID NO:122所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 5,X 7,X 10,X 11,X 12,X 16,X 20,X 37,X 38,X 40,X 46,X 48,X 67,X 68,X 69,X 75,X 81,X 86,X 90,X 115和X 116
QVQLX 5QX 7GAX 10X 11X 12KPGX 16SVKX 20SCKASGYTFTSNWMHWX 37X 38QX 40PGQGLX 4 6WX 48GMIHPNSAIKYNEKFKSRX 67X 68X 69TADKSX 75STAYMX 81LSSLX 86SEDX 90AVYYCARSYYGSSPYFFDYWGQGTX 115X 116TVSS(SEQ ID NO:122),其中,X 5可以 是Q或V,X 7可以是P或S,X 10可以是D或E,X 11可以是L或V,X 12可以是K或V,X 16可以是A或S,X 20可以是L或V,X 37可以是D,M或V,X 38可以是K或R,X 40可以是A或R,X 46可以是D或E,X 48可以是I或M,X 67可以是A或V,X 68可以是S或T,X 69可以是I或L,X 75可以是S或T,X 81可以是E或Q,X 86可以是R或T,X 90可以是S或T,X 115可以是M或T,X 116可以是L或V。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的重链可变区可包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的氨基酸序列。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可以包含轻链可变区VL中的至少一个CDR,所述VL可以包含SEQ ID NO:123所示的氨基酸序列。
例如,所述多特异性抗体第一多肽链中的第一靶向部分中的VL可以包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR可以通过任何形式划分,只要VL与SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列相同,以任何形式划分得到的LCDR都可落入本申请的保护范围内。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可包括轻链可变区VL,所述VL可包含LCDR1、LCDR2和LCDR3中的至少一个,至少两个或至少三个。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR3可包含SEQ ID NO:94所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR3可根据Kabat编号系统定义。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR2可包含SEQ ID NO:87所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR2可根据Kabat编号系统定义。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:82所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可根据Kabat编号系统定义。
例如,本申请所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:82所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:87所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:94所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体13H6D3、hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可包含轻链可变区VL,所述VL可包含SEQ ID NO:123所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的VL与SEQ ID NO:123所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 7,X 8,X 15,X 22,X 41,X 42,X 43,X 44,X 46,X 60,X 71,X 72,X 77,X 79,X 80,X 83,X 87和X 104
DIQMTQX 7X 8SSLSASX 15GDRVTIX 22CRASQDISKYLNWYQQKPX 41X 42X 43X 44KX 46LIYYTSRLHSGVPX 60RFSGSGSGTDX 71X 72LTISX 77LX 79X 80EDX 83ATYX 87CQQGDTLPWTFGGGTKX 104EIK(SEQ ID NO:123),其中,X 7可以是S或T,X 8可以是P或T,X 15可以是L或V,X 22可以是S或T,X 41可以是D或G,X 42可以是G或K,X 43可以是A或T,X 44可以是P或V,X 46可以是F或L,X 60可以是A或S,X 71可以是F或Y,X 72可以是F或T,X 77可以是N或S,X 79可以是E或Q,X 80可以是P或Q,X 83可以是F或V,X 87可以是F或Y,X 104可以是L或V。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的轻链可变区可包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可 包含轻链恒定区,所述轻链恒定区可包括源自Igκ的恒定区或源自Igλ的恒定区。
例如,所述轻链恒定区可包括源自Igκ的恒定区。
例如,所述多特异性抗体第一多肽链中的第一靶向部分的轻链恒定区包含SEQ ID NO:114中任一项所示的氨基酸序列。
例如,所述多特异性抗体的第一多肽链可包含SEQ ID NO:134至140、SEQ ID NO:144至153中任一项所示的氨基酸序列。
例如,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:51所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR3序列可根据Kabat编码系统定义。
例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR3与SEQ ID NO:51所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1
X 1HYGTSPFVY(SEQ ID NO:51),其中,其中,X 1可以是D或E。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR3可包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR3序列可根据Kabat编码系统定义。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR2可包含SEQ ID NO:6所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR2序列可根据Kabat编码系统定义。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR1序列可根据Kabat编码系统定义。
例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:6所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:9所示 的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4F1、hu19D4-25、19D4-25-1A3、19D4-25-1B3、19D4-25-1C2、19D4-25-1E4、19D4-25-2E10或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:6所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:10所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-3C11、19D4-25-1C2-3C11或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可包含重链可变区,所述重链可变区可包SEQ ID NO:52所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分包含VH,所述VH与SEQ ID NO:52所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1,X 5,X 13,X 16,X 17,X 20,X 37,X 48,X 67,X 68,X 73,X 76,X 79,X 82,X 83,X 85,X 86,X 87,X 88,X 92,X 98和X 118
X 1VQLX 5ESGPGLVX 13PSX 16X 17LSX 20TCTVSGFSLTSYAISWX 37RQPPGKGLEWX 48GVIWTGGGTNYNSALKSRX 67X 68ISKDX 73SKX 76QVX 79LKX 82X 83SX 85X 86X 87X 88DTAX 92YYCARX 98HYGTSPFVYWGQGTLVTVSX 118(SEQ ID NO:52),其中,X 1可以是E或Q,X 5可以是K或Q,X 13可以是A或K,X 16可以是E或Q,X 17可以是S或T,X 20可以是I或L,X 37可以是I或V,X 48可以是I或L,X 67可以是L或V,X 68可以是S或T,X 73可以是N或T,X 76可以是N或S,X 79可以是F或S,X 82可以是L或M,X 83可以是N或S,X 85可以是L或V,X 86可以是Q或T,X 87可以是A或T,X 88可以是A或E,X 92可以是S或V,X 98可以是D或E,X 118可以是A或S。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的重链可变区可包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的氨基酸序列。
例如,所述多特异性抗体的第二多肽链包含SEQ ID NO:39和SEQ ID NO:40中任一项所示的氨基酸序列。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可以包含抗体轻链可变区VL中的至少一个CDR,所述VL可以包含SEQ ID NO:58所示的氨基酸序列。
例如,所述VL可以包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。在本申请中,所述分离的多特异性抗体第二多肽链中的第二靶向部分的LCDR可以通过任何形式划分,只要VL与SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列相同,以任何形式划分得到的LCDR都可落入本申请的保护范围内。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可包括轻链可变区VL,所述VL可包含LCDR1、LCDR2和LCDR3中的至少一个,至少两个或至少三个。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR3可包含SEQ ID NO:57所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR3可根据Kabat编号系统定义。
例如,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR3与SEQ ID NO:57所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1,X 4,X 5,X 7和X 9
X 1QSX 4X 5VX 7WX 9(SEQ ID NO:57),其中,X 1可以是Q或S,X 4可以是K,L或S,X 5可以是E,H,K或R,X 7可以是N或P,X 9可以是S或T。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR3可包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR3可根据Kabat编号系统定义。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的 LCDR2可包含SEQ ID NO:18所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR2可根据Kabat编号系统定义。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可根据Kabat编号系统定义。
例如,本申请所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:21所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4F1、hu19D4-25、19D4-25-3C11或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:22所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-1A3或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:23所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-1B3或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:24所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第 二靶向部分可包括抗体19D4-25-1C2、19D4-25-1C2-3C11或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:25所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-1E4或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:26所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体19D4-25-2E10或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可包含轻链可变区VL,所述VL可包含SEQ ID NO:58所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的VL与SEQ ID NO:58所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 7,X 9,X 12,X 14,X 15,X 18,X 20,X 41,X 49,X 64,X 76,X 78,X 80,X 81,X 82,X 84,X 85,X 87,X 88,X 89,X 93,X 96,X 97,X 99,X 101和X 108
DIVLTQX 7PX 9SLX 12VX 14X 15GQX 18AX 20ISCRASESVDNYGISFMNWFX 41QKPGQPPX 49LLIYAASNQGSGVPX 64RFSGSGSGTDFX 76LX 78IX 80X 81X 82EX 84X 85DX 87X 88X 89YFCX 93QSX 96X 97VX 99WX 101FGGGTKX 108EIK(SEQ ID NO:58),其中,X 7可以是S或T,X 9可以是A或L,X 12可以是A或S,X 14可以是S或T,X 15可以是L或P,X 18可以是P或R,X 20可以是S或T,X 41可以是L或Q,X 49可以是K或Q,X 64可以是A或D,X 76可以是S或T,X 78可以是K或N,X 80可以是H或S,X 81可以是P或R,X 82可以是M或V,X 84可以是A或E,X 85可以是D或E,X 87可以是T或V,X 88可以是A或G,X 89可以是M或 V,X 93可以是Q或S,X 96可以是K,L或S,X 97可以是E,H,K或R,X 99可以是N或P,X 101可以是S或T,X 108可以是L或V。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的轻链可变区可包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可包含重链恒定区,所述重链恒定区可包括源自IgG的恒定区或源自IgY的恒定区。
例如,所述多特异性抗体第二多肽链中的第二靶向部分的重链恒定区可包含SEQ ID NO:112至SEQ ID NO:113所示的氨基酸序列。
例如,所述多特异性抗体的第二多肽链可以包含SEQ ID NO:39至SEQ ID NO:40、SEQ ID NO:154至SEQ ID NO:160中任一项所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:95至SEQ ID NO:104、SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29至SEQ ID NO:31、SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:97所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:98所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含 SEQ ID NO:31所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:100所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:102所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:103所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:97所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:98所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:100所示 的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:102所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:103所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:36所示的氨基酸序列。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可特异性结合PD-1蛋白,且所述多特异性抗体第二多肽链中的第二靶向部分可特异性结合PD-L1蛋白。
例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:51所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR3序列可根据Kabat编码系统定义。
例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR3与SEQ ID NO:51所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1
X 1HYGTSPFVY(SEQ ID NO:51),其中,X 1可以是D或E。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR3可包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR3序列可根据Kabat编码系统定义。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR2可包含SEQ ID NO:6所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR2序列可根据Kabat编码 系统定义。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR1序列可根据Kabat编码系统定义。
例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:6所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:9所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4F1、hu19D4-25、19D4-25-1A3、19D4-25-1B3、19D4-25-1C2、19D4-25-1E4、19D4-25-2E10或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
例如,所述多特异性抗体第一多肽链中的第一靶向部分的HCDR1可包含SEQ ID NO:3所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:6所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:10所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-3C11、19D4-25-1C2-3C11或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可包含重链可变区,所述重链可变区可包SEQ ID NO:52所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分包含VH,所述VH与SEQ ID NO:52所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1,X 5,X 13,X 16,X 17,X 20,X 37,X 48,X 67,X 68,X 73,X 76,X 79,X 82,X 83,X 85,X 86,X 87,X 88,X 92,X 98和X 118
X 1VQLX 5ESGPGLVX 13PSX 16X 17LSX 20TCTVSGFSLTSYAISWX 37RQPPGKGLEWX 48GVIWTGGGTNYNSALKSRX 67X 68ISKDX 73SKX 76QVX 79LKX 82X 83SX 85X 86X 87X 88DTAX 92YYCARX 98HYGTSPFVYWGQGTLVTVSX 118(SEQ ID NO:52),其中,X 1可以是E或Q,X 5可以是K或Q,X 13可以是A或K,X 16可以是E或Q,X 17可以 是S或T,X 20可以是I或L,X 37可以是I或V,X 48可以是I或L,X 67可以是L或V,X 68可以是S或T,X 73可以是N或T,X 76可以是N或S,X 79可以是F或S,X 82可以是L或M,X 83可以是N或S,X 85可以是L或V,X 86可以是Q或T,X 87可以是A或T,X 88可以是A或E,X 92可以是S或V,X 98可以是D或E,X 118可以是A或S。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的重链可变区可包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的氨基酸序列。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可以包含抗体轻链可变区VL中的至少一个CDR,所述VL可以包含SEQ ID NO:58所示的氨基酸序列。
例如,所述多特异性抗体第一多肽链中的第一靶向部分的VL可以包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR可以通过任何形式划分,只要VL与SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列相同,以任何形式划分得到的LCDR都可落入本申请的保护范围内。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可包括轻链可变区VL,所述VL可包含LCDR1、LCDR2和LCDR3中的至少一个,至少两个或至少三个。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR3可包含SEQ ID NO:57所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR3可根据Kabat编号系统定义。
例如,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR3与SEQ ID NO:57所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 1,X 4,X 5,X 7和X 9
X 1QSX 4X 5VX 7WX 9(SEQ ID NO:57),其中,X 1可以是Q或S,X 4可 以是K,L或S,X 5可以是E,H,K或R,X 7可以是N或P,X 9可以是S或T。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR3可包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR3可根据Kabat编号系统定义。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR2可包含SEQ ID NO:18所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR2可根据Kabat编号系统定义。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可根据Kabat编号系统定义。
例如,本申请所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:21所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4F1、hu19D4-25、19D4-25-3C11或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:22所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-1A3或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO: 23所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-1B3或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:24所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-1C2、19D4-25-1C2-3C11或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:25所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-1E4或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
例如,本申请所述多特异性抗体第一多肽链中的第一靶向部分的LCDR1可包含SEQ ID NO:15所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:18所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:26所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包括抗体19D4-25-2E10或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可包含轻链可变区VL,所述VL可包含SEQ ID NO:58所示的氨基酸序列。例如,所述多特异性抗体第一多肽链中的第一靶向部分的VL与SEQ ID NO:58所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 7,X 9,X 12,X 14,X 15,X 18,X 20,X 41,X 49,X 64,X 76,X 78,X 80,X 81,X 82,X 84,X 85,X 87,X 88,X 89,X 93,X 96,X 97,X 99,X 101和X 108
DIVLTQX 7PX 9SLX 12VX 14X 15GQX 18AX 20ISCRASESVDNYGISFMNWFX 41QKPGQPP  X 49LLIYAASNQGSGVPX 64RFSGSGSGTDFX 76LX 78IX 80X 81X 82EX 84X 85DX 87X 88X 89YFCX 93QSX 96X 97VX 99WX 101FGGGTKX 108EIK(SEQ ID NO:58),其中,X 7可以是S或T,X 9可以是A或L,X 12可以是A或S,X 14可以是S或T,X 15可以是L或P,X 18可以是P或R,X 20可以是S或T,X 41可以是L或Q,X 49可以是K或Q,X 64可以是A或D,X 76可以是S或T,X 78可以是K或N,X 80可以是H或S,X 81可以是P或R,X 82可以是M或V,X 84可以是A或E,X 85可以是D或E,X 87可以是T或V,X 88可以是A或G,X 89可以是M或V,X 93可以是Q或S,X 96可以是K,L或S,X 97可以是E,H,K或R,X 99可以是N或P,X 101可以是S或T,X 108可以是L或V。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分的轻链可变区可包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可包含轻链恒定区,所述轻链恒定区可包括源自Igκ的恒定区或源自Igλ的恒定区。
例如,所述轻链恒定区可包括源自Igκ的恒定区。
例如,所述多特异性抗体第一多肽链中的第一靶向部分的轻链恒定区包含SEQ ID NO:114所示的氨基酸序列。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR3可包含SEQ ID NO:76所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR3序列可根据Kabat编码系统定义。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR2可包含SEQ ID NO:70所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR2序列可根据Kabat编码系统定义。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:61所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR1序列可根据Kabat编码 系统定义。
例如,所述多特异性抗体第二多肽链中的第二靶向部分的HCDR1可包含SEQ ID NO:61所示的氨基酸序列;所述HCDR2可包含SEQ ID NO:70所示的氨基酸序列;且所述HCDR3可包含SEQ ID NO:76所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体13H6D3、hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM或与其具有相同HCDR3(例如,与其具有相同的HCDR1-3)的抗原结合片段。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可包含重链可变区,所述重链可变区可包含SEQ ID NO:122所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分包含VH,所述VH与SEQ ID NO:122所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 5,X 7,X 10,X 11,X 12,X 16,X 20,X 37,X 38,X 40,X 46,X 48,X 67,X 68,X 69,X 75,X 81,X 86,X 90,X 115和X 116
QVQLX 5QX 7GAX 10X 11X 12KPGX 16SVKX 20SCKASGYTFTSNWMHWX 37X 38QX 40PGQGLX 4 6WX 48GMIHPNSAIKYNEKFKSRX 67X 68X 69TADKSX 75STAYMX 81LSSLX 86SEDX 90AVYYCA RSYYGSSPYFFDYWGQGTX 115X 116TVSS(SEQ ID NO:122),其中,X 5可以是Q或V,X 7可以是P或S,X 10可以是D或E,X 11可以是L或V,X 12可以是K或V,X 16可以是A或S,X 20可以是L或V,X 37可以是D,M或V,X 38可以是K或R,X 40可以是A或R,X 46可以是D或E,X 48可以是I或M,X 67可以是A或V,X 68可以是S或T,X 69可以是I或L,X 75可以是S或T,X 81可以是E或Q,X 86可以是R或T,X 90可以是S或T,X 115可以是M或T,X 116可以是L或V。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的重链可变区可包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的氨基酸序列。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可以包含抗体轻链可变区VL中的至少一个CDR,所述VL可以包含SEQ ID  NO:123所示的氨基酸序列。
例如,所述多特异性抗体第二多肽链中的第二靶向部分中的VL可以包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR可以通过任何形式划分,只要VL与SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列相同,以任何形式划分得到的LCDR都可落入本申请的保护范围内。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可包括轻链可变区VL,所述VL可包含LCDR1、LCDR2和LCDR3中的至少一个,至少两个或至少三个。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR3可包含SEQ ID NO:94所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR3可根据Kabat编号系统定义。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR2可包含SEQ ID NO:87所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR2可根据Kabat编号系统定义。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:82所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可根据Kabat编号系统定义。
例如,本申请所述多特异性抗体第二多肽链中的第二靶向部分的LCDR1可包含SEQ ID NO:82所示的氨基酸序列;所述LCDR2可包含SEQ ID NO:87所示的氨基酸序列;且所述LCDR3可包含SEQ ID NO:94所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分可包括抗体13H6D3、hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM或与其具有相同LCDR3(例如,与其具有相同LCDR1-3)的抗原结合片段。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可包含轻链可变区VL,所述VL可包含SEQ ID NO:123所示的氨基酸序列。例如,所述多特异性抗体第二多肽链中的第二靶向部分的VL与SEQ ID NO:123所示的序列相比,在选自下组的一个或多个氨基酸处存在氨基酸取代(例如,保守氨基酸取代等):X 7,X 8,X 15,X 22,X 41,X 42,X 43,X 44,X 46,X 60,X 71,X 72,X 77,X 79,X 80,X 83,X 87和X 104
DIQMTQX 7X 8SSLSASX 15GDRVTIX 22CRASQDISKYLNWYQQKPX 41X 42X 43X 44KX 46L IYYTSRLHSGVPX 60RFSGSGSGTDX 71X 72LTISX 77LX 79X 80EDX 83ATYX 87CQQGDTLPWTF GGGTKX 104EIK(SEQ ID NO:123),其中,X 7可以是S或T,X 8可以是P或T,X 15可以是L或V,X 22可以是S或T,X 41可以是D或G,X 42可以是G或K,X 43可以是A或T,X 44可以是P或V,X 46可以是F或L,X 60可以是A或S,X 71可以是F或Y,X 72可以是F或T,X 77可以是N或S,X 79可以是E或Q,X 80可以是P或Q,X 83可以是F或V,X 87可以是F或Y,X 104可以是L或V。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分的轻链可变区可包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
在本申请中,所述多特异性抗体第二多肽链中的第二靶向部分可包含重链恒定区,所述重链恒定区可包括源自IgG的恒定区或源自IgY的恒定区。
例如,所述多特异性抗体第二多肽链中的第二靶向部分的重链恒定区可包含SEQ ID NO:112至SEQ ID NO:113所示的氨基酸序列。
在本申请中,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:29至SEQ ID NO:31、SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95至SEQ ID NO:104、SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:97所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:98所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:100所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:102所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:103所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含 SEQ ID NO:97所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:98所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:100所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:102所示的氨基酸序列。
例如,所述多特异性抗体可包含多特异性抗体第一多肽链中的第一靶向部分和多特异性抗体第二多肽链中的第二靶向部分。所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:36所示的氨基酸序列,所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:103所示的氨基酸序列。
例如,所述多特异性抗体第一多肽链中的第一靶向部分可特异性结合PD-1蛋白,且所述多特异性抗体第二多肽链中的第二靶向部分可特异性结合CD28或CD16a蛋白。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:31所示的氨基酸序列,且所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:176或SEQ ID NO:168所示的氨基酸序列。
例如,所述多特异性抗体第一多肽链中的第一靶向部分可特异性结合CD28或CD16a蛋白,且所述多特异性抗体第二多肽链中的第二 靶向部分可特异性结合PD-1蛋白。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:176或SEQ ID NO:168中任一项所示的氨基酸序列,且所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:31所示的氨基酸序列。
在本申请中,所述多特异性抗体的第一多肽链还可包含第三靶向部分。例如,所述多特异性抗体第一多肽链中的第三靶向部分可与所述多特异性抗体第一多肽链中的第一靶向部分的C端直接或间接地连接。例如,所述多特异性抗体第一多肽链中的第三靶向部分可与所述多特异性抗体第一多肽链中的第一靶向部分的C端通过连接子连接。例如,所述连接子可以是本领域常用的连接子。例如,所述连接子可以是柔性连接子。例如,所述连接子可以是G4S连接子。
在本申请中,所述多特异性抗体第一多肽链中的所述第三靶向部分可特异性结合免疫细胞相关抗原。例如,所述免疫细胞相关抗原可包括PD-1、PD-L1、CD3、CD16a和/或CD28。例如,所述多特异性抗体第一多肽链中的所述第三靶向部分可特异性结合CD3或CD16a蛋白。
在本申请中,所述多特异性抗体第一多肽链中的所述第三靶向部分可特异性结合肿瘤发生相关抗原。例如,所述多特异性抗体第一多肽链中的所述第三靶向部分可特异性结合EGFR和/或cMet。
在本申请中,所述多特异性抗体第一多肽链中的所述第三靶向部分可特异性结合肿瘤相关抗原。例如,所述肿瘤相关抗原可包括PD-L1、HER2、CD47、CD19和/或CD20。
在本申请中,所述多特异性抗体的第二多肽链还可包含第四靶向部分。例如,所述多特异性抗体第二多肽链中的第四靶向部分可与所述多特异性抗体第二多肽链中的第二靶向部分的C端直接或间接地连接。例如,所述多特异性抗体第二多肽链中的第四靶向部分可与所述多特异性抗体第二多肽链中的第二靶向部分的C端通过连接子连接。例如,所述连接子可以是本领域常用的连接子。例如,所述连接子可以是柔性连接子。例如,所述连接子可以是G4S连接子。
在本申请中,所述多特异性抗体第二多肽链中的所述第四靶向部分可特异性结合免疫细胞相关抗原。例如,所述免疫细胞相关抗原可包括PD-1、PD-L1、CD3、CD16a和/或CD28。例如,所述多特异性抗体第二多肽链中的所述第四靶向部分可特异性结合CD3或CD16a蛋白。
在本申请中,所述多特异性抗体第二多肽链中的所述第四靶向部分可特异性结合肿瘤发生相关抗原。例如,所述多特异性抗体第二多肽链中的所述第四靶向部分可特异性结合EGFR和/或cMet。
在本申请中,所述多特异性抗体第二多肽链中的所述第四靶向部分可特异性结合肿瘤相关抗原。例如,所述肿瘤相关抗原可包括PD-L1、HER2、CD47、CD19和/或CD20。
在本申请中,所述多特异性抗体可包含两条前述第一多肽链和两条前述第二多肽链。例如,两条前述第一多肽链之间可通过二硫键连接,所述两条前述第一多肽链和两条前述第二多肽链可形成IgG样的抗体。例如,所述多特异性抗体可为同二聚体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-L1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-L1,所述多特异性抗体第二多肽链中的第四靶向部分可靶向PD-1、CD3或CD16a。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:105-111中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:29-31、168和172中任一项所示的VH的氨基酸序列以及SEQ ID NO:32-38、169和173中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向 PD-1,所述多特异性抗体第二多肽链中的第四靶向部分可靶向PD-L1、CD3或CD16a。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:32-38中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:95-104、168和172中任一项所示的VH的氨基酸序列以及SEQ ID NO:105-111、169和173中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-L1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-1,所述多特异性抗体第一多肽链中的第三靶向部分可靶向CD3或CD16a。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:95-104和SEQ ID NO:105-111中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31和SEQ ID NO:32-38中任一项所示的氨基酸序列;且所述第一多肽链中的第三靶向部分可包含SEQ ID NO:168和172中任一项所示的VH的氨基酸序列以及SEQ ID NO:169和173中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分靶向PD-L1,所述多特异性抗体第一多肽链中的第三靶向部分靶向CD3或CD16a。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:29-31和SEQ ID NO:32-38中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95-104和SEQ ID NO:105-111中任一项所示的氨基酸序列;且所述 第一多肽链中的第三靶向部分可包含SEQ ID NO:168和172中任一项所示的VH的氨基酸序列以及SEQ ID NO:169和173中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向CD28或CD16a,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-1,所述多特异性抗体第二多肽链中的第四靶向部分可靶向PD-L1、HER2、CD47、CD19和/或CD20。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:168或SEQ ID NO:176中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:95-104、170、174和178中任一项所示的VH的氨基酸序列以及SEQ ID NO:105-111、171、175和179中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分靶向CD28或CD16a,所述多特异性抗体第二多肽链中的第四靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:168或SEQ ID NO:176中任一项所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:95-104、170、174和178中任一项所示的VH的氨基酸序列以及SEQ ID NO:105-111、171、175和179中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一 多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向CD28或CD16a,所述多特异性抗体第二多肽链中的第二靶向部分靶向PD-1,所述多特异性抗体第一多肽链中的第三靶向部分靶向EGFR或cMET,所述多特异性抗体第二多肽链中的第四靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:168或SEQ ID NO:176中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:95-104、170、174和178中任一项所示的VH的氨基酸序列以及SEQ ID NO:105-111、171、175和179中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向CD28或CD16a,所述多特异性抗体第一多肽链中的第三靶向部分可靶向PD-L1、HER2、CD47、CD19和/或CD20,所述多特异性抗体第二多肽链中的第四靶向部分可靶向EGFR或cMET。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:168或SEQ ID NO:176中任一项所示的氨基酸序列;且所述多特异性抗体第一多肽链中的第三靶向部分可包含SEQ ID NO:95-104、170、174和178中任一项所示的VH的氨基酸序列以及SEQ ID NO:105-111、171、175和179中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一 多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-1,且所述多特异性抗体的第二多肽链的C端可包含IL-2变体、IFNα-2b或IL-15。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:32-38中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;且所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-L1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-L1,且所述多特异性抗体的第二多肽链的C端可包含IL-2变体、IFNα-2b或IL-15。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:105-111中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;且所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-L1,所述多特异性抗体的第一多肽链的C端可包含IL-2、IFNα-2b或IL-15,所述多特异性抗体第二多肽链中的第四靶向部分可包含CD3或CD16a。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述多特 异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:168和172中任一项所示的VH的氨基酸序列以及SEQ ID NO:169和173中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-L1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-1,所述多特异性抗体的第一多肽链的C端可包含IL-2、IFNα-2b或IL-15,第四靶向部分可包含CD3或CD16a。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:168和172中任一项所示的VH的氨基酸序列以及SEQ ID NO:169和173中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-L1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-1,所述多特异性抗体的第一多肽链的C端可包含IL-2、IFNα-2b或IL-15。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的细胞因子可 包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-L1,所述多特异性抗体的第一多肽链的C端可包含IL-2、IFNα-2b或IL-15。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-1,所述多特异性抗体的第一多肽链的C端可包含IL-2、IFNα-2b或IL-15,且多特异性抗体第二多肽链中的第四靶向部分可靶向PD-L1。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:32-38中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:95-104中任一项所示的VH的氨基酸序列以及SEQ ID NO:105-111中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-L1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-L1,所述多特异性抗体的第一多肽链的C端可包含IL-2、IFNα-2b或IL-15,且多特异性抗体第二多肽链中的第四靶向部分靶向PD-1。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:105-111中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列;且所述第二多肽链中的第四靶向部分可包含SEQ ID NO:29-31中任一项所示的VH的氨基酸序列以及SEQ ID NO:32-38中任一项所示的VL的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可靶向PD-1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-L1,所述多特异性抗体第一多肽链中的第三靶向部分可靶向CD3或CD16a,且所述多特异性抗体的第二多肽链的C端可包含IL-2、IFNα-2b或IL-15。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;所述第一多肽链中的第三靶向部分可包含SEQ ID NO:168和172中任一项所示的VH的氨基酸序列以及SEQ ID NO:169和173中任一项所示的VL的氨基酸序列;且所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
在本申请中,所述多特异性抗体第一多肽链中的第一靶向部分可 靶向PD-L1,所述多特异性抗体第二多肽链中的第二靶向部分可靶向PD-1,所述多特异性抗体第一多肽链中的第三靶向部分靶向CD3或CD16a,且所述多特异性抗体的第二多肽链的C端包含IL-2、IFNα-2b或IL-15。例如,所述多特异性抗体第一多肽链中的第一靶向部分可包含SEQ ID NO:95-104中任一项所示的氨基酸序列;所述多特异性抗体第二多肽链中的第二靶向部分可包含SEQ ID NO:29-31中任一项所示的氨基酸序列;所述第一多肽链中的第三靶向部分可包含SEQ ID NO:168和172中任一项所示的VH的氨基酸序列以及SEQ ID NO:169和173中任一项所示的VL的氨基酸序列;且所述多特异性抗体第二多肽链中的细胞因子可包含SEQ ID NO:180或SEQ ID NO:181所示的氨基酸序列。例如,所述多特异性抗体可包含两条第一多肽链和两条第二多肽链。例如,两条第一多肽链之间可通过二硫键连接,所述两条第一多肽链和两条第二多肽链可形成IgG样的抗体。
多肽和免疫缀合物
另一方面,本申请提供了一种或多种多肽,其可包含本申请的分离的抗原结合蛋白。例如,所述多肽可包括融合蛋白。例如,所述多肽可包括双特异性抗体。
另一方面,本申请提供了一种或多种免疫缀合物,所述免疫缀合物可包含本申请的分离的抗原结合蛋白。在某些实施方式中,所述免疫缀合物还可包含药学上可接受的治疗剂、标记物和/或检测剂。
核酸、载体、细胞和药物组合物
另一方面,本申请还提供了分离的一种或多种核酸分子,所述一种或多种核酸分子可编码本申请所述分离的抗原结合蛋白。例如,所述一种或多种核酸分子中的每一个核酸分子可以编码完整的所述抗原结合蛋白,也可以编码其中的一部分(例如,HCDR1-3、重链可变区中的一种或多种)。
例如,当核酸分子分别编码所述抗原结合蛋白的一部分时,核酸分子编码的产物合在一起可以形成有功能的(例如,可结合PD-L1和PD-1)的本申请的分离的抗原结合蛋白。
本申请所述的核酸分子可以为分离的。例如,其可以是通过以下方法产生或合成的:(i)在体外扩增的,例如通过聚合酶链式反应(PCR)扩增产生的,(ii)通过克隆重组产生的,(iii)纯化的,例如通过酶切和凝胶电泳分级分离,或者(iv)合成的,例如通过化学合成。例如,所述分离的核酸可以是通过重组DNA技术制备的核酸分子。
在本申请中,可以通过本领域已知的多种方法来制备编码所述分离的抗原结合蛋白的核酸,这些方法包括但不限于,采用逆转录PCR和PCR获得本申请所述分离的抗原结合蛋白的核酸分子。
另一方面,本申请提供了一种或多种载体,其包含本申请所述的一种或多种核酸分子。每种载体中可包含一种或多种所述核酸分子。此外,所述载体中还可包含其他基因,例如允许在适当的宿主细胞中和在适当的条件下选择该载体的标记基因。此外,所述载体还可包含允许编码区在适当宿主中正确表达的表达控制元件。这样的控制元件为本领域技术人员所熟知的,例如,可包括启动子、核糖体结合位点、增强子和调节基因转录或mRNA翻译的其他控制元件等。在某些实施方式中,所述表达控制序列为可调的元件。所述表达控制序列的具体结构可根据物种或细胞类型的功能而变化,但通常包含分别参与转录和翻译起始的5’非转录序列和5’及3’非翻译序列,例如TATA盒、加帽序列、CAAT序列等。例如,5’非转录表达控制序列可包含启动子区,启动子区可包含用于转录控制功能性连接核酸的启动子序列。所述表达控制序列还可包括增强子序列或上游活化子序列。在本申请中,适当的启动子可包括,例如用于SP6、T3和T7聚合酶的启动子、人U6RNA启动子、CMV启动子及其人工杂合启动子(如CMV),其中启动子的某部分可与其他细胞蛋白(如人GAPDH,甘油醛-3-磷酸脱氢酶)基因启动子的某部分融合,其可包含或不包含另外的内含子。本申请所述的一种或多种核酸分子可以与所述表达控制元件可操作地连接。
所述载体可以包括,例如质粒、粘粒、病毒、噬菌体或者在例如 遗传工程中通常使用的其他载体。例如,所述载体可为表达载体。例如,所述载体可为病毒载体。可以将病毒载体直接给予至患者(体内)或可以通过间接的形式,例如,在体外使用病毒处理细胞,然后将处理过的细胞给予至患者(离体)。病毒载体技术在本领域中是公知的,并在例如Sambrook等(2001,Molecular Cloning:A Laboratory Manual,Cold Spring Harbor Laboratory,New York)和其他病毒学和分子生物学手册中进行了描述。常规的基于病毒的系统可以包括用于基因转移的逆转录病毒载体、慢病毒载体、腺病毒载体、腺相关病毒载体以及单纯疱疹病毒载体。在某些情形中,可以用逆转录病毒、慢病毒和腺相关病毒的方法将基因转移整合进宿主基因组中,使插入的基因长期表达。慢病毒载体是能够转导或感染非分裂细胞并典型地产生较高病毒效价的逆转录病毒载体。慢病毒载体可包含长末端重复序列5’LTR和截短的3’LTR、RRE、rev应答元件(cPPT)、中央终止序列(CTS)和/或翻译后调控元件(WPRE)。本申请所述的载体可以被引入细胞。
另一方面,本申请提供了一种细胞。所述细胞可包含本申请所述的分离的抗原结合蛋白、所述的多肽、所述的免疫缀合物、一种或多种核酸分子和/或本申请所述的一种或多种载体。例如,每种或每个细胞可包含一个或一种本申请所述的核酸分子或载体。例如,每种或每个细胞可包含多个(例如,2个或以上)或多种(例如,2种或以上)本申请所述的核酸分子或载体。例如,可将本申请所述的载体引入所述宿主细胞中,例如原核细胞(例如,细菌细胞)、CHO细胞、NS/0细胞、HEK293T细胞、293F细胞或HEK293A细胞,或者其他真核细胞,如来自植物的细胞、真菌或酵母细胞等。可通过本领域已知的方法将本申请所述的载体引入所述宿主细胞中,例如电穿孔、lipofectine转染、lipofectamin转染等。例如,所述细胞可以包括酵母细胞。例如,所述细胞可以包括大肠杆菌细胞。例如,所述细胞可以包括哺乳动物细胞。例如,所述细胞可以包括免疫细胞。
所述细胞可以包括免疫细胞。在某些情形中,所述细胞可以包括 免疫细胞。例如,所述细胞可包括T细胞、B细胞、天然杀伤(NK)细胞、巨噬细胞、NKT细胞、单核细胞、树突状细胞、粒细胞、淋巴细胞、白细胞和/或外周血单个核细胞。
另一方面,本申请提供了一种药物组合物。所述药物组合物可包含本申请所述的分离的抗原结合蛋白、所述的多肽、所述的免疫缀合物、所述分离的核酸分子、所述的载体、所述的细胞,和/或药学上可接受的佐剂和/或赋形剂。在本申请中,所述药学上可接受的佐剂可以包括缓冲剂、抗氧化剂、防腐剂、低分子量多肽、蛋白质、亲水聚合物、氨基酸、糖、螯合剂、反离子、金属复合物和/或非离子表面活性剂。除非与本申请所述的细胞不相容,否则任何常规介质或试剂均可以考虑用于本申请的药物组合物中。在本申请中,所述药学上可接受的赋形剂可以包括在药物制剂中除主药以外的附加物,也可称为辅料。例如,所述赋形剂可以包括片剂中的粘合剂、填充剂、崩解剂、润滑剂。例如,所述赋形剂可以包括中药丸剂中的酒、醋、药汁等。例如,所述赋形剂可以包括半固体制剂软膏剂、霜剂中的基质部分。例如,所述赋形剂可以包括液体制剂中的防腐剂、抗氧剂、矫味剂、芳香剂、助溶剂、乳化剂、增溶剂、渗透压调节剂、着色剂。
用途和方法
另一方面,本申请提供了一种调节免疫应答的方法,其包括向有需要的受试者施用有效量的所述分离的抗原结合蛋白,所述的多肽,所述的免疫缀合物,所述分离的核酸分子,所述的载体,所述的细胞和/或所述的药物组合物,和/或药学上可接受的治疗剂。
在本申请中,所述调节免疫应答的方法可包括体外方法,离体方法,非诊断或非治疗目的的方法。
另一方面,本申请提供了一种调节免疫应答的方法,其包括向有需要的受试者施用有效量的所述的药物组合,和/或药学上可接受的治疗剂。
在本申请中,所述调节免疫应答的方法可包括体外方法,离体方法,非诊断或非治疗目的的方法。
另一方面,本申请提供了分离的抗原结合蛋白、所述的多肽、所述的免疫缀合物、所述分离的核酸分子、所述的载体、所述的药物组合物用于预防、缓解和/或治疗疾病或病症。
在本申请中,所述疾病或病症可包括肿瘤。例如,所述肿瘤可包括非实体瘤。例如,所述肿瘤可包括与PD-L1的表达相关的肿瘤。术语“与PD-L1的表达相关的肿瘤”通常是指PD-L1表达改变导致疾病进展或逃避免疫监视而形成的肿瘤。例如,所述“与PD-L1的表达相关的肿瘤”可以是PD-L1表达量上调导致疾病进展或逃避免疫监视而形成的肿瘤。所述与PD-L1的蛋白表达相关的肿瘤可以是PD-L1阳性的肿瘤。在PD-L1阳性的肿瘤中,与正常细胞相比,肿瘤细胞表面或肿瘤微环境中的PD-L1的蛋白表达量高约1%,5%,10%,15%,20%,25%,30%,35%,40%,50%,60%,70%,80%或更高。
另一方面,本申请提供了一种所述的分离的抗原结合蛋白、所述的多肽、所述的免疫缀合物、所述的分离的核酸分子、所述的载体,所述的细胞和/或所述的药物组合物在制备药物中的用途,所述药物用于预防、缓解和/或治疗疾病或病症。
在本申请中,所述疾病或病症可包括肿瘤。例如,所述肿瘤可包括实体瘤。例如,所述肿瘤可包括非实体瘤。例如,所述肿瘤可包括与PD-L1的表达相关的肿瘤。术语“与PD-L1的表达相关的肿瘤”通常是指PD-L1表达改变导致疾病进展或逃避免疫监视而形成的肿瘤。例如,所述“与PD-L1的表达相关的肿瘤”可以是PD-L1表达量上调导致疾病进展或逃避免疫监视而形成的肿瘤。所述与PD-L1的蛋白表达相关的肿瘤可以是PD-L1阳性的肿瘤。在PD-L1阳性的肿瘤中,与正常细胞相比,肿瘤细胞表面或肿瘤微环境中的PD-L1的蛋白表达量高约1%,5%,10%,15%,20%,25%,30%,35%,40%,50%,60%,70%,80%或更高。
另一方面,本申请提供了一种预防和/或治疗疾病或病症的方法,其包括向有需要的受试者施用所述的分离的抗原结合蛋白、所述的分离的核酸分子、所述的载体,所述的细胞、所述的药物组合物。
在本申请中,所述疾病或病症可包括肿瘤。例如,所述肿瘤可包括非实体瘤。例如,所述肿瘤可包括与PD-L1的表达相关的肿瘤。术语“与PD-L1的表达相关的肿瘤”通常是指PD-L1表达改变导致疾病进展或逃避免疫监视而形成的肿瘤。例如,所述“与PD-L1的表达相关的肿瘤”可以是PD-L1表达量上调导致疾病进展或逃避免疫监视而形成的肿瘤。所述与PD-L1的蛋白表达相关的肿瘤可以是PD-L1阳性的肿瘤。在PD-L1阳性的肿瘤中,与正常细胞相比,肿瘤细胞表面或肿瘤微环境中的PD-L1的蛋白表达量高约1%,5%,10%,15%,20%,25%,30%,35%,40%,50%,60%,70%,80%或更高。本申请所述药物组合物及方法可与其他类型的癌症疗法结合使用,诸如化学疗法、手术、放射、基因疗法等。本申请中所描述的药物组合物及方法可用于其他依赖于免疫反应的疾病病状,诸如炎症、免疫疾病及感染性疾病。
在本申请中,所述受试者可以包括人或非人动物。例如,所述非人动物可以选自下组:猴、鸡、鹅、猫、狗、小鼠和大鼠。此外,非人动物也可以包括任何除人以外的动物物种,例如家畜动物,或啮齿类动物,或灵长类动物,或家养动物,或家禽动物。所述人可以是高加索人、非洲人、亚洲人、闪族人,或其他种族,或各种种族的杂合体。又例如,所述人可以是老年、成年、青少年、儿童或者婴儿。
可以根据在实验动物中的有效量推测在人类中的有效量。例如,Freireich等人描述了动物和人的剂量的相互关系(基于每平方米身体表面的毫克数)(Freireich et al.,Cancer Chemother.Rep.50,219(1966))。身体表面积可以从患者的身高和体重近似确定。参见例如Scientific Tables,Geigy Pharmaceuticals,Ardsley,N.Y.,537(1970)。
不欲被任何理论所限,下文中的实施例仅仅是为了阐释本申请的抗原结合蛋白、制备方法和用途等,而不用于限制本申请发明的范围。
实施例
实施例1双特异性抗体载体的构建
1.1 5BM和19D4-25-3C11单抗的获得
采用杂交瘤技术获得抗原结合蛋白13H6D3和19D4F1。之后通过抗体的人源化设计、亲和力成熟获得13H6D3的人源化抗体hu13H6D3、5BM、AH00228、AH00229、AH00230、AH00231、AH00232、AH00233、CBM和19D4F1的人源化抗体hu19D4-25、19D4-25-1A3、19D4-25-1B3、19D4-25-1C2、19D4-25-1E4、19D4-25-2E10、19D4-25-3C11、19D4-25-1C2-3C11。杂交瘤的制备方法以及人源化设计的方法可根据本领域许多文献公示的方法进行。
1.2 pCP-5BM-Lh载体构建
使用下表1对应的引物Lh5BM-VL-S+Lh5BM-VL-AS,从抗体5BM重链载体pCP-5BM-H-agYTE(agYTE代表的是YTE突变和N297A突变)中扩增417bp片段。PCR酶及体系按Takara Bio
Figure PCTCN2022110795-appb-000001
HS(Premix)试剂盒配置及使用。片段扩增后进行胶回收纯化待用。
从含Kappa轻链恒定区的载体中使用PCP-CK1-S+PCP-CK1-AS引物扩增350bp轻链Kappa恒定区序列。片段扩增后进行胶回收纯化待用。
对轻链表达载体pCP-L载体进行KpnI+NotI双酶切(KpnI和NotI来自Takara Bio),切胶回收约5.5Kb大小的载体片段。
使用ClonExpress Ultra One Step Cloning Kit(Vazyme)将三片段进行同源重组构建,LB平板挑取10个阳性克隆,进行测序鉴定,选择其中一个构建正确的质粒进入后续Lh载体扩增制备流程。
表1引物序列
Figure PCTCN2022110795-appb-000002
1.3 pCP-3C11-H-agYTE载体构建
使用下表2对应的引物3C11-VH-S+3C11-VH-AS,从抗体19D4-25-3C11VH模板中(agYTE代表的是YTE突变和N297A突变)扩增411bp片段。PCR酶及体系按Takara Bio
Figure PCTCN2022110795-appb-000003
HS(Premix)试剂盒配置及使用。片段扩增后进行胶回收纯化待用。
对轻链表达载体pCP-H-agYTE载体进行KpnI+NheI双酶切(KpnI和NheI来自Takara Bio),切胶回收约6.5Kb大小的载体片段。
使用ClonExpress Ultra One Step Cloning Kit(Vazyme)将三片段进行同源重组构建,LB平板挑取10个阳性克隆,进行测序鉴定,选择其中一个构建正确的质粒进入后续pCP-3C11-H-agYTE扩增制备流程。
表2引物序列
Figure PCTCN2022110795-appb-000004
实施例2双特异性抗体表征实验
通过抗体表达质粒,将抗PDL1抗体5BMVH区域的序列(SEQ ID NO:97)接到人IgG1kappa链恒定区(CL)的N端,将抗PD1抗体19D4-25-3C11VH区域的序列(SEQ ID NO:31)连接到人IgG1重链第一恒定区(CH1)的N端。表达双特异性抗体的质粒转染HEK293细胞后培养,之后将培养液分离并提纯抗体。2xVH双抗抗体(5BMVH-3C11VH,也叫做Lh5BM-3C11)表达水平和一般抗体无异。为了对此分子进行表征研究,将高表达人PD1、PDL1或野生型的HEK293细胞和Lh5BM-3C11共孵育一个小时,洗涤后加荧光标记的抗人IgG1Fc并显色。结果表明(图2),Lh5BM-3C11可高强度染色PD1 或PDL1表达的细胞而对野生型HEK293没有任何染色,表明此双抗可结合PD1和PDL1。
为了进一步表征Lh5BM-3C11而进行了体外PD1拮抗实验。ELISA板包被重组PDL-1-Fc作为捕获物,PD1-生物素标签,然后是辣根过氧化物酶HRP-链霉亲和素作为检测剂。抗PD1单抗(1C2-3C11-AgYTE,其指代的是19D4-25-1C2-3C11与YTE突变、N297突变的Fc融合后得到的抗原结合蛋白)和抗PD1/PDL1双特异性抗体(Lh5BM-3C11)均用作阻断剂。结果(图3)显示,抗PD1抗体可以剂量依赖性地降低PD1与包被的PDL-1的结合。双特异性抗体剂量依赖性地增加HRP信号,解释为双特异性抗PDL-1结合包被的PDL1,抗PD1臂结合被HRP-亲和素结合的PD1-生物素,因此,双特异性抗体剂量依赖性地增加了HRP信号。
实施例3三特异性抗体(抗PD1/PDL1/CD16a的三特异性抗体)表征实验
通过抗体表达质粒,将抗PDL1抗体5BMVH区域的序列(SEQ ID NO:97)接到人IgG1kappa链恒定区(CL)的N端,将抗PD1抗体19D4-25-3C11VH区域的序列(SEQ ID NO:31)连接到人IgG1重链第一恒定区(CH1)的N端。将抗CD16a抗体的VH(SEQ ID NO:168)和VL(SEQ ID NO:169)用连接子(GGGGS)3相连并将VH的N端用连接子连接到Fc的C端。由此构成抗PD1/PDL1/CD16a的三特异性抗体。用表达PD1、PDL1、CD16a或野生型HEK293细胞进行染色。结果显示此三抗可特异性的染色PD1、PDL1或CD16a高表达的细胞而对野生型HEK293没有染色。
为了表征此三特异性抗体能同时连接PD1、PDL1和CD16a蛋白,Biacore实验显示用三特异性抗体包被芯片,按顺序加上PD1,PDL-1或CD16a后观察到峰值依次升高,说明此分子可同时结合PD1,PDL-1和CD16a。
实施例4抗PD1/PDL1/IL-2的双特异性抗体表征实验
通过抗体表达质粒,将抗PDL-1抗体5BMVH区域的序列(SEQ ID NO:97)接到人IgG1kappa链恒定区(CL)的N端,将抗PD1抗体19D4-25-3C11VH区域的序列(SEQ ID NO:31)连接到人IgG1重链第一恒定区(CH1)的N端。将IL-2(SEQ ID NO:180)表达基因用连接子(GGGGS)3连接到Fc的C端。由此构成抗PD1/PDL1/IL-2的双特异性抗体免疫细胞因子(Immunocytokines)。Biacore实验显示用抗PD1/PDL1/IL-2的双特异性抗体包被芯片,按顺序加上PD1,PDL-1或IL-2R后观察到峰值依次升高,说明此分子可同时结合PD1,PDL-1和IL-2R。
将抗PD1/PDL1/IL-2的双特异性抗体和人外周血PBMC一起孵育后,T细胞的增殖和细胞因子的产生明显高于PD1-PDL1双抗刺激的培养,说明了IL-2免疫增强作用。
实施例5抗PD1/PDL1/IFN-a的双特异性抗体的表征实验
通过抗体表达质粒,将抗PDL-1抗体5BM VH区域的序列(SEQ ID NO:97)接到人IgG1kappa链恒定区(CL)的N端,将抗PD1抗体19D4-25-3C11VH区域的序列(SEQ ID NO:31)连接到人IgG1重链第一恒定区(CH1)的N端。将IFN-a(SEQ ID NO:181)表达基因用连接子(GGGGS)3连接到Fc的C端。由此构成抗PD1/PDL1/IFN-α的双特异性抗体免疫细胞因子(Immunocytokines)。Biacore实验显示用抗PD1/PDL1/IFN-α的双特异性抗体包被芯片,按顺序加上PD1,PDL-1或IFNR后观察到峰值依次升高,说明此分子可同时结合PD1,PDL-1和IFNR。
将抗PD1/PDL1/IFN-α的双特异性抗体和人外周血PBMC一起孵育后,T细胞的增殖和细胞因子的产生明显高于PD1-PDL1双抗刺激的培养,说明了IFN-α免疫增强作用。

Claims (269)

  1. 分离的抗原结合蛋白,其包含第一多肽链、第二多肽链,所述第一多肽链包含第一靶向部分,所述第二多肽链包含第二靶向部分,所述第一靶向部分和所述第二靶向部分各自独立地结合免疫细胞相关抗原,所述第一多肽链与所述第二多肽链通过二硫键连接。
  2. 根据权利要求1所述的分离的抗原结合蛋白,其中所述免疫细胞包括T细胞、巨噬细胞、树突状细胞和/或NK细胞。
  3. 根据权利要求1-2中任一项所述的分离的抗原结合蛋白,其中所述免疫细胞相关抗原包括PD-1、PD-L1、CD3、CD16a和/或CD28。
  4. 根据权利要求1-3中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分和第二靶向部分结合相同的免疫细胞相关抗原。
  5. 根据权利要求1-4中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分和第二靶向部分均结合PD-1蛋白或PD-L1蛋白。
  6. 根据权利要求1-5中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分特异性结合PD-1蛋白,且所述第二靶向部分特异性结合PD-L1蛋白。
  7. 根据权利要求1-6中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分特异性结合PD-L1蛋白,且所述第二靶向部分特异性结合PD-1蛋白。
  8. 根据权利要求1-7中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分特异性结合PD-1蛋白,且所述第二靶向部分特异性结合CD28或CD16a蛋白。
  9. 根据权利要求1-8中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分特异性结合CD28或CD16a蛋白,且所述第二靶向部分特异性结合PD-1蛋白。
  10. 根据权利要求1-9中任一项所述的分离的抗原结合蛋白,其中所述第一多肽链还包含第三靶向部分。
  11. 根据权利要求10所述的分离的抗原结合蛋白,其中所述第一多肽链中第三靶向部分与所述第一靶向部分的C端直接或间接地连接。
  12. 根据权利要求10-11中任一项所述的分离的抗原结合蛋白,其中所述第一多肽链中第三靶向部分与所述第一靶向部分的C端通过连接子连接。
  13. 根据权利要求10-12中任一项所述的分离的抗原结合蛋白,其中所述第三靶向部分靶向免疫细胞相关抗原。
  14. 根据权利要求13所述的分离的抗原结合蛋白,其中所述免疫细胞相关抗原包括PD-1、PD-L1、CD3、CD16a和/或CD28。
  15. 根据权利要求14所述的分离的抗原结合蛋白,其中所述第三靶向部分靶向CD3或CD16a蛋白。
  16. 根据权利要求10-15中任一项所述的分离的抗原结合蛋白,其中所述第三靶向部分靶向肿瘤发生相关抗原。
  17. 根据权利要求16所述的分离的抗原结合蛋白,其中所述第三靶向部分靶向EGFR和/或cMet。
  18. 根据权利要求10-17中任一项所述的分离的抗原结合蛋白,其中所述第三靶向部分靶向肿瘤相关抗原。
  19. 根据权利要求18所述的分离的抗原结合蛋白,其中所述肿瘤相关抗原包括PD-L1、HER2、CD47、CD19和/或CD20。
  20. 根据权利要求1-19中任一项所述的分离的抗原结合蛋白,其中所述第二多肽链还包含第四靶向部分。
  21. 根据权利要求20所述的分离的抗原结合蛋白,其中所述第二多肽链中第四靶向部分与所述第二靶向部分的C端直接或间接地连接。
  22. 根据权利要求20-21中任一项所述的分离的抗原结合蛋白,其中所述第二多肽链中第四靶向部分与所述第二靶向部分的C端通过连接子连接。
  23. 根据权利要求20-22中任一项所述的分离的抗原结合蛋白,其中所述第四靶向部分靶向免疫细胞相关抗原。
  24. 根据权利要求23所述的分离的抗原结合蛋白,其中所述免疫细胞相关抗原包括PD-1、PD-L1、CD3、CD16a和/或CD28。
  25. 根据权利要求20-24中任一项所述的分离的抗原结合蛋白,其中所述第四靶向部分靶向肿瘤发生相关抗原。
  26. 根据权利要求25所述的分离的抗原结合蛋白,其中所述第四靶向部分靶向EGFR和/或cMet。
  27. 根据权利要求20-26中任一项所述的分离的抗原结合蛋白,其中所述第四靶向部分靶向肿瘤相关抗原。
  28. 根据权利要求27所述的分离的抗原结合蛋白,其中所述肿瘤相关抗原包括PD-L1、HER2、CD47、CD19和/或CD20。
  29. 根据权利要求1-28中任一项所述的分离的抗原结合蛋白,其中 所述第一多肽链包含细胞因子。
  30. 根据权利要求29所述的分离的抗原结合蛋白,其中所述细胞因子包括IL-2、IFNa、IFNb和/或IL-15。
  31. 根据权利要求1-30中任一项所述的分离的抗原结合蛋白,其中所述第二多肽链包含细胞因子。
  32. 根据权利要求31所述的分离的抗原结合蛋白,其中所述细胞因子包括IL-2、IFNa、IFNb和/或IL-15。
  33. 根据权利要求20-32中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-L1,且所述第四靶向部分靶向PD-1、CD3或CD16a。
  34. 根据权利要求20-32中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-1,且所述第四靶向部分靶向PD-L1、CD3或CD16a。
  35. 根据权利要求10-32中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-1,且所述第三靶向部分靶向CD3或CD16a。
  36. 根据权利要求10-32中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-L1,且所述第三靶向部分靶向CD3或CD16a。
  37. 根据权利要求20-32中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向CD28或CD16a,所述第二靶向部分靶向PD-1,且所述第四靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20。
  38. 根据权利要求20-32中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向CD28或CD16a,且所述第四靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20。
  39. 根据权利要求20-32中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向CD28或CD16a,所述第二靶向部分靶向PD-1,所述第三靶向部分靶向EGFR或cMET,且所述第四靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20。
  40. 根据权利要求20-32中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向CD28或CD16a,所述第三靶向部分靶向PD-L1、HER2、CD47、CD19和/或CD20,且所述第四靶向部分靶向EGFR或cMET。
  41. 根据权利要求1-40中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-1,且所述第二多肽链包含IL-2或IL-15。
  42. 根据权利要求1-40中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-L1,且所述第二多肽链包含IL-2或IL-15。
  43. 根据权利要求20-42中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-L1,所述第一多肽链包含IL-2或IL-15,且第四靶向部分包含CD3或CD16a。
  44. 根据权利要求20-42中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-1,所述第 一多肽链包含IL-2或IL-15,且所述第四靶向部分包含CD3或CD16a。
  45. 根据权利要求1-44中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-1,且所述第一多肽链包含IL-2或IL-15。
  46. 根据权利要求1-44中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-L1,且所述第一多肽链包含IL-2或IL-15。
  47. 根据权利要求20-46中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-1,所述第一多肽链包含IL-2或IL-15,且所述第四靶向部分靶向PD-L1。
  48. 根据权利要求20-46中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-L1,所述第一多肽链包含IL-2或IL-15,且所述第四靶向部分靶向PD-1。
  49. 根据权利要求10-48中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-1,所述第二靶向部分靶向PD-L1,第三靶向部分靶向CD3或CD16a,且所述第二多肽链包含IL-2或IL-15。
  50. 根据权利要求10-48中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向PD-L1,所述第二靶向部分靶向PD-1,第三靶向部分靶向CD3或CD16a,且所述第二多肽链包含IL-2或IL-15。
  51. 根据权利要求1-50中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:51所示的氨基酸序列。
  52. 根据权利要求51所述的分离的抗原结合蛋白,其中所述HCDR3包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列。
  53. 根据权利要求1-52中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含HCDR2,所述HCDR2包含SEQ ID NO:6所示的氨基酸序列。
  54. 根据权利要求1-53中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含HCDR1,所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
  55. 根据权利要求1-54中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含SEQ ID NO:52所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
  56. 根据权利要求55所述的分离的抗原结合蛋白,其中所述第一靶向部分包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
  57. 根据权利要求1-56中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:51所示的氨基酸序列;所述HCDR2包含SEQ ID NO:6所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
  58. 根据权利要求57所述的分离的抗原结合蛋白,其中所述第一靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨 基酸序列;所述HCDR2包含SEQ ID NO:6所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
  59. 根据权利要求57-58中任一项所述的分离的抗原结合蛋白,其中所述HCDR1、HCDR2和HCDR3包含选自下述任意一组的氨基酸序列:
    a)HCDR1:SEQ ID NO:3,HCDR2:SEQ ID NO:6和HCDR3:SEQ ID NO:9;和
    b)HCDR1:SEQ ID NO:3,HCDR2:SEQ ID NO:6和HCDR3:SEQ ID NO:10。
  60. 根据权利要求1-59中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR1,所述H-FR1的C末端与所述HCDR1的N末端直接或间接地相连,且所述H-FR1包含SEQ ID NO:47所示的氨基酸序列。
  61. 根据权利要求60所述的分离的抗原结合蛋白,其中所述H-FR1包含SEQ ID NO:1和SEQ ID NO:2中任一项所示的氨基酸序列。
  62. 根据权利要求1-61中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR2,所述H-FR2位于所述HCDR1与所述HCDR2之间,且所述H-FR2包含SEQ ID NO:48所示的氨基酸序列。
  63. 根据权利要求62所述的分离的抗原结合蛋白,其中所述H-FR2包含SEQ ID NO:4和SEQ ID NO:5中任一项所示的氨基酸序列。
  64. 根据权利要求1-63中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR3,所述H-FR3位于所述HCDR2与所述HCDR3之间,且所述H-FR3包含SEQ ID NO:49所示的氨基酸序列。
  65. 根据权利要求64所述的分离的抗原结合蛋白,其中所述H-FR3包含SEQ ID NO:7和SEQ ID NO:8中任一项所示的氨基酸序列。
  66. 根据权利要求1-65中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR4,所述H-FR4的N末端与所述HCDR3的C末端直接或间接地相连,且所述H-FR4包含SEQ ID NO:50所示的氨基酸序列。
  67. 根据权利要求66所述的分离的抗原结合蛋白,其中所述H-FR4包含SEQ ID NO:11和SEQ ID NO:12中任一项所示的氨基酸序列。
  68. 根据权利要求1-67中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:47所示的氨基酸序列;所述H-FR2包含SEQ ID NO:48所示的氨基酸序列;所述H-FR3包含SEQ ID NO:49所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:50所示的氨基酸序列。
  69. 根据权利要求68所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:1和SEQ ID NO:2中任一项所示的氨基酸序列;所述H-FR2包含SEQ ID NO:4和SEQ ID NO:5中任一项所示的氨基酸序列;所述H-FR3包含SEQ ID NO:7和SEQ ID NO:8中任一项所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:11和SEQ ID NO:12中任一项所示的氨基酸序列。
  70. 根据权利要求68-69中任一项所述的分离的抗原结合蛋白,其中所述H-FR1、H-FR2、H-FR3和H-FR4包含选自下述任意一组的氨基酸 序列:
    a)H-FR1:SEQ ID NO:1,H-FR2:SEQ ID NO:4,H-FR3:SEQ ID NO:7和H-FR4:SEQ ID NO:11;和
    b)H-FR1:SEQ ID NO:2,H-FR2:SEQ ID NO:5,H-FR3:SEQ ID NO:8和H-FR4:SEQ ID NO:12。
  71. 根据权利要求1-70中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:52所示的氨基酸序列。
  72. 根据权利要求71所述的分离的抗原结合蛋白,其中所述VH包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的氨基酸序列。
  73. 根据权利要求1-50中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:57所示的氨基酸序列。
  74. 根据权利要求73所述的分离的抗原结合蛋白,其中所述LCDR3包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列。
  75. 根据权利要求1-50和73-74中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含LCDR2,所述LCDR2包含SEQ ID NO:18所示的氨基酸序列。
  76. 根据权利要求1-50和73-75中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含LCDR1,所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
  77. 根据权利要求1-50和73-76中任一项所述的分离的抗原结合蛋 白,其中所述第一靶向部分包含SEQ ID NO:58所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
  78. 根据权利要求77所述的分离的抗原结合蛋白,其中所述第一靶向部分包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
  79. 根据权利要求1-50和73-78中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:57所示的氨基酸序列;所述LCDR2包含SEQ ID NO:18所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
  80. 根据权利要求79所述的分离的抗原结合蛋白,其中所述第一靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列;所述LCDR2包含SEQ ID NO:18所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
  81. 根据权利要求79-80中任一项所述的分离的抗原结合蛋白,其中所述LCDR1、LCDR2和LCDR3包含选自下述任意一组的氨基酸序列:
    a)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:21;
    b)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:22;
    c)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ  ID NO:23;
    d)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:24;
    e)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:25;和
    f)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:26。
  82. 根据权利要求1-50和73-81中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR1,所述L-FR1的C末端与所述LCDR1的N末端直接或间接地相连,且所述L-FR1包含SEQ ID NO:53所示的氨基酸序列。
  83. 根据权利要求82所述的分离的抗原结合蛋白,其中所述L-FR1包含SEQ ID NO:13和SEQ ID NO:14中任一项所示的氨基酸序列。
  84. 根据权利要求1-50和73-83中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR2,所述L-FR2位于所述LCDR1与所述LCDR2之间,且所述L-FR2包含SEQ ID NO:54所示的氨基酸序列。
  85. 根据权利要求84所述的分离的抗原结合蛋白,其中所述L-FR2包含SEQ ID NO:16和SEQ ID NO:17中任一项所示的氨基酸序列。
  86. 根据权利要求1-50和73-85中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR3,所述L-FR3位于所述LCDR2与所述LCDR3之间,且所述L-FR3包含SEQ ID NO:55所示的氨基酸 序列。
  87. 根据权利要求86所述的分离的抗原结合蛋白,其中所述L-FR3包含SEQ ID NO:19和SEQ ID NO:20中任一项所示的氨基酸序列。
  88. 根据权利要求1-50和73-87中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR4,所述L-FR4的N末端与所述LCDR3的C末端直接或间接地相连,且所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
  89. 根据权利要求88所述的分离的抗原结合蛋白,其中所述L-FR4包含SEQ ID NO:27和SEQ ID NO:28中任一项所示的氨基酸序列。
  90. 根据权利要求1-50和73-89中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:53所示的氨基酸序列;所述L-FR2包含SEQ ID NO:54所示的氨基酸序列;所述L-FR3包含SEQ ID NO:55所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
  91. 根据权利要求90所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:13和SEQ ID NO:14中任一项所示的氨基酸序列;所述L-FR2包含SEQ ID NO:16和SEQ ID NO:17中任一项所示的氨基酸序列;所述L-FR3包含SEQ ID NO:19和SEQ ID NO:20中任一项所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:27和SEQ ID NO:28中任一项所示的氨基酸序列。
  92. 根据权利要求90-91中任一项所述的分离的抗原结合蛋白,其中所述L-FR1、L-FR2、L-FR3和L-FR4包含选自下述任意一组的氨基酸序列:
    a)L-FR1:SEQ ID NO:13,L-FR2:SEQ ID NO:16,L-FR3:SEQ ID NO:19和L-FR4:SEQ ID NO:27;和
    b)L-FR1:SEQ ID NO:14,L-FR2:SEQ ID NO:17,L-FR3:SEQ ID NO:20和L-FR4:SEQ ID NO:28。
  93. 根据权利要求1-50和73-92中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包括VL,所述VL包含SEQ ID NO:58中任一项所示的氨基酸序列。
  94. 根据权利要求93所述的分离的抗原结合蛋白,其中所述VL包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
  95. 根据权利要求1-50中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:76所示的氨基酸序列。
  96. 根据权利要求1-50和95中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含HCDR2,所述HCDR2包含SEQ ID NO:70所示的氨基酸序列。
  97. 根据权利要求1-50和95-96中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含HCDR1,所述HCDR1包含SEQ ID NO:61所示的氨基酸序列。
  98. 根据权利要求1-50和95-97中任一项所述的分离的抗原结合蛋 白,其中所述第一靶向部分包含SEQ ID NO:122所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
  99. 根据权利要求98所述的分离的抗原结合蛋白,其中所述第一靶向部分包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
  100. 根据权利要求1-50和95-99中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:76所示的氨基酸序列;所述HCDR2包含SEQ ID NO:70所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:61所示的氨基酸序列。
  101. 根据权利要求1-50和95-100中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR1,所述H-FR1的C末端与所述HCDR1的N末端直接或间接地相连,且所述H-FR1包含SEQ ID NO:115所示的氨基酸序列。
  102. 根据权利要求101所述的分离的抗原结合蛋白,其中所述H-FR1包含SEQ ID NO:59至SEQ ID NO:60中任一项所示的氨基酸序列。
  103. 根据权利要求1-50和95-102中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR2,所述H-FR2位于所述HCDR1与所述HCDR2之间,且所述H-FR2包含SEQ ID NO:116所示的氨基酸序列。
  104. 根据权利要求103所述的分离的抗原结合蛋白,其中所述H-FR2包含SEQ ID NO:62至SEQ ID NO:69中任一项所示的氨基酸序列。
  105. 根据权利要求1-50和95-104中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR3,所述H-FR3位于所述HCDR2与所述HCDR3之间,且所述H-FR3包含SEQ ID NO:117所示的氨基酸序列。
  106. 根据权利要求105所述的分离的抗原结合蛋白,其中所述H-FR3包含SEQ ID NO:71至SEQ ID NO:75中任一项所示的氨基酸序列。
  107. 根据权利要求1-50和95-106中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR4,所述H-FR4的N末端与所述HCDR3的C末端直接或间接地相连,且所述H-FR4包含SEQ ID NO:118所示的氨基酸序列。
  108. 根据权利要求107所述的分离的抗原结合蛋白,其中所述H-FR4包含SEQ ID NO:77至SEQ ID NO:78中任一项所示的氨基酸序列。
  109. 根据权利要求1-50和95-108中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:115所示的氨基酸序列;所述H-FR2包含SEQ ID NO:116所示的氨基酸序列;所述H-FR3包含SEQ ID NO:117所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:118所示的氨基酸序列。
  110. 根据权利要求109所述的分离的抗原结合蛋白,其中所述第一靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:59至SEQ ID NO:60中任一项所示的氨基酸序列;所述H-FR2包含SEQ ID NO:62至SEQ ID NO:69中任一项所示的氨基酸序列; 所述H-FR3包含SEQ ID NO:71至SEQ ID NO:75中任一项所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:77至SEQ ID NO:78中任一项所示的氨基酸序列。
  111. 根据权利要求109-110中任一项所述的分离的抗原结合蛋白,其中所述H-FR1、H-FR2、H-FR3和H-FR4包含选自下述任意一组的氨基酸序列:
    a)H-FR1:SEQ ID NO:59,H-FR2:SEQ ID NO:62,H-FR3:SEQ ID NO:71和H-FR4:SEQ ID NO:77;
    b)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:63,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
    c)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:64,H-FR3:SEQ ID NO:73和H-FR4:SEQ ID NO:78;
    d)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:65,H-FR3:SEQ ID NO:74和H-FR4:SEQ ID NO:78;
    e)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:66,H-FR3:SEQ ID NO:75和H-FR4:SEQ ID NO:78;
    f)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:67,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
    g)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:65,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
    h)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:64,H-FR3:SEQ ID NO:74和H-FR4:SEQ ID NO:78;
    i)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:68,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;和
    j)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:69,H-FR3:SEQ ID NO:73和H-FR4:SEQ ID NO:78。
  112. 根据权利要求1-50和95-111中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:122所示的氨基酸序列。
  113. 根据权利要求112所述的分离的抗原结合蛋白,其中所述VH包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的氨基酸序列。
  114. 根据权利要求1-50中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:94所示的氨基酸序列。
  115. 根据权利要求1-50和114中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含LCDR2,所述LCDR2包含SEQ ID NO:87所示的氨基酸序列。
  116. 根据权利要求1-50和114-115中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含LCDR1,所述LCDR1包含SEQ ID NO:82所示的氨基酸序列。
  117. 根据权利要求1-50和114-116中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含SEQ ID NO:123中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
  118. 根据权利要求117所述的分离的抗原结合蛋白,其中所述第一 靶向部分包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
  119. 根据权利要求1-50和114-118中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:94所示的氨基酸序列;所述LCDR2包含SEQ ID NO:87所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:82所示的氨基酸序列。
  120. 根据权利要求1-50和114-119中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR1,所述L-FR1的C末端与所述LCDR1的N末端直接或间接地相连,且所述L-FR1包含SEQ ID NO:119所示的氨基酸序列。
  121. 根据权利要求120所述的分离的抗原结合蛋白,其中所述L-FR1包含SEQ ID NO:79至SEQ ID NO:81中任一项所示的氨基酸序列。
  122. 根据权利要求1-50和114-121中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR2,所述L-FR2位于所述LCDR1与所述LCDR2之间,且所述L-FR2包含SEQ ID NO:120所示的氨基酸序列。
  123. 根据权利要求122所述的分离的抗原结合蛋白,其中所述L-FR2包含SEQ ID NO:83至SEQ ID NO:86中任一项所示的氨基酸序列。
  124. 根据权利要求1-50和114-123中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR3,所述L-FR3位于所述LCDR2与所述LCDR3之间,且所述L-FR3包含SEQ ID NO:121所示的氨基 酸序列。
  125. 根据权利要求124所述的分离的抗原结合蛋白,其中所述L-FR3包含SEQ ID NO:88至SEQ ID NO:93中任一项所示的氨基酸序列。
  126. 根据权利要求1-50和114-125中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR4,所述L-FR4的N末端与所述LCDR3的C末端直接或间接地相连,且所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
  127. 根据权利要求126所述的分离的抗原结合蛋白,其中所述L-FR4包含SEQ ID NO:27至SEQ ID NO:28中任一项所示的氨基酸序列。
  128. 根据权利要求1-50和114-127中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:119所示的氨基酸序列;所述L-FR2包含SEQ ID NO:120所示的氨基酸序列;所述L-FR3包含SEQ ID NO:121所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
  129. 根据权利要求128所述的分离的抗原结合蛋白,其中所述第一靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:79至SEQ ID NO:81中任一项所示的氨基酸序列;所述L-FR2包含SEQ ID NO:83至SEQ ID NO:86中任一项所示的氨基酸序列;所述L-FR3包含SEQ ID NO:88至SEQ ID NO:93中任一项所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:27至SEQ ID NO:28中任一项所示的氨基酸序列。
  130. 根据权利要求128-129中任一项所述的分离的抗原结合蛋白,其中所述L-FR1、L-FR2、L-FR3和L-FR4包含选自下述任意一组的氨基酸序列:
    a)L-FR1:SEQ ID NO:79,L-FR2:SEQ ID NO:83,L-FR3:SEQ ID NO:88和L-FR4:SEQ ID NO:27;
    b)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:84,L-FR3:SEQ ID NO:89和L-FR4:SEQ ID NO:28;
    c)L-FR1:SEQ ID NO:81,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:90和L-FR4:SEQ ID NO:28;
    d)L-FR1:SEQ ID NO:81,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:91和L-FR4:SEQ ID NO:28;
    e)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:90和L-FR4:SEQ ID NO:28;
    f)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:92和L-FR4:SEQ ID NO:28;和
    g)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:86,L-FR3:SEQ ID NO:93和L-FR4:SEQ ID NO:28。
  131. 根据权利要求1-50和114-130中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分包括VL,所述VL包含SEQ ID NO:123所示的氨基酸序列。
  132. 根据权利要求131所述的分离的抗原结合蛋白,其中所述VL包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
  133. 根据权利要求1-50中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向CD28,所述第一靶向部分包含VH,所述VH包含SEQ ID NO:176所示的氨基酸序列。
  134. 根据权利要求1-50中任一项所述的分离的抗原结合蛋白,其中所述第一靶向部分靶向CD16a,所述第一靶向部分包含VH,所述VH包含SEQ ID NO:168所示的氨基酸序列。
  135. 根据权利要求1-134所述的分离的抗原结合蛋白,其中所述第二靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:51所示的氨基酸序列。
  136. 根据权利要求135所述的分离的抗原结合蛋白,其中所述第二靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列。
  137. 根据权利要求1-136中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含HCDR2,所述HCDR2包含SEQ ID NO:6所示的氨基酸序列。
  138. 根据权利要求1-137中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含HCDR1,所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
  139. 根据权利要求1-138中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含SEQ ID NO:52所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
  140. 根据权利要求139所述的分离的抗原结合蛋白,其中所述第二 靶向部分包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
  141. 根据权利要求1-140中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:51所示的氨基酸序列;所述HCDR2包含SEQ ID NO:6所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
  142. 根据权利要求141所述的分离的抗原结合蛋白,其中所述第二靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:9和SEQ ID NO:10中任一项所示的氨基酸序列;所述HCDR2包含SEQ ID NO:6所示的氨基酸序列;以及所述HCDR1包含SEQ ID NO:3所示的氨基酸序列。
  143. 根据权利要求141-142中任一项所述的分离的抗原结合蛋白,其中所述HCDR1、HCDR2和HCDR3包含选自下述任意一组的氨基酸序列:
    a)HCDR1:SEQ ID NO:3,HCDR2:SEQ ID NO:6和HCDR3:SEQ ID NO:9;和
    b)HCDR1:SEQ ID NO:3,HCDR2:SEQ ID NO:6和HCDR3:SEQ ID NO:10。
  144. 根据权利要求1-143中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR1,所述H-FR1的C末端与所述HCDR1的N末端直接或间接地相连,且所述H-FR1包含SEQ ID NO:47所示 的氨基酸序列。
  145. 根据权利要求144所述的分离的抗原结合蛋白,其中所述H-FR1包含SEQ ID NO:1和SEQ ID NO:2中任一项所示的氨基酸序列。
  146. 根据权利要求1-145中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR2,所述H-FR2位于所述HCDR1与所述HCDR2之间,且所述H-FR2包含SEQ ID NO:48所示的氨基酸序列。
  147. 根据权利要求146所述的分离的抗原结合蛋白,其中所述H-FR2包含SEQ ID NO:4和SEQ ID NO:5中任一项所示的氨基酸序列。
  148. 根据权利要求1-147中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR3,所述H-FR3位于所述HCDR2与所述HCDR3之间,且所述H-FR3包含SEQ ID NO:49所示的氨基酸序列。
  149. 根据权利要求148所述的分离的抗原结合蛋白,其中所述H-FR3包含SEQ ID NO:7和SEQ ID NO:8中任一项所示的氨基酸序列。
  150. 根据权利要求1-149中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR4,所述H-FR4的N末端与所述HCDR3的C末端直接或间接地相连,且所述H-FR4包含SEQ ID NO:50所示的氨基酸序列。
  151. 根据权利要求150所述的分离的抗原结合蛋白,其中所述H-FR4包含SEQ ID NO:11和SEQ ID NO:12中任一项所示的氨基酸序列。
  152. 根据权利要求1-151中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:47所示的氨基酸序列;所述H-FR2包含SEQ ID NO: 48所示的氨基酸序列;所述H-FR3包含SEQ ID NO:49所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:50所示的氨基酸序列。
  153. 根据权利要求152所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:1和SEQ ID NO:2中任一项所示的氨基酸序列;所述H-FR2包含SEQ ID NO:4和SEQ ID NO:5中任一项所示的氨基酸序列;所述H-FR3包含SEQ ID NO:7和SEQ ID NO:8中任一项所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:11和SEQ ID NO:12中任一项所示的氨基酸序列。
  154. 根据权利要求152-153中任一项所述的分离的抗原结合蛋白,其中所述H-FR1、H-FR2、H-FR3和H-FR4包含选自下述任意一组的氨基酸序列:
    a)H-FR1:SEQ ID NO:1,H-FR2:SEQ ID NO:4,H-FR3:SEQ ID NO:7和H-FR4:SEQ ID NO:11;
    b)H-FR1:SEQ ID NO:2,H-FR2:SEQ ID NO:5,H-FR3:SEQ ID NO:8和H-FR4:SEQ ID NO:12。
  155. 根据权利要求1-154中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:52所示的氨基酸序列。
  156. 根据权利要求155所述的分离的抗原结合蛋白,其中所述VH包含SEQ ID NO:29至SEQ ID NO:31中任一项所示的氨基酸序列。
  157. 根据权利要求1-134中任一项所述的分离的抗原结合蛋白,其 中所述第二靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:57所示的氨基酸序列。
  158. 根据权利要求157所述的分离的抗原结合蛋白,其中所述第二靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列。
  159. 根据权利要求1-134和157-158中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含LCDR2,所述LCDR2包含SEQ ID NO:18所示的氨基酸序列。
  160. 根据权利要求1-134和157-159中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含LCDR1,所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
  161. 根据权利要求1-134和157-160中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含SEQ ID NO:58所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
  162. 根据权利要求161所述的分离的抗原结合蛋白,其中所述第二靶向部分包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
  163. 根据权利要求1-134和157-162中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:57所示的氨基酸序列;所述LCDR2包含SEQ ID NO:18所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
  164. 根据权利要求163所述的分离的抗原结合蛋白,其中所述第二靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:21至SEQ ID NO:26中任一项所示的氨基酸序列;所述LCDR2包含SEQ ID NO:18所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:15所示的氨基酸序列。
  165. 根据权利要求163-164中任一项所述的分离的抗原结合蛋白,其中所述LCDR1、LCDR2和LCDR3包含选自下述任意一组的氨基酸序列:
    a)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:21;
    b)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:22;
    c)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:23;
    d)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:24;
    e)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:25;和
    f)LCDR1:SEQ ID NO:15,LCDR2:SEQ ID NO:18和LCDR3:SEQ ID NO:26。
  166. 根据权利要求1-134和157-165中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR1,所述L-FR1的C末端与 所述LCDR1的N末端直接或间接地相连,且所述L-FR1包含SEQ ID NO:53所示的氨基酸序列。
  167. 根据权利要求166所述的分离的抗原结合蛋白,其中所述L-FR1包含SEQ ID NO:13和SEQ ID NO:14中任一项所示的氨基酸序列。
  168. 根据权利要求1-134和157-167中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR2,所述L-FR2位于所述LCDR1与所述LCDR2之间,且所述L-FR2包含SEQ ID NO:54所示的氨基酸序列。
  169. 根据权利要求168所述的分离的抗原结合蛋白,其中所述L-FR2包含SEQ ID NO:16和SEQ ID NO:17中任一项所示的氨基酸序列。
  170. 根据权利要求1-134和157-169中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR3,所述L-FR3位于所述LCDR2与所述LCDR3之间,且所述L-FR3包含SEQ ID NO:55所示的氨基酸序列。
  171. 根据权利要求170所述的分离的抗原结合蛋白,其中所述L-FR3包含SEQ ID NO:19和SEQ ID NO:20中任一项所示的氨基酸序列。
  172. 根据权利要求1-134和157-171中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR4,所述L-FR4的N末端与所述LCDR3的C末端直接或间接地相连,且所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
  173. 根据权利要求172所述的分离的抗原结合蛋白,其中所述L-FR4包含SEQ ID NO:27和SEQ ID NO:28中任一项所示的氨基酸序列。
  174. 根据权利要求1-134和157-173中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:53所示的氨基酸序列;所述L-FR2包含SEQ ID NO:54所示的氨基酸序列;所述L-FR3包含SEQ ID NO:55所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
  175. 根据权利要求174所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:13和SEQ ID NO:14中任一项所示的氨基酸序列;所述L-FR2包含SEQ ID NO:16和SEQ ID NO:17中任一项所示的氨基酸序列;所述L-FR3包含SEQ ID NO:19和SEQ ID NO:20中任一项所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:27和SEQ ID NO:28中任一项所示的氨基酸序列。
  176. 根据权利要求174-175中任一项所述的分离的抗原结合蛋白,其中所述L-FR1、L-FR2、L-FR3和L-FR4包含选自下述任意一组的氨基酸序列:
    a)L-FR1:SEQ ID NO:13,L-FR2:SEQ ID NO:16,L-FR3:SEQ ID NO:19和L-FR4:SEQ ID NO:27;和
    b)L-FR1:SEQ ID NO:14,L-FR2:SEQ ID NO:17,L-FR3:SEQ ID NO:20和L-FR4:SEQ ID NO:28。
  177. 根据权利要求1-134和157-176中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包括VL,所述VL包含SEQ ID NO:58 中任一项所示的氨基酸序列。
  178. 根据权利要求177所述的分离的抗原结合蛋白,其中所述VL包含SEQ ID NO:32至SEQ ID NO:38中任一项所示的氨基酸序列。
  179. 根据权利要求1-134所述的分离的抗原结合蛋白,其中所述第二靶向部分包含HCDR3,所述HCDR3包含SEQ ID NO:76所示的氨基酸序列。
  180. 根据权利要求1-134和179中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含HCDR2,所述HCDR2包含SEQ ID NO:70所示的氨基酸序列。
  181. 根据权利要求1-134和179-180中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含HCDR1,所述HCDR1包含SEQ ID NO:61所示的氨基酸序列。
  182. 根据权利要求1-134和179-181中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含SEQ ID NO:122所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
  183. 根据权利要求182所述的分离的抗原结合蛋白,其中所述第二靶向部分包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的重链可变区VH的HCDR1、HCDR2和HCDR3。
  184. 根据权利要求1-134和179-183中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包括重链可变区VH,所述VH包含所述HCDR1、HCDR2和HCDR3,所述HCDR3包含SEQ ID NO:76所示的氨基酸序列;所述HCDR2包含SEQ ID NO:70所示的氨基酸序列;以 及所述HCDR1包含SEQ ID NO:61所示的氨基酸序列。
  185. 根据权利要求1-134和179-184中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR1,所述H-FR1的C末端与所述HCDR1的N末端直接或间接地相连,且所述H-FR1包含SEQ ID NO:115所示的氨基酸序列。
  186. 根据权利要求185所述的分离的抗原结合蛋白,其中所述H-FR1包含SEQ ID NO:59至SEQ ID NO:60中任一项所示的氨基酸序列。
  187. 根据权利要求1-134和179-186中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR2,所述H-FR2位于所述HCDR1与所述HCDR2之间,且所述H-FR2包含SEQ ID NO:116所示的氨基酸序列。
  188. 根据权利要求187所述的分离的抗原结合蛋白,其中所述H-FR2包含SEQ ID NO:62至SEQ ID NO:69中任一项所示的氨基酸序列。
  189. 根据权利要求1-134和179-188中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR3,所述H-FR3位于所述HCDR2与所述HCDR3之间,且所述H-FR3包含SEQ ID NO:117所示的氨基酸序列。
  190. 根据权利要求189所述的分离的抗原结合蛋白,其中所述H-FR3包含SEQ ID NO:71至SEQ ID NO:75中任一项所示的氨基酸序列。
  191. 根据权利要求1-134和179-190中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR4,所述H-FR4的N末端与所述HCDR3的C末端直接或间接地相连,且所述H-FR4包含SEQ ID NO: 118所示的氨基酸序列。
  192. 根据权利要求191所述的分离的抗原结合蛋白,其中所述H-FR4包含SEQ ID NO:77至SEQ ID NO:78中任一项所示的氨基酸序列。
  193. 根据权利要求1-134和179-192中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:115所示的氨基酸序列;所述H-FR2包含SEQ ID NO:116所示的氨基酸序列;所述H-FR3包含SEQ ID NO:117所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:118所示的氨基酸序列。
  194. 根据权利要求193所述的分离的抗原结合蛋白,其中所述第二靶向部分包含H-FR1,H-FR2,H-FR3和H-FR4,所述H-FR1包含SEQ ID NO:59至SEQ ID NO:60中任一项所示的氨基酸序列;所述H-FR2包含SEQ ID NO:62至SEQ ID NO:69中任一项所示的氨基酸序列;所述H-FR3包含SEQ ID NO:71至SEQ ID NO:75中任一项所示的氨基酸序列;以及所述H-FR4包含SEQ ID NO:77至SEQ ID NO:78中任一项所示的氨基酸序列。
  195. 根据权利要求193-194中任一项所述的分离的抗原结合蛋白,其中所述H-FR1、H-FR2、H-FR3和H-FR4包含选自下述任意一组的氨基酸序列:
    a)H-FR1:SEQ ID NO:59,H-FR2:SEQ ID NO:62,H-FR3:SEQ ID NO:71和H-FR4:SEQ ID NO:77;
    b)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:63,H-FR3:SEQ  ID NO:72和H-FR4:SEQ ID NO:78;
    c)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:64,H-FR3:SEQ ID NO:73和H-FR4:SEQ ID NO:78;
    d)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:65,H-FR3:SEQ ID NO:74和H-FR4:SEQ ID NO:78;
    e)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:66,H-FR3:SEQ ID NO:75和H-FR4:SEQ ID NO:78;
    f)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:67,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
    g)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:65,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;
    h)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:64,H-FR3:SEQ ID NO:74和H-FR4:SEQ ID NO:78;
    i)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:68,H-FR3:SEQ ID NO:72和H-FR4:SEQ ID NO:78;和
    j)H-FR1:SEQ ID NO:60,H-FR2:SEQ ID NO:69,H-FR3:SEQ ID NO:73和H-FR4:SEQ ID NO:78。
  196. 根据权利要求1-134和179-195中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含重链可变区VH,所述VH包含SEQ ID NO:122所示的氨基酸序列。
  197. 根据权利要求196所述的分离的抗原结合蛋白,其中所述VH包含SEQ ID NO:95至SEQ ID NO:104中任一项所示的氨基酸序列。
  198. 根据权利要求1-134中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含LCDR3,所述LCDR3包含SEQ ID NO:94所示的氨基酸序列。
  199. 根据权利要求1-134和198中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含LCDR2,所述LCDR2包含SEQ ID NO:87所示的氨基酸序列。
  200. 根据权利要求1-134和198-199中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含LCDR1,所述LCDR1包含SEQ ID NO:82所示的氨基酸序列。
  201. 根据权利要求1-134和198-200中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含SEQ ID NO:123中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
  202. 根据权利要求201所述的分离的抗原结合蛋白,其中所述第二靶向部分包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的轻链可变区VL的LCDR1、LCDR2和LCDR3。
  203. 根据权利要求1-134和198-202中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含轻链可变区VL,所述VL包含所述LCDR1、LCDR2和LCDR3,所述LCDR3包含SEQ ID NO:94所示的氨基酸序列;所述LCDR2包含SEQ ID NO:87所示的氨基酸序列;以及所述LCDR1包含SEQ ID NO:82所示的氨基酸序列。
  204. 根据权利要求1-134和198-203中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR1,所述L-FR1的C末端与 所述LCDR1的N末端直接或间接地相连,且所述L-FR1包含SEQ ID NO:119所示的氨基酸序列。
  205. 根据权利要求204所述的分离的抗原结合蛋白,其中所述L-FR1包含SEQ ID NO:79至SEQ ID NO:81中任一项所示的氨基酸序列。
  206. 根据权利要求1-134和198-205中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR2,所述L-FR2位于所述LCDR1与所述LCDR2之间,且所述L-FR2包含SEQ ID NO:120所示的氨基酸序列。
  207. 根据权利要求206所述的分离的抗原结合蛋白,其中所述L-FR2包含SEQ ID NO:83至SEQ ID NO:86中任一项所示的氨基酸序列。
  208. 根据权利要求1-134和198-207中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR3,所述L-FR3位于所述LCDR2与所述LCDR3之间,且所述L-FR3包含SEQ ID NO:121所示的氨基酸序列。
  209. 根据权利要求208所述的分离的抗原结合蛋白,其中所述L-FR3包含SEQ ID NO:88至SEQ ID NO:93中任一项所示的氨基酸序列。
  210. 根据权利要求1-134和198-209中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR4,所述L-FR4的N末端与所述LCDR3的C末端直接或间接地相连,且所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
  211. 根据权利要求210所述的分离的抗原结合蛋白,其中所述L-FR4包含SEQ ID NO:27至SEQ ID NO:28中任一项所示的氨基酸序列。
  212. 根据权利要求1-134和198-211中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:119所示的氨基酸序列;所述L-FR2包含SEQ ID NO:120所示的氨基酸序列;所述L-FR3包含SEQ ID NO:121所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:56所示的氨基酸序列。
  213. 根据权利要求212所述的分离的抗原结合蛋白,其中所述第二靶向部分包含L-FR1,L-FR2,L-FR3和L-FR4,所述L-FR1包含SEQ ID NO:79至SEQ ID NO:81中任一项所示的氨基酸序列;所述L-FR2包含SEQ ID NO:83至SEQ ID NO:86中任一项所示的氨基酸序列;所述L-FR3包含SEQ ID NO:88至SEQ ID NO:93中任一项所示的氨基酸序列;以及所述L-FR4包含SEQ ID NO:27至SEQ ID NO:28中任一项所示的氨基酸序列。
  214. 根据权利要求212-213中任一项所述的分离的抗原结合蛋白,其中所述L-FR1、L-FR2、L-FR3和L-FR4包含选自下述任意一组的氨基酸序列:
    a)L-FR1:SEQ ID NO:79,L-FR2:SEQ ID NO:83,L-FR3:SEQ ID NO:88和L-FR4:SEQ ID NO:27;
    b)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:84,L-FR3:SEQ ID NO:89和L-FR4:SEQ ID NO:28;
    c)L-FR1:SEQ ID NO:81,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:90和L-FR4:SEQ ID NO:28;
    d)L-FR1:SEQ ID NO:81,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:91和L-FR4:SEQ ID NO:28;
    e)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:90和L-FR4:SEQ ID NO:28;
    f)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:85,L-FR3:SEQ ID NO:92和L-FR4:SEQ ID NO:28;和
    g)L-FR1:SEQ ID NO:80,L-FR2:SEQ ID NO:86,L-FR3:SEQ ID NO:93和L-FR4:SEQ ID NO:28。
  215. 根据权利要求1-134和198-214中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分包括VL,所述VL包含SEQ ID NO:123所示的氨基酸序列。
  216. 根据权利要求215所述的分离的抗原结合蛋白,其中所述VL包含SEQ ID NO:105至SEQ ID NO:111中任一项所示的氨基酸序列。
  217. 根据权利要求1-216中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分靶向CD28,所述第二靶向部分包含VH,所述VH包含SEQ ID NO:176所示的氨基酸序列。
  218. 根据权利要求1-216中任一项所述的分离的抗原结合蛋白,其中所述第二靶向部分靶向CD16a,所述第二靶向部分包含VH,所述VH包含SEQ ID NO:168所示的氨基酸序列。
  219. 根据权利要求1-218中任一项所述的分离的抗原结合蛋白,其包括第一靶向部分和第二靶向部分,所述第一靶向部分包含SEQ ID NO:29至SEQ ID NO:31、SEQ ID NO:32至SEQ ID NO:38、SEQ ID NO: 95至SEQ ID NO:104、SEQ ID NO:105至SEQ ID NO:111、SEQ ID NO:168和SEQ ID NO:176中任一项所示的氨基酸序列;所述第二靶向部分包含SEQ ID NO:29至SEQ ID NO:31、SEQ ID NO:32至SEQ ID NO:38、SEQ ID NO:95至SEQ ID NO:104和SEQ ID NO:105至SEQ ID NO:111、SEQ ID NO:168和SEQ ID NO:176中任一项所示的氨基酸序列。
  220. 根据权利要求1-219中任一项所述的分离的抗原结合蛋白,其中第一靶向部分和第二靶向部分包含选自下述任意一组的氨基酸序列:
    a)第一靶向部分:SEQ ID NO:97和第二靶向部分:SEQ ID NO:31;
    b)第一靶向部分:SEQ ID NO:98和第二靶向部分:SEQ ID NO:31;
    c)第一靶向部分:SEQ ID NO:100和第二靶向部分:SEQ ID NO:31;
    d)第一靶向部分:SEQ ID NO:102和第二靶向部分:SEQ ID NO:31;
    e)第一靶向部分:SEQ ID NO:103和第二靶向部分:SEQ ID NO:31;
    f)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:97;
    g)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:98;
    h)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:100;
    i)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:102;
    j)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:103;
    k)第一靶向部分:SEQ ID NO:97和第二靶向部分:SEQ ID NO:36;
    l)第一靶向部分:SEQ ID NO:98和第二靶向部分:SEQ ID NO:36;
    m)第一靶向部分:SEQ ID NO:100和第二靶向部分:SEQ ID NO:36;
    n)第一靶向部分:SEQ ID NO:102和第二靶向部分:SEQ ID NO:36;
    o)第一靶向部分:SEQ ID NO:103和第二靶向部分:SEQ ID NO:36;
    p)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:97;
    q)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:98;
    r)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:100;
    s)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:102;
    t)第一靶向部分:SEQ ID NO:36和第二靶向部分:SEQ ID NO:103;
    u)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:176;
    v)第一靶向部分:SEQ ID NO:31和第二靶向部分:SEQ ID NO:168;
    w)第一靶向部分:SEQ ID NO:176和第二靶向部分:SEQ ID NO:31;
    x)第一靶向部分:SEQ ID NO:168和第二靶向部分:SEQ ID NO:31。
  221. 根据权利要求1-220中任一项所述的分离的抗原结合蛋白,其中所述第二多肽链包含重链恒定区,且所述重链恒定区包括源自IgG的恒定区或源自IgY的恒定区。
  222. 根据权利要求221所述的分离的抗体结合蛋白,其中所述重链恒定区包括源自IgG的恒定区。
  223. 根据权利要求221-222中任一项所述的分离的抗原结合蛋白,其中所述重链恒定区包括源自IgG1、IgG2、IgG3或IgG4的恒定区。
  224. 根据权利要求221-223中任一项所述的分离的抗原结合蛋白,其中所述重链恒定区包括源自IgG1的Fc区。
  225. 根据权利要求224所述的分离的抗原结合蛋白,其中所述重链恒定区中的Fc区包含N297A突变,残基根据Kabat系统进行编号。
  226. 根据权利要求224-225中任一项所述的分离的抗原结合蛋白,其中所述重链恒定区中的Fc区包含M252Y、S254T和T256E突变,残基根据Kabat系统进行编号。
  227. 根据权利要求221-226中任一项所述的分离的抗原结合蛋白,其中所述重链恒定区包含SEQ ID NO:112至SEQ ID NO:113所示的氨基酸序列。
  228. 根据权利要求1-227中任一项所述的分离的抗原结合蛋白,其中所述第一多肽链包含轻链恒定区,且所述轻链恒定区包括源自Igκ的恒定区或源自Igλ的恒定区。
  229. 根据权利要求228所述的分离的抗原结合蛋白,其中所述轻链恒定区包括源自人Igκ的恒定区。
  230. 根据权利要求228-229中任一项所述的分离的抗原结合蛋白,其中所述轻链恒定区包含SEQ ID NO:114所示的氨基酸序列。
  231. 根据权利要求10-230中任一项所述的分离的抗原结合蛋白,其 中所述第三靶向部分包含VH,所述VH包含SEQ ID NO:168、170、172、174、176和178中任一项所示的氨基酸序列。
  232. 根据权利要求10-231中任一项所述的分离的抗原结合蛋白,其中所述第三靶向部分包含VL,所述VL包含SEQ ID NO:169、171、173、175、177和179中任一项所示的氨基酸序列。
  233. 根据权利要求10-232中任一项所述的分离的抗原结合蛋白,其中所述第三靶向部分包括抗体或抗原结合片段。
  234. 根据权利要求233所述的分离的抗原结合蛋白,其中所述抗原结合片段选自下组:Fab,Fab’,F(ab)2,Fv片段,F(ab’)2,scFv,di-scFv,VHH和dAb。
  235. 根据权利要求234所述的分离的抗原结合蛋白,其中所述第三靶向部分为scFv。
  236. 根据权利要求231-235中任一项所述的分离的抗原结合蛋白,其中所述第三靶向部分中VH的C端与所述VL的N端直接或间接地连接。
  237. 根据权利要求231-235中任一项所述的分离的抗原结合蛋白,其中所述第三靶向部分中VL的C端与所述VH的N端直接或间接地连接。
  238. 根据权利要求20-237中任一项所述的分离的抗原结合蛋白,其中所述第四靶向部分包含VH,所述VH包含SEQ ID NO:29-31、95-104、168、170、172、174、176和178中任一项所示的氨基酸序列。
  239. 根据权利要求20-238中任一项所述的分离的抗原结合蛋白,其 中所述第四靶向部分包含VL,所述VL包含SEQ ID NO:32-38、105-111、169、171、173、175、177和179中任一项所示的氨基酸序列。
  240. 根据权利要求20-239中任一项所述的分离的抗原结合蛋白,其中所述第四靶向部分包括抗体或抗原结合片段。
  241. 根据权利要求240所述的分离的抗原结合蛋白,其中所述抗原结合片段选自下组:Fab,Fab’,F(ab)2,Fv片段,F(ab’)2,scFv,di-scFv,VHH和dAb。
  242. 根据权利要求241所述的分离的抗原结合蛋白,其中所述第四靶向部分为scFv。
  243. 根据权利要求238-242中任一项所述的分离的抗原结合蛋白,其中所述第四靶向部分中VH的C端与所述VL的N端直接或间接地连接。
  244. 根据权利要求238-242中任一项所述的分离的抗原结合蛋白,其中所述第四靶向部分中VL的C端与所述VH的N端直接或间接地连接。
  245. 根据权利要求1-244中任一项所述的分离的抗原结合蛋白,其包含两条第一多肽链和两条第二多肽链,所述两条第一多肽链之间通过二硫键连接,所述两条第一多肽链和两条第二多肽链形成IgG样的抗体。
  246. 根据权利要求1-245中任一项所述的分离的抗原结合蛋白,其包括单克隆抗体、单链抗体、嵌合抗体、人源化抗体、多特异性抗体、双特异性抗体和/或全人源抗体。
  247. 多肽,其包含权利要求1-246中任一项所述的分离的抗原结合蛋白。
  248. 免疫缀合物,其包含权利要求1-246中任一项所述的分离的抗原结合蛋白或权利要求247所述的多肽。
  249. 分离的核酸分子,其编码权利要求1-246中任一项所述的分离的抗原结合蛋白,或者权利要求247所述的多肽。
  250. 载体,其包含权利要求249所述的分离的核酸分子。
  251. 细胞,其包含权利要求1-246中任一项所述的分离的抗原结合蛋白,权利要求247所述的多肽,权利要求248所述的免疫缀合物,权利要求249所述的分离的核酸分子和/或权利要求250所述的载体。
  252. 制备权利要求1-246中任一项所述的分离的抗原结合蛋白或权利要求247所述的多肽的方法,所述方法包括再使得权利要求1-246中任一项所述的分离的抗原结合蛋白或权利要求247所述的多肽表达的条件下,培养权利要求251所述的细胞。
  253. 药物组合物,其包含权利要求1-246中任一项所述的分离的抗原结合蛋白,权利要求247所述的多肽,权利要求248所述的免疫缀合物,权利要求249所述的分离的核酸分子,权利要求250所述的载体,权利要求251所述的细胞,和/或药学上可接受的佐剂和/或赋形剂。
  254. 抑制PD-1与PD-L1相互作用的方法,其包括向有需要的受试者施用有效量的权利要求1-246中任一项所述的分离的抗原结合蛋白,权利要求247所述的多肽,权利要求248所述的免疫缀合物,权利要 求249所述的分离的核酸分子,权利要求250所述的载体,和/或权利要求251所述的细胞。
  255. 权利要求1-246中任一项所述的分离的抗原结合蛋白,权利要求247所述的多肽,权利要求248所述的免疫缀合物,权利要求249所述的分离的核酸分子,权利要求250所述的载体,权利要求251所述的细胞和/或权利要求253所述的药物组合物在制备预防和/或治疗疾病或病症的药物中的用途。
  256. 根据权利要求255所述的用途,其中所述疾病或病症包括肿瘤。
  257. 根据权利要求256所述的用途,其中所述肿瘤包括实体瘤。
  258. 根据权利要求256-257中任一项所述的用途,其中所述肿瘤包括非实体瘤。
  259. 根据权利要求256-258中任一项所述的用途,其中所述肿瘤包括乳腺癌、肺癌、胃癌、肠癌、肾癌、黑色素瘤、非小细胞肺癌、结肠癌、膀胱癌、卵巢癌、胰腺癌和/或肝癌。
  260. 权利要求1-246中任一项所述的分离的抗原结合蛋白,权利要求247所述的多肽,权利要求248所述的免疫缀合物,权利要求249所述的分离的核酸分子,权利要求250所述的载体,权利要求251所述的细胞和/或权利要求253所述的药物组合物,其用于预防、缓解和/或治疗疾病或病症。
  261. 根据权利要求260所述的用途,其中所述疾病或病症包括肿瘤。
  262. 根据权利要求261所述的用途,其中所述肿瘤包括实体瘤。
  263. 根据权利要求261-262中任一项所述的用途,其中所述肿瘤包 括非实体瘤。
  264. 根据权利要求261-263中任一项所述的用途,其中所述肿瘤包括乳腺癌、肺癌、胃癌、肠癌、肾癌、黑色素瘤、非小细胞肺癌、结肠癌、膀胱癌、卵巢癌、胰腺癌和/或肝癌。
  265. 一种预防和/或治疗疾病或病症的方法,其包括向有需要的受试者施用有效量的权利要求1-246中任一项所述的分离的抗原结合蛋白,权利要求247所述的多肽,权利要求248所述的免疫缀合物,权利要求249所述的分离的核酸分子,权利要求250所述的载体,权利要求251所述的细胞和/或权利要求253所述的药物组合物。
  266. 根据权利要求265所述的方法,其中所述疾病或病症包括肿瘤。
  267. 根据权利要求266所述的方法,其中所述肿瘤包括实体瘤。
  268. 根据权利要求266-267中任一项所述的方法,其中所述肿瘤包括非实体瘤。
  269. 根据权利要求266-268中任一项所述的方法,其中所述肿瘤包括乳腺癌、肺癌、胃癌、肠癌、肾癌、黑色素瘤、非小细胞肺癌、结肠癌、膀胱癌、卵巢癌、胰腺癌和/或肝癌。
PCT/CN2022/110795 2021-08-19 2022-08-08 靶向pd-l1/pd-1的抗体及其应用 WO2023020315A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110956895 2021-08-19
CN202110956895.6 2021-08-19
CN202210868109.1A CN116102655A (zh) 2021-08-19 2022-07-22 靶向pd-l1/pd-1的抗体及其应用
CN202210868109.1 2022-07-22

Publications (1)

Publication Number Publication Date
WO2023020315A1 true WO2023020315A1 (zh) 2023-02-23

Family

ID=85240029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/110795 WO2023020315A1 (zh) 2021-08-19 2022-08-08 靶向pd-l1/pd-1的抗体及其应用

Country Status (1)

Country Link
WO (1) WO2023020315A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103608040A (zh) * 2011-04-20 2014-02-26 安普利穆尼股份有限公司 结合b7-h1和pd-1的抗体和其他分子
CN106573050A (zh) * 2014-05-29 2017-04-19 宏观基因有限公司 特异性结合多种癌症抗原的三特异性结合分子和其使用方法
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
CN110914306A (zh) * 2017-07-10 2020-03-24 伊莱利利公司 检查点抑制物双特异性抗体
WO2020177627A1 (zh) * 2019-03-02 2020-09-10 上海一宸医药科技有限公司 一种双特异抗体
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103608040A (zh) * 2011-04-20 2014-02-26 安普利穆尼股份有限公司 结合b7-h1和pd-1的抗体和其他分子
CN106573050A (zh) * 2014-05-29 2017-04-19 宏观基因有限公司 特异性结合多种癌症抗原的三特异性结合分子和其使用方法
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
CN110914306A (zh) * 2017-07-10 2020-03-24 伊莱利利公司 检查点抑制物双特异性抗体
WO2020177627A1 (zh) * 2019-03-02 2020-09-10 上海一宸医药科技有限公司 一种双特异抗体
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOTANIDES HELEN, LI YIWEN, MALABUNGA MARIA, CARPENITO CARMINE, EASTMAN SCOTT W., SHEN YANG, WANG GEORGE, INIGO IVAN, SURGULADZE DA: "Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity", CANCER IMMUNOLOGY RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 8, no. 10, 1 October 2020 (2020-10-01), US , pages 1300 - 1310, XP093036393, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-20-0304 *

Similar Documents

Publication Publication Date Title
US11643465B2 (en) Anti-PD-1 antibodies
RU2693661C2 (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
KR102340832B1 (ko) 항 pd-1 항체 및 그의 용도
KR102503084B1 (ko) 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도
US10696745B2 (en) Anti-PD-L1 antibodies
WO2018036472A1 (zh) 一种抗pd1单克隆抗体、其药物组合物及其用途
JP7418346B2 (ja) 4-1BBLを含むHer2標的化抗原結合分子
US20150132288A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
JP2022513432A (ja) 免疫細胞活性化のための二重特異性抗体
CN111699201A (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
WO2019179422A1 (en) Novel bispecific pd-1/lag-3 antibody molecules
JP2023550419A (ja) 二機能性分子
CN110305216B (zh) 新型抗tim-3抗体
CA3189496C (en) Anti-pvrig protein antibody or antibody fragment and use thereof
WO2023020315A1 (zh) 靶向pd-l1/pd-1的抗体及其应用
CN116135884A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
WO2023001025A1 (zh) Pd-l1抗体及其用途
CN116102655A (zh) 靶向pd-l1/pd-1的抗体及其应用
WO2023284741A1 (zh) Pd-1抗体及其用途
WO2023016554A1 (zh) 靶向cd22的抗原结合蛋白及其用途
WO2019196117A1 (en) Anti-cd27 antibodies and use thereof
CN117157314A (zh) Pd-l1抗体、融合蛋白及其用途
CN116410326A (zh) 抗cd40×cldn18.2双特异性抗体及其用途
CN116847863A (zh) 抗人cd22的单克隆抗体及其用途
JP2020514273A (ja) 白斑症の処置のための抗ヒトcxcr3抗体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22857627

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE